

CITATION REPORT

List of articles citing

The prevalence and features of the polycystic ovary syndrome in an unselected population

DOI: 10.1210/jc.2003-032046

Journal of Clinical Endocrinology and Metabolism,
2004, 89, 2745-9.

Source: <https://exaly.com/paper-pdf/37561687/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2017	Phenotype and genotype in polycystic ovary syndrome. 2001 , 25-41		1
2016	Insulin sensitizers in the treatment of polycystic ovary syndrome. 2001 , 65-80		1
2015	Role of hyperinsulinemic insulin resistance in polycystic ovary syndrome. 2001 , 204-214		1
2014	Adrenocortical dysfunction in polycystic ovary syndrome. 2001 , 288-315		
2013	Metabolic Syndrome: Maladaptation to a Modern World. 2004 , 97, 511-520		15
2012	Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 5558-62	5.6	25
2011	Metabolic syndrome: maladaptation to a modern world. 2004 , 97, 511-20		17
2010	Recent advances in the treatment of polycystic ovary syndrome. 2004 , 13, 1295-305		9
2009	American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. 2005 , 11, 126-34		63
2008	Polycystic ovaries and polycystic ovary syndrome in epilepsy: evidence for neurogonadal disease. 2005 , 5, 142-6		20
2007	Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). 2005 , 62, 644-9		173
2006	The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. 2005 , 62, 573-9		57
2005	Polyzystisches Ovarsyndrom. 2005 , 3, 187-198		3
2004	The Prevalence of Polycystic Ovary Syndrome in College Students from Seoul. 2005 , 20, 120		19
2003	Hiperandrogenismo e pele: síndrome do ovário policístico e resistência periférica à insulina. 2005 , 80, 395-410		16
2002	FEM1A is a candidate gene for polycystic ovary syndrome. 2005 , 21, 330-5		11
2001	Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenemic adolescent girls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 2810-5	5.6	82

2000	Resistin stimulation of 17alpha-hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4852-7	5.6	61
1999	Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4797-802	5.6	83
1998	Absence of polycystic ovary syndrome features in human immunodeficiency virus-infected women despite significant hyperinsulinemia and truncal adiposity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 5596-604	5.6	13
1997	Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4650-8	5.6	325
1996	Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?. 2005 , 11, 357-74		387
1995	Polycystic ovarian syndrome and insulin resistance: implications for estrogen use in premenopausal and postmenopausal women. 2005 , 3, 259-69		3
1994	Metabolic syndrome in young Czech women with polycystic ovary syndrome. 2005 , 20, 3328-32		58
1993	Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess. 2005 , 83, 371-5		37
1992	Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. 2005 , 83, 1454-60		393
1991	Diagnostic criteria for polycystic ovary syndrome: a reappraisal. 2005 , 83, 1343-6		110
1990	Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. 2005 , 83, 1717-23		187
1989	Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. 2005 , 84, 766-9		80
1988	Polycystic ovary syndrome in adolescent girls. 2005 , 14, 111-7		16
1987	Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 6630-7	5.6	62
1986	Insulin-sensitisers in the treatment of polycystic ovary syndrome. 2005 , 6, 2419-27		12
1985	Polycystic ovary syndrome in post-menopausal women--marker of the metabolic syndrome. 2005 , 50, 331-6		23
1984	The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study. 2005 , 2, 35		99
1983	Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adolescents. 2005 , 34, 707-23, x		29

1982	Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4237-45	5.6	1491
1981	Polycystic ovarian syndrome: the next cardiovascular dilemma in women?. 2006 , 35, 611-31, x		8
1980	Management of epilepsy in women of childbearing age: practical recommendations. 2006 , 20, 373-87		18
1979	Effects of metformin on inappropriate LH release in women with polycystic ovarian syndrome and insulin resistance. 2006 , 12, 669-83		8
1978	Effects of lifestyle modification in polycystic ovarian syndrome. 2006 , 12, 569-78		90
1977	Sexualidad y reproducción, un campo importante de la endocrinología. 2006 , 53, 34-41		
1976	Prevalencia, definición y manifestaciones clínicas del síndrome del ovario poliquístico. 2006 , 53, 15-33		2
1975	Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. 2006 , 20, 193-205		121
1974	Role of lifestyle modification in the management of polycystic ovary syndrome. 2006 , 20, 293-310		56
1973	Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. 2006 , 55, 1582-9		32
1972	Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 781-5	5.6	282
1971	Role of diet in the treatment of polycystic ovary syndrome. 2006 , 85, 679-88		105
1970	Characterization of unilateral polycystic ovary compared with polycystic ovary syndrome. 2006 , 85, 805-8		3
1969	Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. 2006 , 85, 996-1001		76
1968	Selecting controls is not selecting "normals": design and analysis issues for studying the etiology of polycystic ovary syndrome. 2006 , 86, 1-12		54
1967	Family size in women with polycystic ovary syndrome. 2006 , 85, 1837-9		12
1966	Difference in dietary intake between women with polycystic ovary syndrome and healthy controls. 2006 , 86, 411-7		94
1965	Serum sex hormone-binding globulin levels show too much variability to be used effectively as a screening marker for insulin resistance in women with polycystic ovary syndrome. 2006 , 86, 934-41		13

1964	Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. 2006 , 86 Suppl 1, S7-8	67
1963	Heritability of dehydroepiandrosterone sulfate in women with polycystic ovary syndrome and their sisters. 2006 , 86, 1688-93	28
1962	Genomic variants in polycystic ovary syndrome. 2006 , 366, 14-26	37
1961	Are there differences in ultrasound parameters between Chinese women with polycystic ovaries only and with polycystic ovary syndrome?. 2006 , 125, 92-8	15
1960	Puberty and polycystic ovary syndrome. 2006 , 254-255, 146-53	38
1959	Molecular mechanisms of insulin resistance in polycystic ovary syndrome. 2006 , 12, 324-32	199
1958	Diseases manifesting in the upper genital tract in children and adolescents: a review. 2006 , 19, 3-9	1
1957	Determinants of emotional distress in women with polycystic ovary syndrome. 2006 , 21, 1092-9	101
1956	Polycystic ovary syndrome and mental health: A review. 2006 , 61, 723-32	134
1955	Sleep and epilepsy: what we know, don't know, and need to know. 2006 , 23, 4-20	103
1954	Stress in women: metabolic syndrome and polycystic ovary syndrome. 2006 , 1083, 54-62	18
1953	Surgical treatment of obesity. 2006 , 29, 11-9	18
1952	Insulin resistance in PCOS. 2006 , 30, 13-7	92
1951	Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. 2006 , 30, 45-53	87
1950	Epilepsy and polycystic ovary syndrome: where is the link?. 2006 , 27, 221-30	18
1949	Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling. 2006 , 49, 2572-9	25
1948	Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. 2006 , 6, 77-83	100
1947	Polycystic ovarian syndrome--prognosis and outcomes. 2006 , 20, 751-78	40

1946	An inverse association between ovarian cysts and breast cancer in the breast cancer family registry. 2006 , 118, 197-202		9
1945	Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. 2006 , 160, 241-6		92
1944	Abnormal glucose tolerance in Chinese women with polycystic ovary syndrome. 2006 , 21, 2027-32		76
1943	Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 1357-63	5.6	268
1942	Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4085-91	5.6	69
1941	Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 1741-7	5.6	174
1940	Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 2250-6	5.6	81
1939	Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 1275-83	5.6	90
1938	The combination of increased ovarian volume and follicle number is associated with more severe hyperandrogenism in German women with polycystic ovary syndrome. 2006 , 114, 175-81		21
1937	Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. 2006 , 21, 1400-7		68
1936	Obesity and the role of gut and adipose hormones in female reproduction. 2006 , 12, 585-601		97
1935	Is a Routine Ultrasound Scan Necessary for the Diagnosis of Polycystic Ovarian Syndrome?. 2006 , 14, 211-212		
1934	Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 48-53	5.6	519
1933	Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome. 2006 , 155, 859-65		26
1932	Decreased soluble leptin receptor levels in women with polycystic ovary syndrome. 2006 , 154, 287-94		31
1931	The androgen receptor CAG repeat modifies the impact of testosterone on insulin resistance in women with polycystic ovary syndrome. 2006 , 155, 127-30		50
1930	Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. 2006 , 12, 243-52		79
1929	Obesity and Diabetes. 2006 ,		4

1928	Predictors of abnormal glucose metabolism in women with polycystic ovary syndrome. 2006 , 154, 295-301		19
1927	Adiponectin is an independent determinant of insulin resistance in women with polycystic ovary syndrome. 2006 , 22, 511-5		27
1926	The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. 2006 , 12, 351-61		188
1925	Depression and body image among women with polycystic ovary syndrome. 2006 , 11, 613-25		161
1924	Clinical Q & A. 2006 , 2, 114-115		
1923	Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. 2006 , 103, 7030-5		74
1922	Heritability of polycystic ovary syndrome in a Dutch twin-family study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 2100-4	5.6	371
1921	Functional ovarian hyperandrogenism and polycystic ovary syndrome in prepubertal girls with obesity and/or premature pubarche. 2007 , 20, 475-81		8
1920	Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. 2007 , 157, 669-76		76
1919	Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome. 2007 , 20, 41-51		34
1918	Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 456-61	5.6	118
1917	Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 4546-56	5.6	253
1916	The Genetic Basis of the Polycystic Ovary Syndrome: A Literature Review Including Discussion of PPAR-gamma. 2007 , 2007, 49109		48
1915	Serum adiponectin and lipid concentrations in pregnant women with polycystic ovary syndrome. 2007 , 22, 1830-6		35
1914	Managing anovulatory infertility and polycystic ovary syndrome. 2007 , 335, 663-6		50
1913	Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3498-503	5.6	66
1912	Obesity management in women with polycystic ovary syndrome. 2007 , 3, 73-86		8
1911	Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome. 2007 , 115, 130-5		59

1910	The age-associated decline of androgens in reproductive age and menopausal Black and White women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 4730-3	5.6	58
1909	Clomiphene versus metformin for ovulation induction in polycystic ovary syndrome: the winner is. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3399-401	5.6	20
1908	Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. 2007 , 25, 352-9		91
1907	Genes for enzymes regulating dehydroepiandrosterone sulfonation are associated with levels of dehydroepiandrosterone sulfate in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 2659-64	5.6	34
1906	A 27-year-old woman with a diagnosis of polycystic ovary syndrome. 2007 , 297, 509-19		16
1905	Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. 2007 , 30, 2309-13		61
1904	Secondary causes of obesity. 2007 , 4, 641-650		8
1903	Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 328-37	5.6	126
1902	When Puberty is Precocious. 2007 ,		5
1901	Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome. 2007 , 45, 202-7		38
1900	Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women. 2007 , 157, 195-200		38
1899	Polycystic Ovarian Syndrome and Obstructive Sleep Apnea. 2007 , 3, 278-281		
1898	Acceleration of luteinizing hormone pulse frequency in adolescent girls with a history of central precocious puberty with versus without hyperandrogenism. 2007 , 68, 278-85		9
1897	Diagnosis of polycystic ovary syndrome. 2007 , 50, 168-77		66
1896	Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. 2007 , 14, 284-92		73
1895	Bariatric surgery and adolescent gynecology. 2007 , 19, 427-33		5
1894	Ovulation induction management of PCOS. 2007 , 50, 255-67		31
1893	Obesity and lifestyle management in polycystic ovary syndrome. 2007 , 50, 277-94		48

1892	Use of oral contraceptives in the treatment of women with polycystic ovary syndrome. 2007 , 2, 347-355	
1891	Abdominal adiposity and the polycystic ovary syndrome. 2007 , 18, 266-72	268
1890	The management of insulin resistance in polycystic ovary syndrome. 2007 , 18, 273-9	92
1889	Agreement among insulin sensitivity indexes on the diagnosis of insulin resistance in polycystic ovary syndrome and ovulatory women. 2007 , 133, 203-7	27
1888	Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study. 2007 , 87, 712-4	8
1887	Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. 2007 , 87, 862-9	36
1886	Polycystic ovary syndrome and risk of uterine leiomyomata. 2007 , 87, 1108-15	39
1885	Preliminary evidence of glycogen synthase kinase 3 beta as a genetic determinant of polycystic ovary syndrome. 2007 , 87, 1473-6	17
1884	Discovery of distinct protein profiles for polycystic ovary syndrome with and without insulin resistance by surface-enhanced laser adsorption/ionization time of flight mass spectrometry. 2007 , 88, 145-51	16
1883	Clinical and metabolic features of polycystic ovary syndrome. 2007 , 97, 129-34	40
1882	Polycystic ovary syndrome. 2007 , 370, 685-97	998
1881	Animal Models and Fetal Programming of the Polycystic Ovary Syndrome. 2006 , 259-272	3
1880	Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. 2007 , 356, 551-66	740
1879	Dermatologic manifestations of polycystic ovary syndrome. 2007 , 8, 201-19	53
1878	Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance. 2007 , 23, 231-7	25
1877	Effects of polycystic ovary syndrome on health-related quality of life. 2007 , 7, 597-603	10
1876	Polycystic ovary syndrome: a common reproductive and metabolic disorder necessitating early recognition and treatment. 2007 , 34, 761-89, vi	14
1875	Diet and nutrition in polycystic ovary syndrome (PCOS): pointers for nutritional management. 2007 , 27, 762-73	47

1874	Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. 2007 , 5, 496-501	126
1873	Leptin secretory burst mass correlates with body mass index and insulin in normal women but not in women with polycystic ovary syndrome. 2007 , 56, 1561-5	9
1872	Laser hair removal in women with polycystic ovary syndrome. 2007 , 60, 426-31	14
1871	Obesity and the polycystic ovary syndrome. 2007 , 91, 1151-68, ix-x	19
1870	A randomised, split-face comparison of facial hair removal with the alexandrite laser and intense pulsed light system. 2007 , 39, 767-72	42
1869	The information needs of women diagnosed with Polycystic Ovarian Syndrome--implications for treatment and health outcomes. 2007 , 7, 9	37
1868	Role of obesity and adiposity in polycystic ovary syndrome. 2007 , 31 Suppl 2, S8-13; discussion S31-2	73
1867	Overexpression of the phosphoprotein enriched in diabetes gene product (Ped/pea-15) in women with polycystic ovary syndrome. 2007 , 67, 557-62	6
1866	Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. 2007 , 67, 735-42	119
1865	Vascular compliance in women with polycystic ovary syndrome and healthy women. 2007 , 2, 40-4	2
1864	[Polycystic ovary syndrome. Prototype of a cardio-metabolic syndrome]. 2007 , 48, 144-53	6
1863	Practice patterns of screening for sleep apnea in physicians treating PCOS patients. 2007 , 11, 233-7	21
1862	The adrenal and polycystic ovary syndrome. 2007 , 8, 331-42	83
1861	Genetik ovarieller Störungen. 2007 , 5, 5-12	
1860	Androgen receptor gene CAG(n) trinucleotide repeats polymorphism in Chinese women with polycystic ovary syndrome. 2008 , 33, 165-70	24
1859	Konsensugerechte Therapie des PCOS. 2008 , 6, 185-194	
1858	Proteomics and genomics: A hypothesis-free approach to the study of the role of visceral adiposity in the pathogenesis of the polycystic ovary syndrome. 2008 , 2, 444-55	10
1857	The epidemiology of adult obstructive sleep apnea. 2008 , 5, 136-43	1367

1856 Management of polycystic ovarian syndrome. **2008**, 13, 14-19

1855 Menstrual health and the metabolic syndrome in adolescents. **2008**, 1135, 85-94 28

1854 The clinical evaluation of hirsutism. **2008**, 21, 376-91 40

1853 Evidence for pancreatic beta-cell dysfunction in brothers of women with polycystic ovary syndrome. **2008**, 57, 84-9 38

1852 Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. **2008**, 10, e3 174

1851 Comorbilidades del exceso ponderal en el adolescente. **2008**, 55, 41-59 0

1850 The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 4299-306 5.6 182

1849 Handbook of Obesity. **2008**, 6

1848 Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. **2008**, 23, 642-50 157

1847 Prevalence of symptoms associated with polycystic ovary syndrome. **2008**, 102, 39-43 38

1846 Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS). **2008**, 109, 242-6 62

1845 Whither PCOS? The challenges of establishing hyperandrogenism in adolescent girls. **2008**, 43, 103-5 25

1844 Insulin resistance and polycystic ovary syndrome. **2008**, 18, 511-8 62

1843 Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. **2008**, 89, 1221-1228 38

1842 High serum concentration of total inhibin in polycystic ovary syndrome. **2008**, 90, 1859-63 18

1841 Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome. **2008**, 90, 2310-7 23

1840 Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3. **2008**, 90, 2291-7 24

1839 The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. **2008**, 89, 1039-1048 80

1838	Female reproductive disorders: the roles of endocrine-disrupting compounds and developmental timing. 2008 , 90, 911-40		320
1837	Prevalence of polycystic ovary syndrome in unselected women from southern China. 2008 , 139, 59-64		101
1836	Deciphering the cis-regulatory elements of co-expressed genes in PCOS by in silico analysis. 2008 , 408, 72-84		8
1835	Polycystic ovary syndrome in perimenarchal obese adolescents: experience with magnetic resonance imaging. 2008 , 18, S8-S13		1
1834	The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome. 2008 , 69, 52-60		32
1833	Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1939-45	5.6	81
1832	Basic infertility including polycystic ovary syndrome. 2008 , 92, 1163-92, xi		74
1831	Polycystic ovary syndrome: treatment strategies and management. 2008 , 9, 2995-3008		22
1830	Polycystic ovary syndrome as a developmental disorder. 2008 , 3, 775-787		6
1829	Ovarian hyperthecosis and response to antiandrogens: An uncommon presentation of a common disorder. 2008 , 28, 249-50		1
1828	Polycystic ovary syndrome in women using valproate: a review. 2008 , 24, 562-70		50
1827	Fetal programming of adrenal androgen excess: lessons from a nonhuman primate model of polycystic ovary syndrome. 2008 , 13, 145-158		57
1826	Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. 2008 , 24, 378-84		49
1825	Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. 2008 , 23, 1594-601		29
1824	The effects of insulin sensitizers on the cardiovascular risk factors in women with polycystic ovary syndrome. 2008 , 31, 1124-31		6
1823	Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome. 2008 , 23, 2564-9		31
1822	Polycystic ovary syndrome in asian women. 2008 , 26, 14-21		13
1821	Follicle dynamics and anovulation in polycystic ovary syndrome. 2008 , 14, 367-78		344

1820	Lipid and lipoprotein profile in women with polycystic ovary syndrome. 2008 , 86, 199-204		40
1819	Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome. 2008 , 158, 517-23		26
1818	First evidence of genetic association between AKT2 and polycystic ovary syndrome. 2008 , 31, 2284-7		26
1817	Granulosa cell survival and proliferation are altered in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 881-7	5.6	155
1816	Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA), a candidate gene for polycystic ovary syndrome. 2008 , 23, 1214-9		22
1815	Polycystic ovary syndrome: the controversy of diagnosis by ultrasound. 2008 , 26, 241-51		20
1814	Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. 2008 , 23, 2122-6		71
1813	Type 2 diabetes among women: clinical considerations for pharmacological management to achieve glycemic control and reduce cardiovascular risk. 2008 , 17, 249-60		1
1812	Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. 2008 , 23, 651-61		85
1811	Disorders of Energy Balance. 2008 , 788-838		2
1810	Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. 2008 , 23, 1431-8		73
1809	Impact of obesity on the risk for polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 162-8	5.6	230
1808	Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. 2008 , 23, 1924-31		84
1807	Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys. 2008 , 79, 154-63		84
1806	Statins in the treatment of polycystic ovary syndrome. 2008 , 26, 127-38		28
1805	Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. 2008 , 159, 399-406		50
1804	Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2223-9	5.6	65
1803	Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. 2008 , 158, 793-801		26

1802	Mood and sexual function in polycystic ovary syndrome. 2008 , 26, 45-52		49
1801	Psychological implications of infertility in women with polycystic ovary syndrome. 2008 , 23, 2064-71		73
1800	Metabolic profile in sons of women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1820-6	5.6	72
1799	Epithelial ovarian cancer: testing the 'androgens hypothesis'. 2008 , 15, 1061-8		62
1798	Pathways leading to phosphorylation of p450c17 and to the posttranslational regulation of androgen biosynthesis. 2008 , 149, 2667-77		40
1797	FEM1A and FEM1B: novel candidate genes for polycystic ovary syndrome. 2008 , 23, 2842-9		21
1796	Polycystic Ovary Syndrome. 2008 , 165-174		1
1795	Is pharmacogenomics our future? Metformin, ovulation and polymorphism of the STK11 gene in polycystic ovary syndrome. 2008 , 9, 1163-5		10
1794	Hirsutism in a Fifty-Eight-Year-Old Woman. 2008 , 18, 216-218		
1793	Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1408-11	5.6	55
1792	Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 4780-6	5.6	92
1791	Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 792-800	5.6	76
1790	Pituitary and testicular function in sons of women with polycystic ovary syndrome from infancy to adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3318-24	5.6	44
1789	Nonreplication of the type 5 17beta-hydroxysteroid dehydrogenase gene association with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 300-3	5.6	23
1788	Association of CYP3A7*1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2909-12	5.6	22
1787	Oocyte quality in adult polycystic ovary syndrome. 2008 , 26, 196-203		36
1786	Massive ovarian cyst haemorrhage with haemoperitoneum as a complication of long-term anticoagulation. 2008 , 28, 250-1		4
1785	Pleiotropic effects of thiazolidinediones. 2008 , 9, 1087-108		49

1784	Meibomian gland alterations in polycystic ovary syndrome. 2008 , 33, 133-8	14
1783	Women with polycystic ovary syndrome (PCOS) have equivalent lipid profiles but a lower high-molecular-weight (HMW) adiponectin levels compared with controls matched for age, BMI and insulin resistance. 2008 , 67,	
1782	Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. 2008 , 30, 671-679	82
1781	Association of hypoadiponectinemia with metabolic syndrome in patients with polycystic ovary syndrome. 2008 , 100, 64-8	18
1780	[The polycystic ovary syndrome--metabolic consequences]. 2008 , 48, 16-23	1
1779	Insulin-sensitizing agents and reproductive function in polycystic ovary syndrome patients. 2008 , 20, 364-73	12
1778	Polycystic ovary syndrome in obese adolescents. 2008 , 15, 30-6	17
1777	Lifestyle changes in women with Polycystic Ovary Syndrome. 2008 ,	4
1776	Ovarian dysfunction and the premenopausal origins of coronary heart disease. 2008 , 15, 768-76	30
1775	Polycystic Ovary Syndrome and IVF. 375-380	
1774	Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women?. 2008 , 4, 453-62	40
1773	Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. 2008 , 4, 487-92	38
1772	Insulin Resistance in Polycystic Ovary Syndrome. 2008 , 32, 1	5
1771	. 2009 ,	8
1770	Polycystic ovary syndrome, depression, and affective disorders. 2009 , 15, 475-82	18
1769	Metabolic syndrome and polycystic ovary syndrome... and vice versa. 2009 , 53, 227-37	40
1768	Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 1853-78	5.6 350
1767	Prevalence and predictors of abnormal glucose metabolism in Mediterranean women with polycystic ovary syndrome. 2009 , 25, 199-204	19

1766	Association study of AMP-activated protein kinase subunit genes in polycystic ovary syndrome. 2009 , 161, 405-9		2
1765	Polycystic ovary syndrome, obesity and reproductive implications. 2009 , 5, 529-40; quiz 541-2		38
1764	Glucose metabolism in overweight Hispanic adolescents with and without polycystic ovary syndrome. 2009 , 124, e496-502		15
1763	Prevalence and implications of anxiety in polycystic ovary syndrome: results of an internet-based survey in Germany. 2009 , 24, 1446-51		95
1762	The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 103-8	5.6	110
1761	Obesity and polycystic ovary syndrome. 2009 , 2, 26-35		104
1760	Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. 2009 , 15, 477-88		232
1759	Impaired glucose metabolism in women with polycystic ovary syndrome. 2009 , 68, 186-90		11
1758	Acute effects of testosterone infusion on the serum luteinizing hormone profile in eumenorrheic and polycystic ovary syndrome adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3602-10	5.6	19
1757	Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 4938-45	5.6	74
1756	Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve. 2009 , 24, 1176-83		82
1755	Abnormal uterine bleeding: a focus on polycystic ovary syndrome. 2009 , 5, 313-24		3
1754	Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 6 17beta-hydroxysteroid dehydrogenase gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 5034-8	5.6	25
1753	Characterizing cardiovascular risk in women with polycystic ovary syndrome: more than the sum of its parts?. 2009 , 27, 299-305		5
1752	Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3282-8	5.6	57
1751	Glucocorticoid Receptor in Health and Disease. 2009 , 28, 248-261		4
1750	Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 1973-8	5.6	65
1749	Prevalence of polycystic ovary syndrome in women from opposite-sex twin pairs. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 1987-90	5.6	31

1748	Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls--implications for regulation of pubertal maturation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 2360-6	5.6	84
1747	Predictors of pregnancy in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3458-66	5.6	51
1746	Plasminogen activator inhibitor-1 4G/5G and 5,10-methylene-tetrahydrofolate reductase C677T polymorphisms in polycystic ovary syndrome. 2009 , 15, 19-26		25
1745	Hormonal, sonographic, and body composition changes in egyptian adolescent girls with hyperandrogenic manifestations. 2009 , 5, 489-500		
1744	The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3714-20	5.6	113
1743	Low prevalence of the metabolic syndrome but high occurrence of various metabolic disorders in Chinese women with polycystic ovary syndrome. 2009 , 161, 411-8		30
1742	Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 157-63	5.6	92
1741	Quality of sexual life in hyperandrogenic women treated with an oral contraceptive containing chlormadinone acetate. 2009 , 6, 3376-84		23
1740	A pilot study of the teratogenicity of vagus nerve stimulation in a rabbit model. 2009 , 2, 41-9		15
1739	Increased ovarian follicle atresia in obese Zucker rats is associated with enhanced expression of the forkhead transcription factor FOXO1. 2009 , 42, 216-21		21
1738	Nonhuman primates as models for human adrenal androgen production: function and dysfunction. 2009 , 10, 33-42		44
1737	Polycystic ovary syndrome and cardiovascular disease risk. 2009 , 3, 65-70		1
1736	Assessment of ultrasonographic features of polycystic ovaries is associated with modest levels of inter-observer agreement. 2009 , 2, 6		23
1735	Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. 2009 , 70, 311-21		65
1734	Nurse-led peer support group: experiences of women with polycystic ovary syndrome. 2009 , 65, 2046-55		36
1733	Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome. 2009 , 63, 160-9		23
1732	An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. 2009 , 24, 243-7		74
1731	Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. 2009 , 116, 1633-9		80

1730	Polycystic ovarian syndrome: a misnomer for an enigmatic disease. 2009 , 33, 621-7	8
1729	Serum levels of resistin and hsCRP in women with PCOS. 2009 , 4, 428-432	4
1728	Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. 2009 , 32, 695-700	27
1727	Relevance of an opioid, nospapine in reducing cystogeneses in rat experimental model of polycystic ovary syndrome. 2009 , 32, 837-43	5
1726	Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS). 2009 , 16, 938-46	5
1725	Genetic polymorphisms of GnRH and gonadotrophic hormone receptors affect the phenotype of polycystic ovary syndrome. 2009 , 24, 2014-22	81
1724	Recruitment strategies for an acupuncture randomized clinical trial of reproductive age women. 2009 , 17, 229-35	9
1723	The FTO gene modifies weight, fat mass and insulin sensitivity in women with polycystic ovary syndrome, where its role may be larger than in other phenotypes. 2009 , 35, 328-31	31
1722	Variation in the perilipin gene (PLIN) affects glucose and lipid metabolism in non-Hispanic white women with and without polycystic ovary syndrome. 2009 , 86, 186-92	12
1721	Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. 2009 , 91, 1848-52	48
1720	Prevalence of insulin resistance and determination of risk factors for glucose intolerance in polycystic ovary syndrome: a cross-sectional study of Chinese infertility patients. 2009 , 91, 1864-8	22
1719	Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome. 2009 , 91, 2557-67	28
1718	Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. 2009 , 91, 2545-50	21
1717	Effect of insulin and testosterone on androgen production and transcription of SULT2A1 in the NCI-H295R adrenocortical cell line. 2009 , 92, 793-7	11
1716	Association of the 17-hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) with hyperandrogenemia in polycystic ovary syndrome (PCOS). 2009 , 92, 648-52	14
1715	Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. 2009 , 92, 643-7	49
1714	The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. 2009 , 91, 456-88	1268
1713	CYP11A1 and CYP17 promoter polymorphisms associate with hyperandrogenemia in polycystic ovary syndrome. 2009 , 92, 653-9	43

1712	Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. 2009 , 92, 1053-1058	101
1711	Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. 2009 , 92, 1960-5	57
1710	Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. 2009 , 92, 1966-82	277
1709	Apnea-hypopnea index in nonobese women with polycystic ovary syndrome. 2009 , 105, 226-9	21
1708	Effect of body mass index on clinical manifestations in patients with polycystic ovary syndrome. 2009 , 107, 54-7	16
1707	Insulin Resistance in PCOS. 2009 , 35-61	14
1706	Ovarian stimulation in polycystic ovary syndrome patients: the role of body mass index. 2009 , 18, 333-6	17
1705	Endocrine-disrupting chemicals: an Endocrine Society scientific statement. 2009 , 30, 293-342	2820
1704	Endometrial thickness, Caucasian ethnicity, and age predict clinical pregnancy following fresh blastocyst embryo transfer: a retrospective cohort. 2009 , 7, 33	46
1703	Developmental Programming of Polycystic Ovary Syndrome: Role of Prenatal Androgen Excess. 2009 , 83-103	2
1702	Diagnosis and Management of Polycystic Ovary Syndrome. 2009 ,	0
1701	Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. 2009 , 30, 1-50	282
1700	Diseases of the hair and nails. 2009 , 93, 1195-209	5
1699	Family-based association study of the MCF2L2 gene and polycystic ovary syndrome. 2009 , 68, 171-3	5
1698	Epilepsy, sex hormones and antiepileptic drugs in female patients. 2009 , 9, 1803-14	18
1697	Tackling the human adipose tissue proteome to gain insight into obesity and related pathologies. 2009 , 6, 353-61	24
1696	Obesity and metabolic disease. 2009 , 36, 257-70	7
1695	Oligomenorrhoea in exercising women: a polycystic ovarian syndrome phenotype or distinct entity?. 2009 , 39, 1055-69	7

1694	Should we use statins in treatment of polycystic ovary syndrome?. 2009 , 4, 209-211		1
1693	Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome. 2009 , 25, 335-43		35
1692	Polycystic ovary syndrome in the adolescent. 2009 , 36, 129-52		34
1691	ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. 2009 , 114, 936		383
1690	Primary and Secondary Amenorrhea. 2009 , 150-158		
1689	Visceral fat and cardiovascular risk in patients with polycystic ovary syndrome. 2009 , 4, 623-632		
1688	Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 469-76	5.6	54
1687	The Polycystic Ovary Syndrome [Challenges and Opportunities in Adolescent Medicine. 2009 , 316-339		1
1686	Polycystic ovary syndrome. 2009 , 14, 86-95		7
1685	Hyperandrogénie et hirsutisme. 2010 , 7, 1-8		1
1684	Metformin and N-acetyl Cysteine in Polycystic Ovarian Syndrome—A Comparative Study. 2010 , 1, 117739361000100		
1683	Cumulative baby take-home rate among women with PCOS treated by IVF. 2010 , 26, 582-9		9
1682	A study on clinical and sonographic features in obese and nonobese patients with polycystic ovary syndrome. 2010 , 281, 467-71		5
1681	A prospective randomized trial comparing the clinical and endocrinological outcome with rosiglitazone versus laparoscopic ovarian drilling in patients with polycystic ovarian disease resistant to ovulation induction with clomiphene citrate. 2010 , 281, 939-44		25
1680	Polycystic ovaries: review of medical information on the internet for patients. 2010 , 281, 839-43		8
1679	A comparative study on the outcomes of in vitro fertilization between women with polycystic ovary syndrome and those with sonographic polycystic ovary-only in GnRH antagonist cycles. 2010 , 282, 199-205		27
1678	Comparison of metformin and clomiphene citrate therapy for induction of ovulation in the polycystic ovary syndrome. 2010 , 282, 439-43		8
1677	Letrozole versus laparoscopic ovarian diathermy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. 2010 , 282, 567-71		28

1676	Age, body mass index, and serum level of DHEA-S can predict glucocorticoid receptor function in women with polycystic ovary syndrome. 2010 , 37, 129-34	5
1675	Polycystic ovary syndrome. 2010 , 4, 280-4	11
1674	Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. 2010 , 21, 2303-8	110
1673	Androgen- and estrogen-secreting adrenal cancers. 2010 , 37, 638-48	8
1672	Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. 2010 , 8, 41	628
1671	Racial and ethnic disparities in reproductive endocrinology and infertility. 2010 , 202, 413-9	75
1670	Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). 2010 , 11, 12	56
1669	Predictive value of ovarian stroma measurement for cardiovascular risk in polycystic ovary syndrome: a case control study. 2010 , 3, 25	3
1668	Association study of four key folliculogenesis genes in polycystic ovary syndrome. 2010 , 117, 756-60	29
1667	Antiepileptic drugs, sex hormones, and PCOS. 2011 , 52, 199-211	58
1666	The suitability of polycystic ovary syndrome-specific questionnaires for measuring the impact of PCOS on quality of life in clinical trials. 2010 , 13, 440-6	20
1665	The frequency of polycystic ovary syndrome in females with resistant acne vulgaris. 2010 , 9, 142-8	13
1664	The significance of the first Latin American Consensus on polycystic ovary syndrome. 2010 , 64, 536-40	
1663	3D Ultrasonography and infertility. 67-74	
1662	Ultrasonography and the treatment of infertility in polycystic ovary syndrome. 81-86	
1661	Kıo sandara ir policistinikıauıııindromas. 2010 , 46, 142	4
1660	Insulin resistance is not conserved in myotubes established from women with PCOS. 2010 , 5, e14469	22
1659	Acne in adult women: epidemiological, diagnostic and therapeutic aspects. 2010 , 85, 789-95	20

1658	ESPECTRO FENOTIPICO DEL SINDROME DE OVARIO POLIQUSTICO. 2010 , 75,		0
1657	Association of polycystic ovary syndrome and a non-dipping blood pressure pattern in young women. 2010 , 65, 475-9		7
1656	Ethnic variations in the expression of polycystic ovary syndrome. 25-46		2
1655	GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome. 2010 , 163, 55-62		39
1654	Prevalence of polycystic ovary syndrome and related disorders in mexican women. 2010 , 69, 274-80		86
1653	Diabetes in Women. 2010 ,		1
1652	Evaluation of arterial blood pressure and renal sodium handling in a model of female rats in persistent estrus. 2010 , 32, 385-9		3
1651	Statins for women with polycystic ovary syndrome not actively trying to conceive. 2010 ,		1
1650	Evidence for statin therapy in polycystic ovary syndrome. 2010 , 1, 15-22		10
1649	Polycystic ovary syndrome in the pediatric population. 2010 , 8, 375-94		52
1648	Current evidence of acupuncture on polycystic ovarian syndrome. 2010 , 26, 473-8		23
1647	Síndrome de ovario poliquistico e infertilidad. 2010 , 21, 387-396		
1646	Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 3863-70	5.6	49
1645	Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome. 2010 , 162, 1093-9		41
1644	Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 722-30	5.6	104
1643	Current procedures for managing polycystic ovary syndrome. 2010 , 5, 77-91		4
1642	Maitake mushroom (<i>Grifola frondosa</i>) extract induces ovulation in patients with polycystic ovary syndrome: a possible monotherapy and a combination therapy after failure with first-line clomiphene citrate. 2010 , 16, 1295-9		15
1641	Insulin resistance in polycystic ovary syndrome: maker or marker?. 2010 , 5, 67-75		3

1640	The adverse effects of obesity on conception and implantation. 2010 , 140, 347-64		314
1639	Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots. 2010 , 162, 611-5		46
1638	Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. 2010 , 2010, 758656		53
1637	Serological markers of autoimmunity in pregnant women with polycystic ovary syndrome: a pilot study. 2010 , 26, 889-93		3
1636	Is polycystic ovary syndrome an exception for reproductive aging?. 2010 , 25, 1775-81		71
1635	Developmental programming: differential effects of prenatal testosterone excess on insulin target tissues. 2010 , 151, 5165-73		44
1634	Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 343-8	5.6	39
1633	Best practice options for hair removal in patients with unwanted facial hair using combination therapy with laser: guidelines drawn up by an expert working group. 2010 , 221, 34-42		26
1632	Oligoovulatory and anovulatory cycles in women with polycystic ovary syndrome (PCOS): what's the difference?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, E485-9	5.6	26
1631	Metformin during pregnancy in polycystic ovary syndrome: another vitamin bites the dust. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 5199-202	5.6	10
1630	Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndrome. 2010 , 25, 2612-21		23
1629	The role of the polycystic ovary syndrome susceptibility locus D19S884 allele 8 in maternal glycemia and fetal size. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 3242-50	5.6	9
1628	Maternal obesity and associated reproductive consequences. 2010 , 6, 197-203		7
1627	Déistage et prise en charge du déficit en 21-hydroxylase à révélation tardive chez les femmes avec hyperandrogénie. 2010 , 71, e15-e19		0
1626	Detection and management of late-onset 21-hydroxylase deficiency in women with hyperandrogenism. 2010 , 71, 14-8		17
1625	Does the presence of polycystic ovary syndrome increase the risk of obstetrical complications in women with gestational diabetes?. 2010 , 23, 545-9		14
1624	Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. 2010 , 26, 173-8		54
1623	Metabolic abnormalities in adolescents with polycystic ovary syndrome in south China. 2010 , 8, 142		33

1622	Polycystic Ovarian Syndrome in Taiwanese Women. 2010 , 2, 218-223	3
1621	Appropriate BMI levels for PCOS patients in Southern China. 2010 , 25, 1295-302	36
1620	The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. 2010 , 33, 234-8	124
1619	Polycystic Ovarian Syndrome. 2010 , 3, 71-75	4
1618	The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. 2010 , 25, 544-51	1082
1617	Assessment of diagnostic competence of plasmatic androgens on polycystic ovary syndrome based on receiver operator characteristic curves. 2010 , 26, 600-6	8
1616	The role of family history in clinical symptoms and therapeutic outcomes of women with polycystic ovary syndrome. 2010 , 108, 35-9	3
1615	Association of biochemical hyperandrogenism with type 2 diabetes and obesity in Chinese women with polycystic ovary syndrome. 2010 , 108, 148-51	37
1614	Ovarian function and obesity--interrelationship, impact on women's reproductive lifespan and treatment options. 2010 , 316, 172-9	86
1613	Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. 2010 , 82, 139-46	73
1612	Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. 2010 , 93, 880-4	47
1611	Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty. 2010 , 93, 1185-91	42
1610	Calcitropic hormones, insulin resistance, and the polycystic ovary syndrome. 2010 , 93, 1208-14	97
1609	Heart rate recovery improves after weight loss in overweight and obese women with polycystic ovary syndrome. 2010 , 93, 1173-8	15
1608	Predictors of urinary albumin excretion in women with polycystic ovary syndrome. 2010 , 93, 2285-90	10
1607	Increased circulating soluble P-selectin in polycystic ovary syndrome. 2010 , 93, 2311-5	14
1606	Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome. 2010 , 94, 255-60.e1-2	6
1605	Can serum apolipoprotein C-I demonstrate metabolic abnormality early in women with polycystic ovary syndrome?. 2010 , 94, 205-10	25

1604	Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary syndrome. 2010 , 94, 261-7		51
1603	Adipose tissue and reproduction in women. 2010 , 94, 795-825		52
1602	Different phenotypes of polycystic ovary syndrome by Rotterdam criteria are differently steroidogenic but similarly insulin resistant. 2010 , 93, 1362-5		13
1601	Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome). 2010 , 94, 1787-92		29
1600	Epigenetics in polycystic ovary syndrome: a pilot study of global DNA methylation. 2010 , 94, 781-3.e1		77
1599	Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). 2010 , 94, 1118-21		81
1598	Common genetic variation in MTNR1B is associated with serum testosterone, glucose tolerance, and insulin secretion in polycystic ovary syndrome patients. 2010 , 94, 2486-9, 2489.e1-2		12
1597	Variation in metabolic and cardiovascular risk in women with different polycystic ovary syndrome phenotypes. 2010 , 94, 2493-6		62
1596	Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice. 2010 , 94, 2665-9		6
1595	Hirsutism scoring in polycystic ovary syndrome: concordance between clinicians' and patients' self-scoring. 2010 , 94, 2815-6		5
1594	Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: a Mendelian randomization meta-analysis. 2010 , 99, 174-83		42
1593	Metabolism and karyotype analysis of oocytes from patients with polycystic ovary syndrome. 2010 , 25, 2305-15		50
1592	Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS. 2010 , 20, 150-5		37
1591	Serum inhibin A concentration in women with polycystic ovarian syndrome and the correlation to ethnicity, androgens and insulin resistance. 2010 , 20, 675-80		6
1590	Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 2038-49	5.6	669
1589	N-acetyl cysteine plus clomiphene citrate versus metformin and clomiphene citrate in treatment of clomiphene-resistant polycystic ovary syndrome: a randomized controlled trial. 2010 , 19, 2043-8		19
1588	Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor- α . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 935-42	5.6	36
1587	The role of chronic inflammation and Leu55Met PON1 polymorphism in the pathogenesis of polycystic ovary syndrome. 2010 , 26, 673-83		12

1586	Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. 2010 , 26, 743-8		14
1585	The Frequency of Fibromyalgia Syndrome in Patients with Polycystic Ovary Syndrome. 2010 , 18, 120-126		1
1584	Metabolic syndrome in adolescents with polycystic ovary syndrome. 2011 , 27, 820-2		14
1583	Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients. 2011 , 20, 533-8		49
1582	Combined metformin and clomiphene citrate versus highly purified FSH for ovulation induction in clomiphene-resistant PCOS women: a randomised controlled trial. 2011 , 27, 190-6		8
1581	Polycystic ovary syndrome: an overview. 2011 , 24, 94-101		6
1580	Automated screening of Polycystic Ovary Syndrome using machine learning techniques. 2011 ,		15
1579	Implantation failure: molecular mechanisms and clinical treatment. 2011 , 17, 242-53		258
1578	The metabolic aspects of polycystic ovary syndrome. 2011 , 6, 331-341		
1577	Socioeconomic status and polycystic ovary syndrome. 2011 , 20, 413-9		28
1576	Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. 2011 , 26, 1469-77		101
1575	Effects of exercise on insulin resistance and body composition in overweight and obese women with and without polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, E48-56	5.6	126
1574	Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. 2011 , 20, 37-43		40
1573	Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. 2011 , 7, 219-31		775
1572	Acupuncture for polycystic ovarian syndrome. 2011 , CD007689		14
1571	FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. 2011 , 6, e16390		76
1570	Lifestyle changes in women with polycystic ovary syndrome. 2011 , CD007506		160
1569	Statins for women with polycystic ovary syndrome not actively trying to conceive. 2011 , CD008565		26

1568	Achieving a successful pregnancy in women with polycystic ovary syndrome. 2011 , 40, 865-94	5
1567	Ovarian hypertension: polycystic ovary syndrome. 2011 , 40, 433-49, ix-x	51
1566	Endothelial dysfunction in a rat model of PCOS: evidence of increased vasoconstrictor prostanoid activity. 2011 , 152, 4927-36	14
1565	Evaluation of the association between GHR exon 3 polymorphism and polycystic ovary syndrome among Han Chinese women. 2011 , 21, 248-51	7
1564	Periodontal disease in polycystic ovary syndrome. 2011 , 95, 320-3	36
1563	Polycystic ovary syndrome: an ancient disorder?. 2011 , 95, 1544-8	94
1562	Polycystic ovary syndrome and maternal obesity affect oocyte size in in vitro fertilization/intracytoplasmic sperm injection cycles. 2011 , 95, 2146-9, 2149.e1	75
1561	Replication of association of a novel insulin receptor gene polymorphism with polycystic ovary syndrome. 2011 , 95, 1736-41.e1-11	44
1560	Type 2 diabetes susceptibility single-nucleotide polymorphisms are not associated with polycystic ovary syndrome. 2011 , 95, 2538-41.e1-6	25
1559	Lower serum apelin levels in women with polycystic ovary syndrome. 2011 , 95, 2520-3.e1-2	22
1558	Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study. 2011 , 96, 224-229.e2	22
1557	The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome--a double-blind randomized placebo-controlled study. 2011 , 96, 445-451.e1	9
1556	Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome. 2011 , 96, 1043-7	31
1555	Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome. 2011 , 96, 1508-13	82
1554	Determining the normal cut-off levels for hyperandrogenemia in Chinese women of reproductive age. 2011 , 154, 187-91	16
1553	Association of genetic variants in the two isoforms of 5 β -reductase, SRD5A1 and SRD5A2, in lean patients with polycystic ovary syndrome. 2011 , 157, 175-9	23
1552	Dynamics and bifurcation of a model for hormonal control of the menstrual cycle with inhibin delay. 2011 , 234, 95-107	7
1551	The role of low-grade inflammation in the polycystic ovary syndrome. 2011 , 335, 30-41	172

1550	Ghrelin and reproductive disorders. 2011 , 340, 70-9	32
1549	Prevalence of polycystic ovarian syndrome in Indian adolescents. 2011 , 24, 223-7	87
1548	Depression symptoms and body dissatisfaction association among polycystic ovary syndrome women. 2011 , 71, 270-6	58
1547	CYP19 gene expression in subcutaneous adipose tissue is associated with blood pressure in women with polycystic ovary syndrome. 2011 , 76, 1383-8	10
1546	Metabolic syndrome and oocyte quality. 2011 , 22, 103-9	70
1545	Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome. 2011 , 31, 97-103	27
1544	Single Nucleotide Polymorphisms (SNPs) and Variable Number Tandem Repeats (VNTRs) in mtDNA D-loop and CO II- tRNALys Intergenic Region with PCOS. 2011 , 22, 129-138	0
1543	Hirsutismo: diagnóstico y conducta práctica. 2011 , 15, 1-6	
1542	Pharmacological treatment of obesity in patients with polycystic ovary syndrome. 2011 , 2011, 402052	8
1541	Polycystic Ovary Syndrome in Korean Women: Clinical Characteristics and Diagnostic Criteria. 2011 , 26, 203	1
1540	No evidence of benefit for universal screening with 75 g oral glucose tolerance test in polycystic ovary syndrome. 2011 , 195, 578-9	2
1539	Harnessing expression data to identify novel candidate genes in polycystic ovary syndrome. 2011 , 6, e20120	12
1538	Epigenetic mechanism underlying the development of polycystic ovary syndrome (PCOS)-like phenotypes in prenatally androgenized rhesus monkeys. 2011 , 6, e27286	101
1537	Management of Polycystic Ovary Syndrome in the Non-Infertility Patient. 2011 , 31, 1-7	
1536	Management of Polycystic Ovary Syndrome in the Non-Infertility Patient. 2011 , 31, 8	
1535	Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. 2011 , 117, 145-152	140
1534	Hirsutisme: diagnostic et conduite pratique. 2011 , 6, 1-6	
1533	The ovarian dysgenesis syndrome. 2011 , 2, 25-35	52

1532	Lifestyle changes in women with polycystic ovary syndrome. 2011 , CD007506	97
1531	Combined metformin and clomiphene citrate versus laparoscopic ovarian diathermy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. 2011 , 37, 169-77	20
1530	Exercise for the treatment and management of overweight women with polycystic ovary syndrome: a review of the literature. 2011 , 12, e202-10	39
1529	Clinical features and natural history of hepatocellular adenomas: the impact of obesity. 2011 , 34, 664-74	78
1528	Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas heart study. 2011 , 74, 89-96	42
1527	Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. 2011 , 74, 332-9	48
1526	Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. 2011 , 75, 520-7	33
1525	Health-related quality of life and psychological distress in polycystic ovary syndrome: a hidden facet in South Asian women. 2011 , 118, 319-28	34
1524	The role of continuing metformin therapy during pregnancy in the reduction of gestational diabetes and improving pregnancy outcomes in women with polycystic ovary syndrome. 2011 , 16, 204-208	8
1523	Screening for sleep-disordered breathing and excessive daytime sleepiness in adolescent girls with polycystic ovarian syndrome. 2011 , 159, 591-6	35
1522	Systemic inflammation, cellular influx and up-regulation of ovarian VCAM-1 expression in a mouse model of polycystic ovary syndrome (PCOS). 2011 , 92, 33-44	39
1521	State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). 2011 , 2011, 9	45
1520	Physical activity in women with polycystic ovary syndrome: prevalence, predictors, and positive health associations. 2011 , 204, 352.e1-6	28
1519	The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. 2011 , 28, 591-6	27
1518	CAG repeat length polymorphism in the androgen receptor gene and breast cancer risk: data on Indian women and survey from the world. 2011 , 127, 751-60	7
1517	Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate. 2011 , 284, 923-9	15
1516	Does laparoscopic ovarian diathermy change clomiphene-resistant PCOS into clomiphene-sensitive?. 2011 , 284, 503-7	10
1515	Association of metabolic syndrome in polycystic ovarian syndrome: an observational study. 2011 , 61, 176-181	9

1514	Adipose tissue dysfunction in polycystic ovary syndrome. 2011 , 11, 179-84		71
1513	The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study. 2011 , 9, 144		34
1512	The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. 2011 , 9, 39		161
1511	Family association study between INSR gene polymorphisms and PCOS in Han Chinese. 2011 , 9, 76		20
1510	Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. 2011 , 26, 3123-9		322
1509	Intact primary mitochondrial function in myotubes established from women with PCOS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, E1298-302	5.6	25
1508	Hirsutism: causes and treatment for women. 2011 , 20, 985-6, 988, 990		4
1507	Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3493-501	5.6	80
1506	Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, E719-27	5.6	51
1505	Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 2178-85	5.6	67
1504	The effect of vertical sleeve gastrectomy on a rat model of polycystic ovarian syndrome. 2011 , 152, 3700-5		9
1503	Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 1827-34	5.6	72
1502	True and sham acupuncture produced similar frequency of ovulation and improved LH to FSH ratios in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3143-50	5.6	59
1501	Insulin resistance in non-obese women with polycystic ovary syndrome: relation to byproducts of oxidative stress. 2011 , 119, 451-5		38
1500	Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 µg ethinyl estradiol and 2 mg cyproterone acetate. 2011 , 27, 971-7		3
1499	Higher metabolic risk with National Institutes of Health versus Rotterdam diagnostic criteria for polycystic ovarian syndrome in Turkish women. 2011 , 9, 375-80		19
1498	The New Zealand obese mouse model of obesity insulin resistance and poor breeding performance: evaluation of ovarian structure and function. 2011 , 209, 307-15		32
1497	Fatty liver index in polycystic ovary syndrome. 2011 , 165, 935-43		40

1496	Skeletal muscle mitochondrial function in polycystic ovarian syndrome. 2011 , 165, 631-7		18
1495	COMPLICATIONS OF PREGNANCY IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME. 2011 , 22, 188-206		0
1494	An Analysis of Online Resources for Women with Polycystic Ovary Syndrome. 2011 , 15, 361-369		2
1493	Plasma apelin levels in patients with polycystic ovary syndrome. 2012 , 13, 27-31		16
1492	Hemochromatosis, HFE C282Y homozygosity, and polycystic ovary syndrome: report of two cases and possible effects of androgens and hepcidin. 2011 , 126, 138-40		2
1491	Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. 2011 , 165, 789-96		43
1490	Polycystic ovary syndrome: current infertility management. 2011 , 54, 675-84		12
1489	The pluripotential effects of hypolipidemic treatment for polycystic ovary syndrome (PCOS): dyslipidemia, cardiovascular risk factors and beyond. 2011 , 17, 908-21		8
1488	Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 1311-9	5.6	32
1487	First assessment of menstrual cycle function and reproductive endocrine status in Samoan women. 2011 , 26, 2518-24		10
1486	Evidence for increased cardiovascular events in the fathers but not mothers of women with polycystic ovary syndrome. 2011 , 26, 2226-31		17
1485	Exercise therapy in polycystic ovary syndrome: a systematic review. 2011 , 17, 171-83		146
1484	No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight-matched controls. 2011 , 26, 1478-85		39
1483	Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. 2011 , 26, 202-13		97
1482	Effect of short-term standard therapeutic regimens on neuropeptide Y and adipose tissue hormones in overweight insulin-resistant women with polycystic ovary syndrome. 2011 , 53, 15-24		6
1481	Independent predictors of cardiovascular risk in polycystic ovarian syndrome. 2011 , 27, 915-9		7
1480	Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome. 2011 , 27, 609-14		6
1479	Polycystic ovary syndrome and the peripheral blood white cell count. 2011 , 31, 242-4		25

1478	Hirsutism score and the severity of hyperandrogenism associated with polycystic ovary syndrome in the southeastern region of Turkey. 2011 , 39, 1529-35	5
1477	The promoter variant -803 G>A in the RBP4 gene is not associated with BMI, metabolic parameters or blood pressure in Caucasian children. 2011 , 119, 628-32	6
1476	Polycystic ovary syndrome - A metabolic malady, the mother of all lifestyle disorders in women - Can Indian health budget tackle it in future?. 2011 , 15, 239-41	15
1475	Comparison of in vitro fertilisation success in patients with polycystic ovary syndrome and tubal factor. 2011 , 27, 117-20	12
1474	Insulin resistance variability in women with anovulatory and ovulatory polycystic ovary syndrome, and normal controls. 2011 , 43, 141-5	8
1473	Effects of metformin use in pregnant patients with polycystic ovary syndrome. 2012 , 5, 166-9	18
1472	A study on the clinical and hormonal profile of patients with hirsutism. 2012 , 3, 88-91	2
1471	Cardiovascular Risk Factors in Bulgarian Patients with Polycystic Ovary Syndrome and/or Obesity. 2012 , 2012, 306347	9
1470	Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. 2012 , 18, 112-26	103
1469	Metabolomic biomarkers in women with polycystic ovary syndrome: a pilot study. 2012 , 18, 546-53	39
1468	Models and mechanisms of metabolic regulation: genes, stress, and the HPA and HPG axes. 2012 , 44, 598-606	8
1467	Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS. 2012 , 2012, 434830	13
1466	Psychological disturbances and quality of life in obese and infertile women and men. 2012 , 2012, 236217	12
1465	Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. 2012 , 18, 618-37	399
1464	Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome. 2012 , 19, 512-9	22
1463	Association study of CYP17 and HSD11B1 in polycystic ovary syndrome utilizing comprehensive gene coverage. 2012 , 18, 320-4	25
1462	Obesity and PCOS: implications for diagnosis and treatment. 2012 , 30, 496-506	137
1461	Insulin resistant phenotype of polycystic ovary syndrome does not seem to be caused by variation in FTO. 2012 , 44, 810-3	4

1460	High-Sensitivity C-Reactive Protein in Patients with Polycystic Ovary Syndrome. 2012 , 19, 389-396		3
1459	Steroidogenic regulatory factor FOS is underexpressed in polycystic ovary syndrome (PCOS) adipose tissue and genetically associated with PCOS susceptibility. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E1750-7	5.6	16
1458	How do Individuals with Complete Androgen Insensitivity Syndrome, Mayer-Rokitansky-Küster-Hauser Syndrome or Polycystic Ovary Syndrome Experience Contact to Other Affected Persons?. 2012 , 72, 1009-1017		7
1457	Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study. 2012 , 27, 1840-5		46
1456	Comparison of the phenotype of Chinese versus Dutch Caucasian women presenting with polycystic ovary syndrome and oligo/amenorrhoea. 2012 , 27, 1481-8		31
1455	Risk of preterm delivery in non-diabetic women with polycystic ovarian syndrome. 2012 , 32, 770-6		25
1454	Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?. 2012 , 27, 2494-502		89
1453	Minimal stimulation or clomiphene citrate as first-line therapy in women with polycystic ovary syndrome: a randomized controlled trial. 2012 , 28, 87-90		8
1452	Leptin-to-adiponectin, adiponectin-to-leptin ratios, and insulin are specific and sensitive markers associated with polycystic ovary syndrome: a case-control study from Bahrain. 2012 , 10, 98-102		10
1451	Increased frequency of the DI genotype of the angiotensin-I converting enzyme and association of the II genotype with insulin resistance in polycystic ovary syndrome. 2012 , 166, 695-702		13
1450	Clinico-investigative Profile of Patients of Hirsutism in a Tertiary Level Institution. 2012 , 4, 69-74		8
1449	Aloe barbadensis Mill. formulation restores lipid profile to normal in a letrozole-induced polycystic ovarian syndrome rat model. 2012 , 4, 109-15		26
1448	Prediction of metabolic syndrome in women with polycystic ovary syndrome. 2012 , 13, 178-83		5
1447	Study of early atherosclerotic markers in women with polycystic ovary syndrome. 2012 , 16, 1004-8		17
1446	Development of obesity and polycystic ovary syndrome in adolescents. 2012 , 78, 269-78		33
1445	Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome. 2012 , 87, 29		42
1444	Role of the CAG repeat polymorphism of the androgen receptor gene in polycystic ovary syndrome (PCOS). 2012 , 120, 73-9		40
1443	Elevated androgens during puberty in female rhesus monkeys lead to increased neuronal drive to the reproductive axis: a possible component of polycystic ovary syndrome. 2012 , 27, 531-40		61

1442	Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. 2012 , 27, 1209-16		60
1441	Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3951-5	5.6	23
1440	Correlation between Iron Status Parameters and Hormone Levels in Women with Polycystic Ovary Syndrome. 2012 , 5, CMWH.S8780		5
1439	Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation. 2012 , CD001895		13
1438	Androgens and polycystic ovary syndrome. 2012 , 7, 91-102		7
1437	Serum levels of angiopoietin-related growth factor (AGF) are increased in polycystic ovary syndrome. 2012 , 60, 813-7		7
1436	Dysregulation of glucose metabolism even in Chinese PCOS women with normal glucose tolerance. 2012 , 59, 765-70		14
1435	Obesity is the predominant predictor of impaired glucose tolerance and metabolic disturbance in polycystic ovary syndrome. 2012 , 91, 1167-72		20
1434	Associations between psychologic symptoms and life satisfaction in women with polycystic ovary syndrome. 2012 , 21, 179-87		19
1433	Association of fibrillin-3 and transcription factor-7-like 2 gene variants with metabolic phenotypes in PCOS. 2012 , 20, 1273-8		15
1432	Effects of resveratrol on growth and function of rat ovarian granulosa cells. 2012 , 98, 1563-73		37
1431	CD4(+)CD28(null) T lymphocyte frequency, a new marker of cardiovascular risk: relationship with polycystic ovary syndrome phenotypes. 2012 , 98, 1609-15		15
1430	Adipose tissue insulin resistance in peripubertal girls with first-degree family history of polycystic ovary syndrome. 2012 , 98, 1627-34		25
1429	Sleep apnea and epilepsy: who's at risk?. 2012 , 25, 363-7		61
1428	Polycystic Ovary Syndrome: Fertility Management. 2012 , 1, 159-165		
1427	Clinical variability in approaches to polycystic ovary syndrome. 2012 , 25, 259-61		24
1426	Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents. 2012 , 25, 390-5		24
1425	In vitro fertilisation: perinatal risks and early childhood outcomes. 2012 , 15, 62-8		15

1424	Serum myeloperoxidase and adenosine deaminase activities in polycystic ovary syndrome. 2012 , 28, 115-8	8
1423	A comparative study on the impact of fresh variables on the success of frozen-thawed embryo transfer cycles using 2PN sibling embryos in women with/without polycystic ovary syndrome. 2012 , 28, 351-5	5
1422	The influence of obesity on androstenedione to testosterone ratio in women with polycystic ovary syndrome (PCOS) and hyperandrogenemia. 2012 , 28, 249-52	12
1421	Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset. 2012 , 28, 264-8	6
1420	Is subclinical hypothyroidism contributing dyslipidemia and insulin resistance in women with polycystic ovary syndrome?. 2012 , 28, 615-8	32
1419	Obesity at age 20 and the risk of miscarriages, irregular periods and reported problems of becoming pregnant: the Adventist Health Study-2. 2012 , 27, 923-31	19
1418	Serum trace elements and heavy metals in polycystic ovary syndrome. 2012 , 31, 452-6	34
1417	The effects of old, new and emerging medicines on metabolic aberrations in PCOS. 2012 , 3, 27-47	75
1416	Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. 2012 , 27, 3067-73	359
1415	Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. 2012 , 32, 195-201	67
1414	Medical management of metabolic dysfunction in PCOS. 2012 , 77, 306-11	37
1413	Metabolic and cardiovascular genes in polycystic ovary syndrome: a candidate-wide association study (CWAS). 2012 , 77, 317-22	23
1412	Neuroendocrine dysfunction in polycystic ovary syndrome. 2012 , 77, 332-7	106
1411	Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. 2012 , 49, 90-5	136
1410	Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. 2012 , 18, 146-70	281
1409	Angiopoietins/TIE2 system and VEGF are involved in ovarian function in a DHEA rat model of polycystic ovary syndrome. 2012 , 153, 3446-56	42
1408	Dysbiosis of Gut Microbiota (DOGMA)--a novel theory for the development of Polycystic Ovarian Syndrome. 2012 , 79, 104-12	108
1407	Exercise and sedentary habits among adolescents with PCOS. 2012 , 25, 172-4	23

1406	Association between polycystic ovarian syndrome, overweight, and metabolic syndrome in adolescents. 2012 , 25, 208-12	31
1405	The expression of sex steroid synthesis and inactivation enzymes in subcutaneous adipose tissue of PCOS patients. 2012 , 132, 120-6	43
1404	Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters. 2012 , 97, 218-24	48
1403	The risk of gestational diabetes mellitus among Mexican women with a history of infertility and polycystic ovary syndrome. 2012 , 97, 1467-71	32
1402	ADIPOQ gene polymorphisms and susceptibility to polycystic ovary syndrome: a HuGE survey and meta-analysis. 2012 , 161, 117-24	10
1401	Polycystic ovary syndrome and diabetes screening: a survey of gynecologists and reproductive endocrinologists. 2012 , 162, 178-81	7
1400	Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. 2012 , 33, 981-1030	928
1399	Altered glucose disposition and insulin sensitivity in peri-pubertal first-degree relatives of women with polycystic ovary syndrome. 2012 , 2012, 14	11
1398	Polycystic ovary syndrome resembling histopathological alterations in ovaries from prenatal androgenized female rats. 2012 , 5, 15	19
1397	Adrenocortical steroid response to ACTH in different phenotypes of non-obese polycystic ovary syndrome. 2012 , 5, 42	6
1396	Abnormal expression of genes involved in inflammation, lipid metabolism, and Wnt signaling in the adipose tissue of polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E765-70	5.6 54
1395	The prevalence of metabolic syndrome in clomiphene citrate resistant polycystic ovary syndrome. 2012 , 28, 365-9	3
1394	Prevalence of polycystic ovary syndrome among the privately insured, United States, 2003-2008. 2012 , 207, 299.e1-7	21
1393	Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008. 2012 , 207, 377.e1-8	39
1392	The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. 2012 , 86, 268-75	22
1391	Association of polycystic ovary syndrome susceptibility single nucleotide polymorphism rs2479106 and PCOS in Caucasian patients with PCOS or hirsutism as referral diagnosis. 2012 , 163, 39-42	36
1390	Markers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome. 2012 , 164, 161-6	13
1389	Association study of gene LPP in women with polycystic ovary syndrome. 2012 , 7, e46370	4

1388	Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3251-60	5.6	94
1387	Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications. 2012 , 46, 403-18		18
1386	Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome. 2012 , 28, 245-8		12
1385	Analysis of mitochondrial DNA sequence variants in patients with polycystic ovary syndrome. 2012 , 286, 653-9		23
1384	Polycystic ovarian syndrome: role of imaging in diagnosis. 2012 , 32, 1643-57		27
1383	CAG repeat polymorphism of androgen receptor gene and X-chromosome inactivation in daughters of women with polycystic ovary syndrome (PCOS): relationship with endocrine and metabolic parameters. 2012 , 28, 516-20		9
1382	Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. 2012 , 42, 694-9		42
1381	Establishment of polycystic ovary syndrome-derived human embryonic stem cell lines. 2012 , 28, 25-8		5
1380	Polycystic ovary syndrome: why there is no cure. 2012 , 7, 475-477		2
1379	Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome. 2012 , 13, 1307-12		41
1378	Diagnosis and management of endometrial hyperplasia. 2012 , 19, 562-71		71
1377	Evaluation of body fat distribution in PCOS and its association with carotid atherosclerosis and insulin resistance. 2012 , 28, 111-4		44
1376	Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare. 2012 , 10, 96		23
1375	Adipocyte dysfunction in a mouse model of polycystic ovary syndrome (PCOS): evidence of adipocyte hypertrophy and tissue-specific inflammation. 2012 , 7, e48643		20
1374	Parents' Readiness to Change Affects BMI Reduction Outcomes in Adolescents with Polycystic Ovary Syndrome. 2012 , 2012, 298067		15
1373	Hyperandrogenism in Women: Polycystic Ovary Syndrome. 2012 , 32, 197		3
1372	Association between metabolic syndrome and premicroalbuminuria among Iranian women with Polycystic Ovary Syndrome: a case control study. 2012 , 5, 187-92		7
1371	Appetite Regulatory Peptides and Insulin Resistance. 2012 ,		1

- 1370 Study on the influence of adiponectin genetic variants and adiponectin levels among Indonesian women with polycystic ovary syndrome. **2012**, 83
- 1369 Polycystic Ovary Syndrome in the Non-Gynaecological Practice [Can We Use a Common Medical Approach?. **2012**,
- 1368 Sensitive and specific markers for insulin resistance, hyperandrogenemia, and inappropriate gonadotrophin secretion in women with polycystic ovary syndrome: a case-control study from Bahrain. **2012**, 4, 201-6 8
- 1367 Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. **2012**, 39, 341-7 38
- 1366 Association of thrombophilia and polycystic ovarian syndrome in women with history of recurrent pregnancy loss. **2012**, 28, 590-3 9
- 1365 High Risk, High Stakes: Optimizing Cardiovascular Risk Assessment in Women. **2012**, 6, 176-184
- 1364 Clomiphene citrate alternatives for the initial management of polycystic ovary syndrome: an evidence-based approach. **2012**, 285, 1737-45 21
- 1363 Histological evaluation of rat larynx in experimental polycystic ovary syndrome model. **2012**, 269, 1945-50 5
- 1362 Endocrine and metabolic characteristics of polycystic ovary syndrome in Chinese women with different phenotypes. **2012**, 76, 425-30 16
- 1361 Sexual function in women with polycystic ovary syndrome. **2012**, 9, 224-30 38
- 1360 Catechol-O-methyltransferase (COMT) single nucleotide polymorphisms and haplotypes are not major risk factors for polycystic ovary syndrome. **2012**, 350, 72-7 2
- 1359 Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome. **2012**, 42, 321-8 24
- 1358 Factors affecting the degree of hirsutism in patients with polycystic ovary syndrome. **2012**, 285, 767-70 10
- 1357 Unilateral or bilateral vagotomy induces ovulation in both ovaries of rats with polycystic ovarian syndrome. **2013**, 11, 68 18
- 1356 Ovulation induction in women with polycystic ovary syndrome. **2013**, 78, 767-72 34
- 1355 Pelvic floor muscle strength and urinary incontinence in hyperandrogenic women with polycystic ovary syndrome. **2013**, 24, 1709-14 7
- 1354 Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes. **2013**, 100, 1081-8 44
- 1353 Genetic variants associated with insulin signaling and glucose homeostasis in the pathogenesis of insulin resistance in polycystic ovary syndrome: a systematic review. **2013**, 30, 883-95 18

1352	Association study between FSHR Ala307Thr and Ser680Asn variants and polycystic ovary syndrome (PCOS) in Northern Chinese Han women. 2013 , 30, 717-21	20
1351	Three decades after Gjønaess's laparoscopic ovarian drilling for treatment of PCOS; what do we know? An evidence-based approach. 2013 , 288, 409-22	42
1350	Update in polycystic ovary syndrome: new criteria of diagnosis and treatment in Japan. 2013 , 12, 71-77	33
1349	Polycystic Ovary Syndrome Across Racial and Ethnic Groups. 2013 , 185-199	
1348	Studies on Women's Health. 2013 ,	5
1347	miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. 2013 , 62, 2278-86	177
1346	Evaluating reported candidate gene associations with polycystic ovary syndrome. 2013 , 99, 1774-8	17
1345	Hydrocarbons (jet fuel JP-8) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. 2013 , 36, 104-16	175
1344	Ethnic differences in the phenotypic expression of polycystic ovary syndrome. 2013 , 78, 755-60	86
1343	Polycystic ovary syndrome and nonalcoholic fatty liver in obese adolescents: association with metabolic risk profile. 2013 , 100, 1745-51	22
1342	[Biological insulin resistance in Congolese woman with polycystic ovary syndrome (PCOS)]. 2013 , 41, 707-10	5
1341	Circulating high-sensitivity C-reactive protein and soluble CD40 ligand are inter-related in a cohort of women with polycystic ovary syndrome. 2013 , 168, 178-82	12
1340	Biological correlates of major depression and generalized anxiety disorder in women with polycystic ovary syndrome. 2013 , 74, 244-7	34
1339	Proteomics and polycystic ovary syndrome. 2013 , 10, 435-47	19
1338	Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4655-63	5.6 117
1337	Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4565-92	5.6 1000
1336	Ovarian cystic lesions: a current approach to diagnosis and management. 2013 , 51, 1067-85	14
1335	Increased frequency of the anti-mullerian-inhibiting hormone receptor 2 (AMHR2) 482 A>G polymorphism in women with polycystic ovary syndrome: relationship to luteinizing hormone levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1866-70	5.6 13

1334	High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome. 2013 , 169, 248-51		46
1333	Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. 2013 , 87, 358-62		39
1332	[Hyperandrogenism in women]. 2013 , 42, 1487-99		7
1331	Active and passive smoking and the risk of myocardial infarction in 24,968 men and women during 11 year of follow-up: the Tromsø Study. 2013 , 28, 659-67		51
1330	An interleukin-6 gene promoter polymorphism is associated with polycystic ovary syndrome in South Indian women. 2013 , 30, 1541-6		33
1329	DHEA-mediated inhibition of the pentose phosphate pathway alters oocyte lipid metabolism in mice. 2013 , 154, 4835-44		32
1328	Basal and meal-stimulated ghrelin, PYY, CCK levels and satiety in lean women with polycystic ovary syndrome: effect of low-dose oral contraceptive. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4475-82	5.6	18
1327	Differences in the management of adolescents with polycystic ovary syndrome across pediatric specialties. 2013 , 26, 234-8		28
1326	Evaluation of ovarian function in 35-40-year-old women with polycystic ovary syndrome. 2013 , 170, 165-70		4
1325	Genetic investigation into ethnic disparity in polycystic ovarian syndrome. 2013 , 29, 878-82		3
1324	Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4798-807	5.6	67
1323	Accurate screening for insulin resistance in PCOS women using fasting insulin concentrations. 2013 , 29, 541-4		18
1322	Body mass index at age 20 and subsequent childbearing: the Adventist Health Study-2. 2013 , 22, 460-6		9
1321	Different phenotypes of polycystic ovary syndrome in Turkish women: clinical and endocrine characteristics. 2013 , 29, 931-5		16
1320	Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI. 2013 , 14, 42-9		40
1319	Association between inflammatory biomarker serum procalcitonin and obesity in women with polycystic ovary syndrome. 2013 , 97, 232-9		22
1318	Twenty years of endocrinologic treatment in transsexualism: analyzing the role of chromosomal analysis and hormonal profiling in the diagnostic work-up. 2013 , 100, 1103-10		27
1317	Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index. 2013 , 99, 1786-90		8

1316	White blood cell differential counts in patients with polycystic ovary syndrome: a pilot study on Chinese women. 2013 , 170, 162-4		8
1315	Does supplementation of in-vitro culture medium with melatonin improve IVF outcome in PCOS?. 2013 , 26, 22-9		73
1314	Increased expression of P450scc and CYP17 in development of endogenous hyperandrogenism in a rat model of PCOS. 2013 , 43, 184-90		24
1313	Neuroendocrine considerations in the treatment of men and women with epilepsy. 2013 , 12, 72-83		86
1312	Transitory activation of the central and ovarian norepinephrine systems during cold stress-induced polycystic ovary in rats. 2013 , 25, 23-33		9
1311	The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. 2013 , 14, 95-109		254
1310	Proteomic and metabolomic approaches to the study of polycystic ovary syndrome. 2013 , 370, 65-77		39
1309	Sexual dysfunction assessment and hormonal correlations in patients with polycystic ovary syndrome. 2013 , 25, 127-32		38
1308	The Polycystic Ovary Syndrome and recent human evolution. 2013 , 373, 39-50		50
1307	Metabolic complications of obesity. 2013 , 27, 179-93		34
1306	Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1088-96	5.6	100
1305	Study of carbohydrate metabolism indices and adipocytokine profile and their relationship with androgens in polycystic ovary syndrome after menopause. 2013 , 168, 83-90		11
1304	The relationship between insulin resistance and CpG island methylation of LMNA gene in polycystic ovary syndrome. 2013 , 67, 1041-7		12
1303	Plasma selenium levels in Turkish women with polycystic ovary syndrome. 2013 , 168, 183-6		43
1302	PCOS: perspectives from a pediatric endocrinologist and a pediatric gynecologist. 2013 , 43, 104-13		3
1301	Ontogeny of polycystic ovary syndrome and insulin resistance in utero and early childhood. 2013 , 100, 2-11		46
1300	Metformin treatment in different phenotypes of polycystic ovary syndrome. 2013 , 288, 1131-6		4
1299	Interventions for the metabolic dysfunction in polycystic ovary syndrome. 2013 , 78, 777-81		13

1298	Should the ketogenic diet be considered for enhancing fertility?. 2013 , 74, 10-3		12
1297	Tear osmolarity and ocular surface changes in patient with polycystic ovary syndrome. 2013 , 38, 621-5		16
1296	Screening for diabetes and cardiometabolic disease in women with polycystic ovary syndrome. 2013 , 13, 115-123		2
1295	Genotype-phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women. 2013 , 28, 538-44		76
1294	Definition criteria and diagnostic assessments. 2013 , 6-19		
1293	Familial aggregation of circulating C-reactive protein in polycystic ovary syndrome. 2013 , 28, 770-6		3
1292	Prevalence of hyperandrogenic states in late adolescent and young women: epidemiological survey on italian high-school students. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 1641-50	5.6	30
1291	Dietary intake, glucose metabolism and sex hormones in women with polycystic ovary syndrome (PCOS) compared with women with non-PCOS-related infertility. 2013 , 109, 2190-8		19
1290	Effects of endogenous androgens and abdominal fat distribution on the interrelationship between insulin and non-insulin-mediated glucose uptake in females. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 1541-8	5.6	23
1289	Research resource: the Endometrium Database Resource (EDR). 2013 , 27, 548-54		
1288	CYP21A2 mutations in women with polycystic ovary syndrome (PCOS). 2013 , 45, 383-6		4
1287	[A questionnaire for the assessment of women's perception of their own femininity: a study on women with Mayer-Rokitansky-Kuster-Hauser-syndrome and women with polycystic ovary syndrome]. 2013 , 63, 334-40		2
1286	Evaluation of lipid parameters and family history of diabetes mellitus in polycystic ovary syndrome. 2013 , 40, 414-417		
1285	Lipid accumulation product is related to metabolic syndrome in women with polycystic ovary syndrome. 2013 , 121, 115-8		26
1284	Polycystic ovarian syndrome. 2013 , 79, 310-21		21
1283	Prevalence of hepatic steatosis in women with polycystic ovary syndrome. 2013 , 6, 9-14		30
1282	Anthropometric characteristics and dietary pattern of women with polycystic ovary syndrome. 2013 , 17, 672-6		28
1281	Lack of association between C385A functional polymorphism of the fatty acid amide hydrolase gene and polycystic ovary syndrome. 2013 , 121, 338-42		4

1280	Exercise training in polycystic ovarian syndrome enhances flow-mediated dilation in the absence of changes in fatness. 2013 , 45, 2234-42	26
1279	Effects of polycystic ovary syndrome and menopause on rat soft palate and base of tongue. 2013 , 148, 595-601	5
1278	Analysis of the vascular responses in a murine model of polycystic ovary syndrome. 2013 , 218, 205-13	11
1277	Know your Enemy: The Rationale of Using Inositol in the Treatment of Polycystic Ovary Syndrome. 2013 , 02,	
1276	Abdominal obesity is associated with a lower ankle-brachial index in women with polycystic ovary syndrome. 2013 , 64, 105-11	2
1275	Do in utero events contribute to current health disparities in reproductive medicine?. 2013 , 31, 325-32	4
1274	Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. 2013 , 21, 1526-32	167
1273	Nitric oxide-mediated cutaneous microvascular function is impaired in polycystic ovary syndrome but can be improved by exercise training. 2013 , 591, 1475-87	31
1272	Human infertility: are endocrine disruptors to blame?. 2013 , 2, R15-29	75
1271	Clinical Roundup: Selected Treatment Options for Polycystic Ovary Syndrome. 2013 , 19, 101-106	
1270	Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone. 2013 , 29, 474-7	11
1269	Association between the (TAAAA)n SHBG polymorphism and PCOS: a systematic review and meta-analysis. 2013 , 29, 645-50	10
1268	Sensitization of endocrine organs to anterior pituitary hormones by the autonomic nervous system. 2013 , 117, 37-44	14
1267	Prevalencia e incidencia de los principales trastornos endocrinos y metabólicos. 2013 , 24, 735-741	2
1266	Correlation between plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G polymorphism and metabolic/proinflammatory factors in polycystic ovary syndrome. 2013 , 29, 936-9	11
1265	Phosphorylation of human cytochrome P450c17 by p38 β selectively increases 17,20 lyase activity and androgen biosynthesis. 2013 , 288, 23903-13	45
1264	Maternal prenatal weight gain and autism spectrum disorders. 2013 , 132, e1276-83	65
1263	Glucose metabolism in obese and lean adolescents with polycystic ovary syndrome. 2013 , 26, 319-24	5

1262	Polycystic ovary syndrome in adolescents: (women's health series). 2013 , 106, 570-6	6
1261	Effects of insulin-sensitizing agents and insulin resistance in women with polycystic ovary syndrome. 2013 , 40, 100-5	14
1260	New insights into steroidogenesis in normo- and hyperandrogenic polycystic ovary syndrome patients. 2013 , 57, 437-44	20
1259	[Contribution of hyperandrogenism to the development of metabolic syndrome in obese women with polycystic ovary syndrome]. 2013 , 35, 562-8	2
1258	Polycystic ovary syndrome: clinical presentation in normal-weight compared with overweight adolescents. 2013 , 19, 471-8	5
1257	[Clinical manifestations, biochemical, ultrasonographic and metabolic of polycystic ovary syndrome in adolescents]. 2013 , 35, 249-54	10
1256	Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment. 2013 , 13, 180-5	21
1255	Menstruation and Menstrual Disorders. 2013 , 163-177	2
1254	Genome-wide methylated DNA immunoprecipitation analysis of patients with polycystic ovary syndrome. 2013 , 8, e64801	30
1253	Common variant rs9939609 in gene FTO confers risk to polycystic ovary syndrome. 2013 , 8, e66250	29
1252	Downregulated expression of peroxiredoxin 4 in granulosa cells from polycystic ovary syndrome. 2013 , 8, e76460	14
1251	Epidemiology, diagnosis, and management of polycystic ovary syndrome. 2013 , 6, 1-13	670
1250	Extended high frequency audiometry in polycystic ovary syndrome. 2013 , 2013, 482689	11
1249	Correlation between Expression of Glucose Transporters in Granulosa Cells and Oocyte Quality in Women with Polycystic Ovary Syndrome. 2014 , 29, 40-7	20
1248	BMI-associated alleles do not constitute risk alleles for polycystic ovary syndrome independently of BMI: a case-control study. 2014 , 9, e87335	13
1247	The local effects of ovarian diathermy in an ovine model of polycystic ovary syndrome. 2014 , 9, e111280	9
1246	Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. 2014 , 2014, 719050	150
1245	Optimal management of subfertility in polycystic ovary syndrome. 2014 , 6, 613-21	5

1244	Cellular reprogramming for understanding and treating human disease. 2014 , 2, 67	26
1243	Aldehyde dehydrogenase 1A1: friend or foe to female metabolism?. 2014 , 6, 950-73	28
1242	Prolactin in Human Reproduction. 2014 , 45-65.e11	4
1241	Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. 2014 , 20, 14172-84	54
1240	FTO Gene Variants Are Associated with PCOS Susceptibility and Hyperandrogenemia in Young Korean Women. 2014 , 38, 302-10	18
1239	Effects of a Combination of Alpha Lipoic Acid and Myo-Inositol on Insulin Dynamics in Overweight/Obese Patients with PCOS. 2014 , 03,	15
1238	Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS). 2014 , 13, 213-21	21
1237	A Comparative Study between GnRH Antagonist and Long Agonist Protocols in Patients with Polycystic Ovarian Syndrome (PCOS) Undergoing in vitro Fertilization. 2014 , 03,	
1236	Does Polycystic Ovarian Syndrome Increase Insulin Resistance Above and Beyond Obesity?. 2014 , 03,	
1235	Relationship between flavonoids intake and metabolic syndrome in Korean women with polycystic ovary syndrome. 2014 , 47, 176	4
1234	Low Frequency Electro-Acupuncture and Physical Exercise Induces Menstruation in A Young Woman with Amenorrhea Related to Polycystic Ovary Syndrome: A Case Report. 2014 , 03,	
1233	Obesidade e síndrome dos ovários policísticos: vínculo fisiopatológico e impacto no fenótipo das pacientes. 2014 , 13,	0
1232	Handbook of diet and nutrition in the menstrual cycle, periconception and fertility. 2014 ,	5
1231	The influence of combined oral contraceptives containing drospirenone on hypothalamic-pituitary-adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome. 2015 , 14, 109-17	5
1230	White blood cells levels and PCOS: direct and indirect relationship with obesity and insulin resistance, but not with hyperandrogenemia. 2015 , 14, 91-100	11
1229	Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome. 2014 , 290, 1023-30	30
1228	Research Profile of Polycystic Ovary Syndrome—A Bibliometric Perspective of Literatures from 1984-2013. 2014 , 8, 311-327	
1227	Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. 2014 , 30, 205-8	65

1226	Association of Gly972Arg variant of insulin receptor substrate-1 and Gly1057Asp variant of insulin receptor substrate-2 with polycystic ovary syndrome in the Chinese population. 2014 , 7, 92	8
1225	Excess of nerve growth factor in the ovary causes a polycystic ovary-like syndrome in mice, which closely resembles both reproductive and metabolic aspects of the human syndrome. 2014 , 155, 4494-506	13
1224	Eine interdisziplinäre Herausforderung. 2014 , 19, 36-44	
1223	The impact of self-reported ethnicity versus genetic ancestry on phenotypic characteristics of polycystic ovary syndrome (PCOS). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E2107-16 ^{5.6}	15
1222	Fibroblast growth factor 21 and its relation to metabolic parameters in women with polycystic ovary syndrome. 2014 , 74, 465-9	13
1221	High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS). 2014 , 30, 781-4	17
1220	A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. 2014 , 18, 317-24	64
1219	Hypoxanthine Guanine Phosphoribosyl Transferase Is the Most Stable Reference Gene for Gene Expression Analysis by Quantitative PCR in Peripheral Blood Mononuclear Cells from Women with the Polycystic Ovary Syndrome. 2014 , 33, 356-363	1
1218	Association between follicular fluid leptin and serum insulin levels in nonoverweight women with polycystic ovary syndrome. 2014 , 2014, 980429	5
1217	Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition. 2014 , 126, 67-74	26
1216	Lower cocaine- and amphetamine-regulated transcript levels pose a risk for developing PCOS. 2014 , 46, 702-6	1
1215	Spironolactone and dimethylsulfoxide effect on glucose metabolism and oxidative stress markers in polycystic ovarian syndrome rat model. 2014 , 122, 154-62	12
1214	Children's Hospital Association consensus statements for comorbidities of childhood obesity. 2014 , 10, 304-17	52
1213	Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review. 2014 , 14, 93	34
1212	Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome. 2014 , 29, 518-24	12
1211	The polycystic ovary syndrome evolutionary paradox: a genome-wide association studies-based, in silico, evolutionary explanation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E2412-20 ^{5.6}	38
1210	Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome. 2014 , 16, 545-52	10
1209	Lifestyle modification intervention among infertile overweight and obese women with polycystic ovary syndrome. 2014 , 26, 301-8	23

1208	Obesity, metabolic syndrome, and disorders of energy balance. 2014 , 956-1014.e1	2
1207	Impact of sleep-disordered breathing on metabolic dysfunctions in patients with polycystic ovary syndrome. 2014 , 15, 1547-53	26
1206	Adrenal androgens and androgen precursors-definition, synthesis, regulation and physiologic actions. 2014 , 4, 1369-81	50
1205	Polycystic ovary syndrome in Iranian adolescents. 2014 , 26, 559-65	12
1204	Prevalence and predictors of metabolic abnormalities in Chinese women with PCOS: a cross-sectional study. 2014 , 14, 76	27
1203	Exploring the potential association between brominated diphenyl ethers, polychlorinated biphenyls, organochlorine pesticides, perfluorinated compounds, phthalates, and bisphenol A in polycystic ovary syndrome: a case-control study. 2014 , 14, 86	69
1202	Free testosterone: clinical utility and important analytical aspects of measurement. 2014 , 63, 59-84	42
1201	Ovulation induction in nonobese polycystic ovary syndrome women supplemented with Doppler studies. 2014 , 4, 211-213	
1200	Impact of obesity on intracytoplasmic sperm injection outcome in polycystic ovarian syndrome patients. 2014 , 4, 108-111	
1199	Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population. 2014 , 62, 868-74	37
1198	Studies of cardiovascular risk factors in polycystic ovary syndrome patients combined with subclinical hypothyroidism. 2014 , 30, 553-6	10
1197	Obesity, Metabolic Dysfunction, and Inflammation in Polycystic Ovary Syndrome. 2014 , 117-144	3
1196	The impact of obesity on clinical, metabolic and hormonal features in patients with polycystic ovary syndrome. 2014 , 5,	
1195	Diagnostic evaluation of patients presenting with hirsutism. 2014 , 5,	
1194	Intrauterine environment and polycystic ovary syndrome. 2014 , 32, 159-65	65
1193	Persistent environmental pollutants and couple fecundity: an overview. 2014 , 147, R97-R104	27
1192	Prevalence of the polycystic ovary syndrome in female residents of Chengdu, China. 2014 , 77, 217-23	27
1191	Long-term use of methamphetamine disrupts the menstrual cycles and hypothalamic-pituitary-ovarian axis. 2014 , 8, 183-8	9

1190	Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. 2014 , 27, 177-82	18
1189	Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria. 2014 , 101, 1135-1141.e2	39
1188	Prevalence of hyperandrogenism and polycystic ovary syndrome in female to male transsexuals. 2014 , 61, 351-8	16
1187	Effect of body mass index on in vitro fertilization outcomes in women with polycystic ovary syndrome. 2014 , 211, 163.e1-6	35
1186	Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. 2014 , 101, 1129-34	37
1185	The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. 2014 , 80, 425-31	49
1184	Modeling endocrine control of the pituitary-ovarian axis: androgenic influence and chaotic dynamics. 2014 , 76, 136-56	10
1183	Clinical evidence of statin therapy in non-dyslipidemic disorders. 2014 , 88, 20-30	16
1182	Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients. 2014 , 101, 1757-65.e1	22
1181	Epicardial adipose tissue thickness and NGAL levels in women with polycystic ovary syndrome. 2014 , 7, 24	6
1180	A study on prevalence of abnormal glucose tolerance and correlation of insulin resistance with dyslipidemia in South-Indian women with polycystic ovary syndrome. 2014 , 34, 188-192	0
1179	Pregnancy complications and metabolic disease in women with clomiphene citrate-resistant anovulation randomized to receive laparoscopic electrocautery of the ovaries or ovulation induction with gonadotropins: a 10-year follow-up. 2014 , 101, 270-4	12
1178	Azelaic acid in the treatment of acne in adult females: case reports. 2014 , 27 Suppl 1, 18-25	13
1177	High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: a randomized, controlled pilot trial. 2014 , 101, 1740-6	49
1176	Current insights into gonadotropic pituitary function in the polycystic ovary syndrome. 2014 , 3, 64-70	1
1175	Polycystic ovary syndrome. 2014 , 43, 123-47	64
1174	Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. 2014 , 20, 748-58	261
1173	Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 1027-36	5.6 183

1172	The inflammatory gene pathway is not a major contributor to polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E567-71	5.6	7
1171	Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome. 2014 , 29, 1508-17		33
1170	The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. 2014 , 29, 791-801		162
1169	Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E447-52	5.6	91
1168	Polycystic Ovary Syndrome. 2014 ,		1
1167	Bisphenol A (BPA) and its potential role in the pathogenesis of the polycystic ovary syndrome (PCOS). 2014 , 30, 260-5		48
1166	Role of Statins in PCOS Management. 2014 , 181-203		0
1165	Endocrine autoimmune diseases and female infertility. 2014 , 10, 37-50		70
1164	Advanced glycation end products and their relevance in female reproduction. 2014 , 29, 135-45		76
1163	Common polymorphisms of calpain-10 and the risk of polycystic ovary syndrome in Tunisian population: a case-control study. 2014 , 41, 6569-74		6
1162	Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome. 2014 , 27, 347-52		22
1161	Modeling endocrine regulation of the menstrual cycle using delay differential equations. 2014 , 257, 11-22		4
1160	Elevated serum chemerin in Chinese women with hyperandrogenic PCOS. 2014 , 30, 746-50		13
1159	Early embryonic androgen exposure induces transgenerational epigenetic and metabolic changes. 2014 , 28, 1329-36		48
1158	Serum metabolomics study of polycystic ovary syndrome based on liquid chromatography-mass spectrometry. 2014 , 13, 1101-11		61
1157	Trp28Arg/Ile35Thr LHB gene variants are associated with elevated testosterone levels in women with polycystic ovary syndrome. 2014 , 550, 68-73		9
1156	Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations. 2014 , 71, 847.e1-847.e10; quiz 857-8		41
1155	Complement protein C3 and coronary artery calcium in middle-aged women with polycystic ovary syndrome and controls. 2014 , 30, 511-5		10

1154	Intraindividual right-left comparison of sonographic features in polycystic ovary syndrome (PCOS) diagnosis. 2014 , 181, 124-9		5
1153	In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome. 2014 , 29, 545-51		27
1152	Expression of anti-Müllerian hormone in letrozole rat model of polycystic ovary syndrome. 2014 , 30, 885-9		7
1151	Evaluation of the Macula, Retinal Nerve Fiber Layer, and Choroid Thickness in Women With Polycystic Ovary Syndrome Using Spectral-Domain Optical Coherence Tomography. 2014 , 21, 1044-1049		10
1150	Psychological aspects of the polycystic ovary syndrome. 2014 , 30, 95-9		17
1149	Prevalence of hyperandrogenism and polycystic ovary syndrome in female to male transsexuals. 2014 , 61, 351-358		7
1148	Bifurcation analysis of a menstrual cycle model reveals multiple mechanisms linking testosterone and classical PCOS. 2014 , 361, 31-40		4
1147	The VEGF +405 G>C 5' untranslated region polymorphism and risk of PCOS: a study in the South Indian Women. 2014 , 31, 1383-9		26
1146	Contraception use and pregnancy outcomes in women with polycystic ovary syndrome: data from the Australian Longitudinal Study on Women's Health. 2014 , 29, 802-8		46
1145	Hypomethylation of the LH/choriogonadotropin receptor promoter region is a potential mechanism underlying susceptibility to polycystic ovary syndrome. 2014 , 155, 1445-52		52
1144	The expression of the miR-25/93/106b family of micro-RNAs in the adipose tissue of women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E2754-61	5.6	25
1143	Platelet-derived growth factor BB and DD and angiopoietin1 are altered in follicular fluid from polycystic ovary syndrome patients. 2014 , 81, 748-56		23
1142	Evidence for decreased expression of ADAMTS-1 associated with impaired oocyte quality in PCOS patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E1015-21	5.6	28
1141	The association between androgen receptor gene CAG polymorphism and polycystic ovary syndrome: a case-control study and meta-analysis. 2014 , 31, 1211-9		19
1140	Genetic variants of the HSD11B1 gene promoter may be protective against polycystic ovary syndrome. 2014 , 41, 5961-9		5
1139	Testosterone treatment increases androgen receptor and aromatase gene expression in myotubes from patients with PCOS and controls, but does not induce insulin resistance. 2014 , 451, 622-6		13
1138	The effect of obesity on inflammatory markers in patients with PCOS: a BMI-matched case-control study. 2014 , 290, 315-9		44
1137	Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial. 2014 , 290, 321-8		26

1136	Lack of association of INS VNTR polymorphism with polycystic ovary syndrome: a meta-analysis. 2014 , 31, 675-81	8
1135	Differential genes in adipocytes induced from polycystic and non-polycystic ovary syndrome-derived human embryonic stem cells. 2014 , 60, 136-42	2
1134	Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy. 2014 , 20, 905-23	43
1133	Berberine and monacolin effects on the cardiovascular risk profile of women with oestrogen-induced hypercholesterolemia. 2014 , 21, 221-6	11
1132	Polycystic ovary syndrome: update on diagnosis and treatment. 2014 , 127, 912-9	77
1131	Hospital-based prevalence of polycystic ovarian syndrome among Omani women. 2014 , 19, 135-138	5
1130	The efficacy of converting high response Ovulation induction cycles to in vitro fertilization in patients with PCOS. 2014 , 19, 51-56	1
1129	Cluster analysis of cardiovascular and metabolic risk factors in women of reproductive age. 2014 , 101, 1404-10	32
1128	Normal cut-off values for hyperandrogenaemia in Iranian women of reproductive age. 2014 , 172, 51-5	13
1127	Maternal characteristics and pregnancy outcomes after assisted reproductive technology by infertility diagnosis: ovulatory dysfunction versus tubal obstruction. 2014 , 101, 1019-25	20
1126	Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study. 2014 , 101, 1123-8.e1	46
1125	To what extent does the use of the Rotterdam criteria affect the prevalence of polycystic ovary syndrome? A community-based study from the Southwest of Iran. 2014 , 174, 100-5	32
1124	Family-based analysis of INSR polymorphisms in Chinese PCOS. 2014 , 29, 239-44	12
1123	Excess mortality in mothers of patients with polycystic ovary syndrome. 2014 , 29, 1780-6	3
1122	Phytotherapy for Polycystic Ovarian Syndrome: A review of the literature and evaluation of practitioners' experiences. 2014 , 4, 159-171	8
1121	Practice Patterns in Screening for Metabolic Disease in Women with PCOS of Diverse Race-Ethnic Backgrounds. 2014 , 20, 855-63	9
1120	A life course perspective on polycystic ovary syndrome. 2014 , 6, 115-22	10
1119	Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. 2014 , 58, 182-7	40

- 1118 Obstructive sleep apnea predisposes to nonalcoholic Fatty liver disease in patients with polycystic ovary syndrome. **2014**, 20, 244-51 22
- 1117 Laser facial hair removal protocol and key consultation considerations. **2014**, 3, 436-441
- 1116 33. Hypocaloric diets in overweight and obese patients with polycystic ovary syndrome. **2014**, 533-552
- 1115 Reproductive endocrinology and infertility. 187-189
- 1114 Irregular bleeding in a 25-year-old woman. 207-210
- 1113 Effects of combining low-dose aspirin with a Chinese patent medicine on follicular blood flow and pregnancy outcome. **2014**, 10, 2372-6 12
- 1112 Association analysis of SNP-63 and indel-19 variant in the calpain-10 gene with polycystic ovary syndrome in women of reproductive age1. **2015**, 83, 35-42
- 1111 Autonomic dysfunction in patients with polycystic ovary syndrome. **2015**, 54, 381-4 7
- 1110 The Role of Diet and Lifestyle Modification in the Treatment of Polycystic Ovary Syndrome. **2015**, 27-50
- 1109 Diagnosis and Management of Polycystic Ovary Syndrome in Adolescent Girls. **2015**, 44, e223-30 7
- 1108 Metabolomics reveals impaired maturation of HDL particles in adolescents with hyperinsulinaemic androgen excess. **2015**, 5, 11496 10
- 1107 SheHealthy. **2015**, 0
- 1106 Relationship between risk factors for infertility in women and lead, cadmium, and arsenic blood levels: a cross-sectional study from Taiwan. **2015**, 15, 1220 23
- 1105 Interaction between common variants of FTO and MC4R is associated with risk of PCOS. **2015**, 13, 55 13
- 1104 Altered microRNAs expression profiling in cumulus cells from patients with polycystic ovary syndrome. **2015**, 13, 238 39
- 1103 The Obesity-Fertility Protocol: a randomized controlled trial assessing clinical outcomes and costs of a transferable interdisciplinary lifestyle intervention, before and during pregnancy, in obese infertile women. **2015**, 2, 47 12
- 1102 Hirsutism: managing the basics. 1-10
- 1101 Diagnostic criteria of polycystic ovary syndrome. 74-78

1100	Ovulation induction in women with polycystic ovary syndrome. 226-232	
1099	How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?. 2015 , 26, 862-5	5
1098	Ocular blood flow in polycystic ovary syndrome. 2015 , 41, 1080-6	6
1097	Value of ultrasonography in the diagnosis of polycystic ovary syndrome - literature review. 2015 , 15, 410-22	14
1096	Complications and challenges associated with polycystic ovary syndrome: current perspectives. 2015 , 7, 745-63	91
1095	Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. 2015 , 52, 117-23	30
1094	Hyperandrogenism in female athletes with functional hypothalamic amenorrhea: a distinct phenotype. 2015 , 7, 103-11	6
1093	Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. 2015 , 70, 765-9	74
1092	Psychosocial Factors Associated with Polycystic Ovary Syndrome: a Case Control Study. 2015 , 4, 225-31	19
1091	EVALUATION OF PARA- AND PERIRENAL FAT THICKNESS AND ITS ASSOCIATION WITH METABOLIC DISORDERS IN POLYCYSTIC OVARY SYNDROME. 2015 , 21, 878-86	6
1090	Epidemiology and Diagnostic Criteria of Polycystic Ovary Syndrome. 2015 , 16, 189	
1089	MicroRNA-223 Expression is Upregulated in Insulin Resistant Human Adipose Tissue. 2015 , 2015, 943659	64
1088	Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty. 2015 , 58, 1-7	15
1087	Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis. 2015 , 7, 4555-77	109
1086	Advanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS?. 2015 , 7, 10129-44	23
1085	Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome. 2015 , 10, e0126119	18
1084	Evaluation of follicular synchronization caused by estrogen administration and its reproductive outcome. 2015 , 10, e0127595	4
1083	Pathway Analysis Based on a Genome-Wide Association Study of Polycystic Ovary Syndrome. 2015 , 10, e0136609	27

1082	Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome. 2015 , 2015, 254169		7
1081	Statistical Genomic Approach Identifies Association between FSHR Polymorphisms and Polycystic Ovary Morphology in Women with Polycystic Ovary Syndrome. 2015 , 2015, 483726		6
1080	Prevalence of glucose tolerance test abnormalities in women with polycystic ovarian syndrome. 2015 , 1739-1745		2
1079	Placental STAT3 signaling is activated in women with polycystic ovary syndrome. 2015 , 30, 692-700		47
1078	Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. 2015 , 28, 853-8		11
1077	Adiposity and metabolic dysfunction in polycystic ovary syndrome. 2015 , 21, 107-16		13
1076	Follicular fluid concentrations of lipids and their metabolites are associated with intraovarian gonadotropin-stimulated androgen production in women undergoing in vitro fertilization. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1845-54	5.6	10
1075	Adverse Pregnancy Conditions, Infertility, and Future Cardiovascular Risk: Implications for Mother and Child. 2015 , 29, 391-401		21
1074	Confocal Microscopic Analysis of the Spindle and Chromosome Configurations of in vitro-Matured Oocytes from Different Types of Polycystic Ovary Syndrome Patients. 2015 , 80, 179-86		5
1073	Change of anti-Mullerian-hormone levels during follicular phase in PCOS patients. 2015 , 31, 26-30		5
1072	Polycystic ovary syndrome: chemical pharmacotherapy. 2015 , 16, 1369-93		26
1071	Successive and cyclic oral contraceptive pill pretreatment improves IVF/ICSI outcomes of PCOS patients and ameliorates hyperandrogenism and antral follicle excess. 2015 , 31, 332-6		8
1070	Obesity and Fertility. 2015 ,		1
1069	Serum chemerin levels in women with polycystic ovary syndrome / Polikistik over sendromlu kadın hastalarda serum chemerin seviyeleri. 2015 ,		2
1068	Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association. 2015 , 132, 2424-47		168
1067	Serum Uric Acid Concentration in Overweight and Obese Women with Polycystic Ovary Syndrome / Nivelul acidului uric la femeile supraponderale obeze cu sindromul ovarelor polichistice. 2015 , 23,		0
1066	The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome. 2015 , 76, 620-7		9
1065	Serum ferritin levels and polycystic ovary syndrome in obese and nonobese women. 2015 , 54, 403-7		11

1064	Assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome. 2015 , 136, 1165-8	15
1063	Polycystic ovary syndrome (PCOS) and endocrine disrupting chemicals (EDCs). 2015 , 16, 365-71	59
1062	Transcription Factor-7-Like 2 Gene Variants Affect the Metabolic Phenotypes of Polycystic Ovary Syndrome. 2015 , 67, 228-35	2
1061	Targets to treat metabolic syndrome in polycystic ovary syndrome. 2015 , 19, 1561-74	23
1060	Cutaneous manifestations of the subtypes of polycystic ovary syndrome in Korean patients. 2015 , 29, 42-7	15
1059	DENND1A gene variants in Bahraini Arab women with polycystic ovary syndrome. 2015 , 560, 30-3	19
1058	Leutinizing hormone/choriogonadotropin receptor and follicle stimulating hormone receptor gene variants in polycystic ovary syndrome. 2015 , 32, 607-14	27
1057	Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study. 2015 , 24, 299-307	95
1056	Androgen Receptor Coregulator CTBP1-AS Is Associated With Polycystic Ovary Syndrome in Chinese Women: A Preliminary Study. 2015 , 22, 829-37	21
1055	Dietary habits in adolescent girls with polycystic ovarian syndrome. 2015 , 31, 269-71	6
1054	Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 653-60	5.6 67
1053	Depression in relation to biochemical parameters and age in women with polycystic ovary syndrome. 2015 , 184, 43-7	18
1052	Potential effects of aerobic exercise on the expression of perilipin 3 in the adipose tissue of women with polycystic ovary syndrome: a pilot study. 2015 , 172, 47-58	11
1051	Association between rs7903146 and rs12255372 polymorphisms of transcription factor 7-like 2 gene and polycystic ovary syndrome: a systematic review and meta-analysis. 2015 , 49, 635-42	7
1050	No relationship between osteoprotegerin concentrations and endothelial dysfunction in non-obese women with and without polycystic ovary syndrome. 2015 , 291, 1075-80	4
1049	Characteristics and contributions of hyperandrogenism to insulin resistance and other metabolic profiles in polycystic ovary syndrome. 2015 , 94, 494-500	15
1048	Associations between adipocyte fatty acid-binding protein and clinical parameters in polycystic ovary syndrome. 2015 , 291, 447-50	4
1047	Association of TNF-alpha, IL-6 and IL-1beta gene polymorphisms with polycystic ovary syndrome: a meta-analysis. 2015 , 16, 5	28

1046	Comprehensive assessment of expression of insulin signaling pathway components in subcutaneous adipose tissue of women with and without polycystic ovary syndrome. 2015 , 2, 99-104	6
1045	Evaluation of affective temperament and anxiety-depression levels of patients with polycystic ovary syndrome. 2015 , 185, 214-8	27
1044	Preliminary study of blood methylmercury effects on reproductive hormones and relevant factors among infertile and pregnant women in Taiwan. 2015 , 135, 411-7	6
1043	Peripheral blood-derived cytokine gene polymorphisms and metabolic profile in women with polycystic ovary syndrome. 2015 , 76, 227-235	15
1042	Psychological Implications of PCOS. 2015 , 63-69	
1041	The evaluation of endometrial sulfate glycosaminoglycans in women with polycystic ovary syndrome. 2015 , 31, 278-81	10
1040	Development of the first urinary reproductive hormone ranges referenced to independently determined ovulation day. 2015 , 53, 1099-108	38
1039	[Association analysis of SNP-63 and indel-19 variant in the calpain-10 gene with polycystic ovary syndrome in women of reproductive age]. 2015 , 83, 35-42	3
1038	Evidence-based approach to cutaneous hyperandrogenism in women. 2015 , 73, 672-90	31
1037	Optimal management of polycystic ovary syndrome in adolescence. 2015 , 100, 1076-83	13
1036	Personality profile in patients with polycystic ovary syndrome. 2015 , 31, 540-2	7
1035	Serum metabolomics study of polycystic ovary syndrome based on UPLC-QTOF-MS coupled with a pattern recognition approach. 2015 , 407, 4683-95	47
1034	The prevalence of metabolic syndrome in polycystic ovary syndrome in a South Indian population and the use of neck circumference in defining metabolic syndrome. 2015 , 35, 469-475	2
1033	Obstetric outcomes in women with polycystic ovary syndrome and isolated polycystic ovaries undergoing in vitro fertilization: a retrospective cohort analysis. 2015 , 28, 475-8	11
1032	Symptom patterns and phenotypic subgrouping of women with polycystic ovary syndrome: association between endocrine characteristics and metabolic aberrations. 2015 , 30, 937-46	23
1031	An association study between USP34 and polycystic ovary syndrome. 2015 , 8, 30	4
1030	d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. 2015 , 31, 483-6	32
1029	ROLE OF INSULIN SENSITIZERS ON CARDIOVASCULAR RISK FACTORS IN POLYCYSTIC OVARIAN SYNDROME: A META-ANALYSIS. 2015 , 21, 645-67	3

1028	Clinical characteristics of polycystic ovary syndrome: investigating differences in White and South Asian women. 2015 , 83, 542-9	18
1027	Psychiatric comorbidity in women with polycystic ovary syndrome. 2015 , 41, 1229-33	27
1026	Atypical polycystic ovary syndrome--a genetic analysis. 2015 , 123, 55-60	
1025	Fasting Glucose Changes in Adolescents with Polycystic Ovary Syndrome Compared with Obese Controls: A Retrospective Cohort Study. 2015 , 28, 451-6	2
1024	Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. 2015 , 36, 487-525	401
1023	High-visfatin levels in women with polycystic ovary syndrome: evidence from a meta-analysis. 2015 , 31, 808-14	31
1022	Advanced glycation end products: A link between metabolic and endothelial dysfunction in polycystic ovary syndrome?. 2015 , 64, 1564-73	34
1021	Principles and Practice of Controlled Ovarian Stimulation in ART. 2015 ,	2
1020	Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis. 2015 , 31, 833-9	36
1019	Polycystic ovarian syndrome is accompanied by repression of gene signatures associated with biosynthesis and metabolism of steroids, cholesterol and lipids. 2015 , 8, 24	31
1018	Android fat distribution affects some hemostatic parameters in women with polycystic ovary syndrome compared with healthy control subjects matched for age and body mass index. 2015 , 104, 467-73	7
1017	Metabolic and lipoprotein aspects of polycystic ovarian syndrome. 2015 , 10, 281-293	1
1016	miR-483-5p and miR-486-5p are down-regulated in cumulus cells of metaphase II oocytes from women with polycystic ovary syndrome. 2015 , 31, 565-72	54
1015	Reproductive System Outcome Among Patients with Polycystic Ovarian Syndrome. 2015 , 44, 787-97	9
1014	Putative role for insulin resistance in depression risk in polycystic ovary syndrome. 2015 , 104, 707-14.e1	36
1013	Clinical utility of magnetic resonance imaging and ultrasonography for diagnosis of polycystic ovary syndrome in adolescent girls. 2015 , 104, 1302-9.e1-4	21
1012	Targets to treat androgen excess in polycystic ovary syndrome. 2015 , 19, 1545-60	12
1011	Association between red blood cell distribution width and polycystic ovary syndrome. 2015 , 40, 181-7	6

1010	Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. 2015 , 291, 1181-6	51
1009	Roles of leptin in reproduction, pregnancy and polycystic ovary syndrome: consensus knowledge and recent developments. 2015 , 64, 79-91	45
1008	PCOS in adolescence and type 2 diabetes. 2015 , 15, 564	24
1007	The effect of chromium supplementation on polycystic ovary syndrome in adolescents. 2015 , 28, 114-8	23
1006	Diagnostic characteristics and metabolic risk factors of cases with polycystic ovary syndrome during adolescence. 2015 , 28, 78-83	13
1005	Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary syndrome patients and normal cycling women. 2015 , 41, 254-63	28
1004	DHEA, DHEAS and PCOS. 2015 , 145, 213-25	94
1003	Experiences and Perspectives of Pregnancy in Women with Multiple Sclerosis. 2015 , 33, 47-52	1
1002	Evaluation of Oxidative Stress and hsCRP in Polycystic Ovarian Syndrome in a Tertiary Care Hospital. 2015 , 30, 161-6	12
1001	Predictors of depression in women with polycystic ovary syndrome. 2015 , 18, 95-101	18
1000	Awareness of lifestyle modification in females diagnosed with polycystic ovarian syndrome in India: explorative study. 2016 , 470-476	2
999	Short and Long-Term Efficacy of Laparoscopic Ovarian Diathermy in Women with Polycystic Ovary Syndrome. 2016 , 29, 441-448	2
998	Anti-Mullerian hormone and response to ovulation induction with clomiphene citrate in women with polycystic ovary syndrome. 2016 , 603-608	2
997	The association between polycystic ovary syndrome and breast cancer: a meta-analysis. 2016 , 59, 367-72	14
996	Lipid Profile of Women with Polycystic Ovary Syndrome Attending a Tertiary Care Hospital of Dhaka City. 2016 , 8, 47-49	
995	The Metformin-Induced Changes on BMI, TSH, and Thyroid Hormones Profile of Patients with Polycystic Ovarian Syndrome. 2016 , 5,	
994	Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. 2016 , 15, 35-44	12
993	Correlation between ovarian morphology and biochemical and hormonal parameters in polycystic ovary syndrome. 2016 , 32, 742-5	2

992	Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk. 2016 , 2016, 8671762	18
991	The Salivary Microbiome in Polycystic Ovary Syndrome (PCOS) and Its Association with Disease-Related Parameters: A Pilot Study. 2016 , 7, 1270	20
990	The Association of -429T>C and -374T>A Polymorphisms in the RAGE Gene with Polycystic Ovary Syndrome. 2016 , 13, 451-6	5
989	Poly Cystic Ovarian Syndrome: An Updated Overview. 2016 , 7, 124	108
988	Polycystic ovarian syndrome: clinical and biological diagnosis. 2016 , 74, 661-667	10
987	Hypoglycaemic agents for pregnant women with polycystic ovarian syndrome. 2016 ,	
986	Hypertension and Ischemic Heart Disease in Women. 2016 , 22, 3885-92	9
985	Association of Thyroid Stimulating Hormone with Insulin Resistance in Women with Polycystic Ovarian Syndrome. 2016 , 11, 69-73	
984	Endocrine abnormalities in HIV-infected women are associated with peak viral load - the Children and Women: AntiRetrovirals and Markers of Aging (CARMA) Cohort. 2016 , 84, 452-62	5
983	In situ androgen and estrogen biosynthesis in endometrial cancer: focus on androgen actions and intratumoral production. 2016 , 23, R323-35	17
982	Diagnosis and management of polycystic ovary syndrome in the UK (2004-2014): a retrospective cohort study. 2016 , 6, e012461	22
981	The effect of berberine on insulin resistance in women with polycystic ovary syndrome: detailed statistical analysis plan (SAP) for a multicenter randomized controlled trial. 2016 , 17, 512	8
980	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. 2016 , 22 Suppl 3, 1-203	557
979	Clinical Scenario of the Metabolic Syndrome. 2016 , 32, 336-341	12
978	Effects of brain-derived neurotrophic factor on oocyte maturation and embryonic development in a rat model of polycystic ovary syndrome. 2016 , 28, 1904-1915	7
977	Impaired receptivity and decidualization in DHEA-induced PCOS mice. 2016 , 6, 38134	20
976	Genome-wide association analysis of pain severity in dysmenorrhea identifies association at chromosome 1p13.2, near the nerve growth factor locus. 2016 , 157, 2571-2581	22
975	Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. 2016 , 2, 14	59

974	Association of obesity and overweight with the prevalence of insulin resistance, pre-diabetes and clinical-biochemical characteristics among infertile Mexican women with polycystic ovary syndrome: a cross-sectional study. 2016 , 6, e012107	19
973	The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis. 2016 , 84, 23-9	21
972	Association of G22A and A4223C ADA1 gene polymorphisms and ADA activity with PCOS. 2016 , 62, 213-22	4
971	Follicular fluid norepinephrine and dopamine concentrations are higher in polycystic ovary syndrome. 2016 , 32, 460-3	3
970	Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. 2016 , 39, 639-48	43
969	Evolutionary determinants of polycystic ovary syndrome: part 1. 2016 , 106, 33-41	20
968	IGF-1 and IGFBP-1 in peripheral blood and decidua of early miscarriages with euploid embryos: comparison between women with and without PCOS. 2016 , 32, 538-42	9
967	Criteria, prevalence, and phenotypes of polycystic ovary syndrome. 2016 , 106, 6-15	397
966	Prevalence and clinical features of polycystic ovarian syndrome in adolescents with previous childhood growth hormone deficiency. 2016 , 29, 571-8	
965	Sonographic evaluation of polycystic ovaries. 2016 , 37, 25-37	15
964	Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. 2016 , 32, 431-8	47
963	Polycystic Ovarian Syndrome: Is It Time to Rename PCOS to HA-PODS?. 2016 , 66, 81-7	5
962	Premenopausal Circulating Androgens and Risk of Endometrial Cancer: results of a Prospective Study. 2016 , 7, 178-87	13
961	One hundred top-cited articles in endocrinology and metabolism: a bibliometric analysis. 2016 , 54, 564-571	6
960	Surface electromyography and ultrasound evaluation of pelvic floor muscles in hyperandrogenic women. 2016 , 27, 587-91	4
959	The Role of Physical Activity in Preconception, Pregnancy and Postpartum Health. 2016 , 34, e28-37	44
958	Low aneuploidy rate in early pregnancy loss abortuses from patients with polycystic ovary syndrome. 2016 , 33, 85-92	17
957	Increased risk of humerus and lower leg fractures in postmenopausal women with self-reported premenopausal hirsutism and/or oligomenorrhea. 2016 , 203, 162-6	4

956	Relationship between polycystic ovary syndrome and ancestry in European Americans. 2016 , 106, 1772-1777	5
955	Hiperandrogenismo. 2016 , 53, 45-50	
954	Síndrome del ovario poliquístico y piel. 2016 , 31, 485-495	
953	Age related normogram for antral follicle count in general population and comparison with previous studies. 2016 , 206, 120-124	13
952	Raising threshold for diagnosis of polycystic ovary syndrome excludes population of patients with metabolic risk. 2016 , 106, 1244-1251	13
951	Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis. 2016 , 70, 450-61	29
950	Fertility-related quality of life from two RCT cohorts with infertility: unexplained infertility and polycystic ovary syndrome. 2016 , 31, 2268-79	25
949	Obesity-related metabolic and reproductive dysfunction: variations between the sexes. 2016 , 11, 387-393	1
948	Polycystic ovary syndrome and environmental toxins. 2016 , 106, 948-58	81
947	Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. 2016 , 106, 1510-1520.e2	72
946	Discovery of Novel Lipid Profiles in PCOS: Do Insulin and Androgen Oppositely Regulate Bioactive Lipid Production?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 810-821	5.6 38
945	Alterations in nasal mucociliary activity in polycystic ovary syndrome. 2016 , 207, 169-172	5
944	Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome. 2016 , 25, 875-81	46
943	Inositol as putative integrative treatment for PCOS. 2016 , 33, 770-780	46
942	Increased adiponin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome. 2016 , 85, 910-917	27
941	Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome - a new insight. 2016 , 32, 931-935	5
940	Association of prenatal and early life exposure to tetrachloroethylene (PCE) with polycystic ovary syndrome and other reproductive disorders in the cape cod health study: A retrospective cohort study. 2016 , 65, 87-94	7
939	Peri-muscular adipose tissue may play a unique role in determining insulin sensitivity/resistance in women with polycystic ovary syndrome. 2017 , 32, 185-192	12

938	[Cutaneous manifestations of metabolic syndrome]. 2016 , 67, 982-988		5
937	Effects of Resveratrol on Polycystic Ovary Syndrome: A Double-blind, Randomized, Placebo-controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 4322-4328	5.6	77
936	PHYSIOLOGY AND ENDOCRINOLOGY SYMPOSIUM: Insulin action and lipotoxicity in the development of polycystic ovary syndrome: A review. 2016 , 94, 1803-11		9
935	Application of receiver operating characteristic curve in the assessment of the value of body mass index, waist circumference and percentage of body fat in the Diagnosis of Polycystic Ovary Syndrome in childbearing women. 2016 , 9, 51		11
934	Suitability of the National Health Care Surveys to Examine Behavioral Health Services Associated with Polycystic Ovary Syndrome. 2018 , 45, 252-268		2
933	Influence of race/ethnicity on cardiovascular risk factors in polycystic ovary syndrome, the Dallas Heart Study. 2016 , 85, 92-9		24
932	Characterization of embryonic stem cell model of polycystic ovary syndrome. 2016 , 52, 507-11		
931	Health-Related Quality of Life in Adolescents and Young Adults with Polycystic Ovary Syndrome: A Systematic Review. 2016 , 29, 551-557		37
930	Impaired olfactory function in patients with polycystic ovary syndrome. 2016 , 32, 313-6		1
929	Use of anti-Müllerian hormone testing during ovarian reserve screening to identify women at risk of polycystic ovary syndrome. 2016 , 135, 73-6		1
928	Predictors of Gestational Diabetes Mellitus in Chinese Women with Polycystic Ovary Syndrome: A Cross-Sectional Study. 2016 , 81, 220-4		5
927	Assessment of serum chemerin, vaspin and omentin-1 levels in patients with polycystic ovary syndrome. 2016 , 44, 796-805		26
926	Environmental determinants of polycystic ovary syndrome. 2016 , 106, 16-24		49
925	Developmental origins of polycystic ovary syndrome (PCOS), a case control study comparing birth weight in women with PCOS and control group. 2016 , 32, 856-859		6
924	The high-molecular weight multimer form of adiponectin is a useful marker of polycystic ovary syndrome in Bahraini Arab women. 2016 , 13, e33-e38		2
923	Ovarian endometrioid adenocarcinoma in a young woman with hemorrhagic shock due to tumor disintegration: A case report. 2016 , 5, 47-51		
922	The Liver in Systemic Diseases. 2016 ,		1
921	Laser treatment for female facial hirsutism: are quality-of-life benefits sustainable?. 2016 , 41, 248-52		57

920	A snapshot of the lives of women with polycystic ovary syndrome: A photovoice investigation. 2016 , 21, 1170-82	21
919	Vigorous exercise is associated with superior metabolic profiles in polycystic ovary syndrome independent of total exercise expenditure. 2016 , 105, 486-93	23
918	Common Variants in the Sex Hormone-Binding Globulin (SHBG) Gene Influence SHBG Levels in Women with Polycystic Ovary Syndrome. 2016 , 68, 66-74	17
917	MicroRNA Species in Follicular Fluid Associating With Polycystic Ovary Syndrome and Related Intermediary Phenotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 1579-89	5.6 34
916	Levonorgestrel-Releasing Intrauterine System for Women With Polycystic Ovary Syndrome: Metabolic and Clinical Effects. 2016 , 23, 877-84	6
915	A Nonrandomized Trial of Progressive Resistance Training Intervention in Women With Polycystic Ovary Syndrome and Its Implications in Telomere Content. 2016 , 23, 644-54	27
914	Health-related quality of life questionnaire for polycystic ovary syndrome (PCOSQ-50): development and psychometric properties. 2016 , 25, 1791-801	19
913	Recurrent Pregnancy Loss. 2016 ,	5
912	A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. 2016 , 293, 509-15	34
911	Association of single-nucleotide polymorphisms rs2197076 and rs2241883 of FABP1 gene with polycystic ovary syndrome. 2016 , 33, 75-83	8
910	Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. 2016 , 15, 78-91	197
909	Altered cardiorespiratory response to exercise in overweight and obese women with polycystic ovary syndrome. 2016 , 4, e12719	5
908	Beneficial effect of Curcumin in Letrozole induced polycystic ovary syndrome. 2016 , 5, 116-122	45
907	Observation of phenotypic variation among Indian women with polycystic ovary syndrome (PCOS) from Delhi and Srinagar. 2016 , 32, 566-70	13
906	Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome. 2016 , 53, 271-9	39
905	Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case-control study. 2016 , 27, 403-14	22
904	Metabolic syndrome, diet and exercise. 2016 , 37, 140-151	31
903	Brown adipose tissue transplantation ameliorates polycystic ovary syndrome. 2016 , 113, 2708-13	89

902	Contemporary Reproductive Outcomes for Patients With Polycystic Ovary Syndrome: A Retrospective Observational Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 1664-72 ^{5.6}	27
901	Assessing new terminal body and facial hair growth during pregnancy: toward developing a simplified visual scoring system for hirsutism. 2016 , 105, 494-500	5
900	A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. 2016 , 39, 747-54	23
899	Distinguishing characteristics of metabolically healthy versus metabolically unhealthy obese adolescent girls with polycystic ovary syndrome. 2016 , 105, 1603-11	17
898	A possible link between luteinizing hormone and macrophage migration inhibitory factor levels in polycystic ovary syndrome. 2016 , 41, 261-9	4
897	Ultrasound assessment of polycystic ovaries: Ovarian volume and morphology; which is more accurate in making the diagnosis?!. 2016 , 47, 347-350	3
896	Cut-off levels for hyperandrogenemia among Samoan women: An improved methodology for deriving normative data in an obese population. 2016 , 49, 782-6	2
895	Serum metabolomics study of Traditional Chinese medicine formula intervention to polycystic ovary syndrome. 2016 , 120, 127-33	17
894	Hormones and pathogenesis of uterine fibroids. 2016 , 34, 13-24	55
893	Mass spectrometry methods measured androgen and estrogen concentrations during pregnancy and in newborns of mothers with polycystic ovary syndrome. 2016 , 174, 25-32	45
892	Polycystic ovary syndrome is associated with increased osteopontin levels. 2016 , 174, 415-23	8
891	The Effects of Chromium Supplementation on Endocrine Profiles, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. 2016 , 172, 72-78	29
890	White Matter Microstructure and Cognitive Function in Young Women With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 314-23	5.6 28
889	Ovarian infertility is associated with cardiovascular disease risk factors in later life: A Japanese cross-sectional study. 2016 , 83, 33-9	19
888	Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. 2016 , 293, 447-56	30
887	Association study of androgen signaling pathway genes in polycystic ovary syndrome. 2016 , 105, 467-73.e4	7
886	The Mitochondrial tRNA ^{Leu} (UUR) A3302G Mutation may be Associated With Insulin Resistance in Woman With Polycystic Ovary Syndrome. 2016 , 23, 228-33	18
885	Gender Role, Gender Identity and Sexual Orientation in CAIS ("XY-Women") Compared With Subfertile and Infertile 46,XX Women. 2016 , 53, 109-24	32

884	The relationship between Anti-müllerian hormone and the clinical, biochemical and sonographic parameters in women with polycystic ovarian syndrome. 2016 , 21, 11-15	7
883	Study of Association of Leptin and Insulin Resistance Markers in Patients of PCOS. 2016 , 31, 104-7	18
882	Type 2 Diabetes. 2016 ,	2
881	Gynecologic and Obstetric Consequences of Obesity in Adolescent Girls. 2017 , 30, 156-168	25
880	The WNT/ β -catenin signaling pathway may be involved in granulosa cell apoptosis from patients with PCOS in North China. 2017 , 46, 93-99	21
879	Hyperinsulinemia and obese phenotype differently influence blood pressure in young normotensive patients with polycystic ovary syndrome. 2017 , 55, 625-634	8
878	Local effect of bisphenol A on the estradiol synthesis of ovarian granulosa cells from PCOS. 2017 , 33, 21-25	23
877	Dietary carbohydrate composition is associated with polycystic ovary syndrome: a case-control study. 2017 , 30, 90-97	14
876	Does the Oral Contraceptive Pill Increase Plasma Intercellular Adhesion Molecule-1, Monocyte Chemoattractant Protein-1, and Tumor Necrosis Factor- α Levels in Women with Polycystic Ovary Syndrome: A Pilot Study. 2017 , 30, 58-62	10
875	Shedding new light on female fertility: The role of vitamin D. 2017 , 18, 273-283	53
874	Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. 2017 , 33, 1545-1557	23
873	Pelvic floor dysfunction and polycystic ovary syndrome. 2017 , 20, 262-267	5
872	GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. 2017 , 10, 401-408	33
871	Single-nucleotide polymorphism of INS, INSR, IRS1, IRS2, PPAR-G and CAPN10 genes in the pathogenesis of polycystic ovary syndrome. 2017 , 96, 87-96	15
870	Alanine Aminotransferase Is a Marker of Lipotoxicity Consequences and Hyperandrogenemia in Women with Polycystic Ovary Syndrome. 2017 , 15, 145-152	3
869	Role of androgen ratios in the prediction of the metabolic phenotype in polycystic ovary syndrome. 2017 , 137, 110-115	2
868	Acute exercise elicits differential expression of insulin resistance genes in the skeletal muscle of patients with polycystic ovary syndrome. 2017 , 86, 688-697	15
867	Increased risk of disordered eating in polycystic ovary syndrome. 2017 , 107, 796-802	50

866	Inter-observer variability in the assessment of ultrasound features of polycystic ovaries. 2017 , 22, 226-232	
865	Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20-38 years in China. 2017 , 13, 1337-1342	6
864	Effects of long-term exogenous testosterone administration on ovarian morphology, determined by transvaginal (3D) ultrasound in female-to-male transsexuals. 2017 , 32, 1457-1464	26
863	Hyperandrogenism in adolescent girls: relationship with the somatotrophic axis. 2017 , 30, 561-568	3
862	Brown adipose tissue activation by rutin ameliorates polycystic ovary syndrome in rat. 2017 , 47, 21-28	30
861	Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. 2017 , 42, 145-153	14
860	Polycystic ovarian syndrome and its potential association with bipolar disorder in patients with eating disorder. 2017 , 8, 142-150	
859	New biomarkers for diagnosis and management of polycystic ovary syndrome. 2017 , 471, 248-253	36
858	Competing Factors Link to Bone Health in Polycystic Ovary Syndrome: Chronic Low-Grade Inflammation Takes a Toll. 2017 , 7, 3432	20
857	Women's Health: Polycystic Ovarian Syndrome, Menopause, and Osteoporosis. 2017 , 44, 377-398	7
856	Significantly lengthened telomere in granulosa cells from women with polycystic ovarian syndrome (PCOS). 2017 , 34, 861-866	20
855	Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis. 2017 , 87, 217-230	26
854	An epidemiological survey: Effect of predisposing factors for PCOS in Indian urban and rural population. 2017 , 22, 313-316	28
853	Genetic architecture of acne vulgaris. 2017 , 31, 1978-1990	27
852	Polycystic ovary syndrome: Understanding the role of the brain. 2017 , 46, 1-14	48
851	MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease. 2017 , 177, R125-R143	68
850	Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome. 2017 , 17, 26	2
849	Metabolic and androgen profile in underweight women with polycystic ovary syndrome. 2017 , 296, 363-371	9

848	Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. 2017 , 45, 1403-1412	49
847	Dietary patterns and the phenotype of polycystic ovary syndrome: the chance of ongoing pregnancy. 2017 , 34, 668-676	10
846	Polycystic ovary syndrome: analysis of the global research architecture using density equalizing mapping. 2017 , 34, 627-638	13
845	Association study of HNF1A in women with polycystic ovary syndrome. 2017 , 34, 677-682	2
844	Assessment of circulating betatrophin concentrations in lean glucose-tolerant women with polycystic ovary syndrome. 2017 , 37, 633-638	13
843	The relationship between atypical depression and insulin resistance in patients with polycystic ovary syndrome and major depression. 2017 , 258, 171-176	9
842	Risk factors for preeclampsia in infertile Chinese women with polycystic ovary syndrome: A prospective cohort study. 2017 , 19, 504-509	14
841	Polycystic Ovary Syndrome: An Under-recognized Cause of Abnormal Uterine Bleeding in Adolescents Admitted to a Children's Hospital. 2017 , 30, 349-355	14
840	Polycystic ovary syndrome: early diagnosis and intervention are necessary for fertility preservation in young women with endometrial cancer under 35 years of age. 2017 , 16, 67-71	17
839	Elevated serum interferon Inducible protein-10 in women with polycystic ovary syndrome. 2017 , 33, 363-367	4
838	Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study. 2017 , 107, 253-260.e1	16
837	Steroid hormone profiling in obese and nonobese women with polycystic ovary syndrome. 2017 , 7, 14156	22
836	Increased expression of PGRN protein in follicular fluid and mRNA in granulosa cells in overweight patients with polycystic ovary syndrome. 2017 , 218, 106-112	8
835	Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. 2017 , 6, 647-658	66
834	Correlation between follicular fluid levels of sRAGE and vitamin D in women with PCOS. 2017 , 34, 1507-1513	14
833	Presence of polycystic ovary syndrome is associated with longer anogenital distance in adult Mediterranean women. 2017 , 32, 2315-2323	38
832	Does cardiovascular risk vary according to the criteria for a diagnosis of polycystic ovary syndrome?. 2017 , 43, 1848-1854	9
831	Reproductive and metabolic features during puberty in sons of women with polycystic ovary syndrome. 2017 , 6, 607-613	14

830	Are expanding disease definitions unnecessarily labelling women with polycystic ovary syndrome?. 2017 , 358, j3694	25
829	Effects of probiotics supplementation on macrophage migration inhibitory factor and clinical laboratory feature of polycystic ovary syndrome. 2017 , 36, 317-324	15
828	Insulin resistance and obesity among infertile women with different polycystic ovary syndrome phenotypes. 2017 , 7, 5339	28
827	Age-stratified thresholds of anti-Müllerian hormone improve prediction of polycystic ovary syndrome over a population-based threshold. 2017 , 87, 733-740	19
826	Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature. 2017 , 6, 437-445	43
825	Identification of reference genes for qRT-PCR in granulosa cells of healthy women and polycystic ovarian syndrome patients. 2017 , 7, 6961	14
824	Early miscarriage rate in lean polycystic ovary syndrome women after euploid embryo transfer - a matched-pair study. 2017 , 35, 576-582	20
823	Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis. 2017 , 296, 661-677	26
822	What Do Transgender Patients Teach Us About Idiopathic Intracranial Hypertension?. 2017 , 41, 326-329	24
821	Metabolomics biomarker analysis of threatened abortion in polycystic ovary syndrome: a clinical discovery study. 2017 , 7, 52923-52929	2
820	The Complex Interaction Between Polycystic Ovary Syndrome and Hereditary Angioedema: Case Reports and Review of the Literature. 2017 , 72, 417-424	1
819	Association between polycystic ovary syndrome and the risk of stroke and all-cause mortality: insights from a meta-analysis. 2017 , 33, 904-910	25
818	Plasmatic and Intracellular Markers of Oxidative Stress in Normal Weight and Obese Patients with Polycystic Ovary Syndrome. 2017 , 125, 506-513	8
817	Hautmanifestationen beim metabolischen Syndrom. 2017 , 16, 96-102	
816	5β-reductase activity in women with polycystic ovary syndrome: a systematic review and meta-analysis. 2017 , 15, 21	12
815	Ovarian morphology is associated with insulin resistance in women with polycystic ovary syndrome: a cross sectional study. 2017 , 3, 8	12
814	Oxidative stress and polycystic ovary syndrome: evaluation during ovarian stimulation for ICSI. 2016 ,	12
813	The relationship of urocortin-2 with insulin resistance patients having PCOS. 2017 , 33, 124-127	5

812	Telomeric repeat-containing RNA (TERRA) related to polycystic ovary syndrome (PCOS). 2017 , 86, 552-559	14
811	Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). 2017 , 33, 39-42	50
810	A new dawn for androgens: Novel lessons from 11-oxygenated C19 steroids. 2017 , 441, 76-85	80
809	High androgen levels protect against hypothyroidism. 2017 , 96, 39-46	10
808	Metformin and pioglitazone combination therapy ameliorate polycystic ovary syndrome through AMPK/PI3K/JNK pathway. 2018 , 15, 2120-2127	15
807	A Study on Omentin-1 and Prostate Specific Antigen in Women on Treatment for Polycystic Ovary Syndrome. 2019 , 34, 108-114	3
806	Hirsutismo: diagnóstico y conducta práctica. 2017 , 21, 1-7	
805	Mental health status assessment in polycystic ovarian syndrome infertility patients: A pilot study. 2017 , 37, 750-754	3
804	Increased Risk of Psychiatric Disorders in Women with Polycystic Ovary Syndrome in Southwest China. 2017 , 130, 262-266	21
803	Vitamin D and Female Reproduction. 2017 ,	
802	The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. 2017 , 8, 96351-96358	130
801	Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols. 2017 , 8, 341	26
800	Psychological burden among women with polycystic ovarian syndrome in Oman: a case-control study. 2017 , 9, 897-904	9
799	Investigation of Demodex folliculorum frequency in patients with polycystic ovary syndrome. 2017 , 92, 807-810	10
798	Fertilization failure and gamete health: Is there a link?. 2017 , 9, 395-419	2
797	Cryptotanshinone Regulates Androgen Synthesis through the ERK/c-Fos/CYP17 Pathway in Porcine Granulosa Cells. 2017 , 2017, 5985703	5
796	Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits. 2017 , 8, 13-23	19
795	Gynecological Morbidity. 2017 , 342-353	1

794	[Epigenetics of polycystic ovary syndrome]. 2017 , 145, 907-915	11
793	Genetic variant in vitamin D-binding protein is associated with metabolic syndrome and lower 25-hydroxyvitamin D levels in polycystic ovary syndrome: A cross-sectional study. 2017 , 12, e0173695	13
792	Understanding polycystic ovary syndrome from the patient perspective: a concept elicitation patient interview study. 2017 , 15, 162	7
791	Evolution of metabolic alterations 5 Years after early puberty in a cohort of girls predisposed to polycystic ovary syndrome. 2017 , 15, 56	4
790	Relationship between serum anti-Mullerian hormone and clinical parameters in polycystic ovary syndrome. 2017 , 64, 531-541	18
789	Relationship of insulin resistance with recurrent pregnancy loss. 2017 , 6, 1312	2
788	Vitamin D and aspects of female fertility. 2017 , 16, 5-21	15
787	Quality of life in overweight (obese) and normal-weight women with polycystic ovary syndrome. 2017 , 11, 423-429	21
786	Altered Circulating Inflammatory Cytokines Are Associated with Anovulatory Polycystic Ovary Syndrome (PCOS) Women Resistant to Clomiphene Citrate Treatment. 2017 , 23, 1083-1089	20
785	Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis. 2018 , 23, 64-77	19
784	The Effects of Vitamin D Supplementation on Biomarkers of Inflammation and Oxidative Stress Among Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2018 , 50, 271-279	41
783	Pleiotropic roles of melatonin in endometriosis, recurrent spontaneous abortion, and polycystic ovary syndrome. 2018 , 80, e12839	19
782	Metabolic risk assessment of Indian women with polycystic ovarian syndrome in relation to four Rotterdam criteria based phenotypes. 2018 , 224, 60-65	9
781	Subclinical Hypothyroidism Impact on the Characteristics of Patients with Polycystic Ovary Syndrome. A Meta-Analysis of Observational Studies. 2018 , 83, 105-115	12
780	Reproductive health, obesity, and cardiometabolic risk factors among Samoan women. 2018 , 30, e23106	1
779	Clinical, Hormonal, and Metabolic Parameters in Women with Subclinical Hypothyroidism and Polycystic Ovary Syndrome: A Cross-Sectional Study. 2018 , 27, 659-664	12
778	High Androgens in Postmenopausal Women and the Risk for Atherosclerosis and Cardiovascular Disease: The Rotterdam Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1622-1630	5.6 60
777	EXOGENOUS TESTOSTERONE DOES NOT INDUCE OR EXACERBATE THE METABOLIC FEATURES ASSOCIATED WITH PCOS AMONG TRANSGENDER MEN. 2018 , 24, 565-572	13

776	Downregulation of serum long noncoding RNA GAS5 may contribute to insulin resistance in PCOS patients. 2018 , 34, 784-788		15
775	Limitations of insulin resistance assessment in polycystic ovary syndrome. 2018 , 7, 403-412		10
774	Letrozole versus clomiphene citrate in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. 2018 , 297, 1081-1088		22
773	Follicular localization of growth differentiation factor 8 and its receptors in normal and polycystic ovary syndrome ovaries. 2018 , 98, 683-694		8
772	Impaired Lipolysis, Diminished Fat Oxidation, and Metabolic Inflexibility in Obese Girls With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 546-554	5.6	26
771	Association between polycystic ovary syndrome and hot flash presentation during the midlife period. 2018 , 25, 691-696		5
770	Muscle as medicine: an autoethnographic study of coping with polycystic ovarian syndrome through strength training. 2018 , 10, 476-492		2
769	Infertility in Women with Polycystic Ovary Syndrome. 2018 ,		1
768	Infertility and Subfertility Cofactors in Women with PCOS. 2018 , 63-79		
767	PCOS and pregnancy: a review of available therapies to improve the outcome of pregnancy in women with polycystic ovary syndrome. 2018 , 13, 87-98		11
766	Evaluation of different ranges of LH:FSH ratios in polycystic ovarian syndrome (PCOS) - Clinical based case control study. 2018 , 260, 51-57		31
765	Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes. 2018 , 34, 518-523		18
764	Health-related quality of life in patients with polycystic ovary syndrome: validation of the German PCOSQ-G. 2018 , 297, 1027-1035		12
763	Oxidative stress in granulosa cells contributes to poor oocyte quality and IVF-ET outcomes in women with polycystic ovary syndrome. 2018 , 12, 518-524		49
762	Metabolic syndrome, hypertension, and hyperlipidemia in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. 2018 , 109, 356-364.e32		46
761	Suspected ontogeny of a recently described hypo-androgenic PCOS-like phenotype with advancing age. 2018 , 59, 661-676		6
760	Pediatric obesity: Current concepts. 2018 , 64, 98-156		31
759	Differential association of DENND1A genetic variants with polycystic ovary syndrome in Tunisian but not Bahraini Arab women. 2018 , 647, 79-84		12

758	Pregnancy outcomes of PCOS overweight/obese patients after controlled ovarian stimulation with the GnRH antagonist protocol and frozen embryo transfer. 2018 , 16, 36	12
757	Apa-I polymorphism in VDR gene is related to metabolic syndrome in polycystic ovary syndrome: a cross-sectional study. 2018 , 16, 38	9
756	Polycystic ovary syndrome and hyperglycaemia in pregnancy. A narrative review and results from a prospective Danish cohort study. 2018 , 145, 167-177	21
755	High level of C-type natriuretic peptide induced by hyperandrogen-mediated anovulation in polycystic ovary syndrome mice. 2018 , 132, 759-776	15
754	Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. 2018 , 14, 270-284	472
753	Psychological distress, anger and quality of life in polycystic ovary syndrome: associations with biochemical, phenotypical and socio-demographic factors. 2018 , 39, 128-137	29
752	Magnesium-Zinc-Calcium-Vitamin D Co-supplementation Improves Hormonal Profiles, Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. 2018 , 182, 21-28	28
751	Does a male polycystic ovarian syndrome equivalent exist?. 2018 , 41, 49-57	21
750	Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis. 2018 , 59, 30-38	25
749	Polycystic ovarian syndrome: Prevalence and impact on the wellbeing of Australian women aged 16-29 years. 2018 , 58, 222-233	17
748	Links Between Polycystic Ovary Syndrome and Gestational Diabetes Mellitus. 2018 , 189-206	
747	An exploration of the hypothesis that testosterone is implicated in the psychological functioning of women with polycystic ovary syndrome (PCOS). 2018 , 110, 42-45	15
746	Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance. 2018 , 34, 238-242	7
745	Treatment strategies for women with polycystic ovary syndrome. 2018 , 34, 272-277	48
744	Polycystic Ovarian Syndrome. 2018 , 361-369.e2	
743	Clinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome. 2018 , 38, 236-240	5
742	The Effects of Selenium Supplementation on Gene Expression Related to Insulin and Lipid in Infertile Polycystic Ovary Syndrome Women Candidate for In Vitro Fertilization: a Randomized, Double-Blind, Placebo-Controlled Trial. 2018 , 183, 218-225	17
741	Adolescent Gynecology. 2018 ,	

740	High-fat diet exposure from pre-pubertal age induces polycystic ovary syndrome (PCOS) in rats. 2018 , 155, 141-151	25
739	Prevalence of polycystic ovary syndrome in Thai University adolescents. 2018 , 34, 476-480	8
738	Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome. 2018 , 644, 129-136	12
737	Predictors of Depression in Iranian Women with Polycystic Ovarian Syndrome. 2018 , 54, 1274-1283	7
736	Family-based analysis of GGT1 and HNF1A gene polymorphisms in patients with polycystic ovary syndrome. 2018 , 36, 115-119	2
735	Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. 2018 , 27, 174-182	10
734	Fertility concerns and related information needs and preferences of women with PCOS. 2018 , 2018, hoy019	11
733	Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. 2018 , 17, 277-285	22
732	Association between rs1800795 polymorphism in the interleukin-6 gene and the risk of polycystic ovary syndrome: A meta-analysis. 2018 , 97, e11558	13
731	Polycystic ovarian syndrome (PCOS) awareness among young women of central India. 2018 , 7, 3960	2
730	Prevalence of metabolic syndrome in women with polycystic ovarian syndrome: an observational study in a tertiary care centre in Pondicherry, India. 2018 , 7, 3774	1
729	Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity. 2018 , 15,	111
728	Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association. 2018 , 41, 2648-2668	127
727	Polycystic ovarian syndrome is linked to increased oxidative stress in Omani women. 2018 , 10, 763-771	19
726	ATF4 Contributes to Ovulation via Regulating COX2/PGE2 Expression: A Potential Role of ATF4 in PCOS. 2018 , 9, 669	6
725	Lysyl oxidase blockade ameliorates anovulation in polycystic ovary syndrome. 2018 , 33, 2096-2106	8
724	A cross-sectional comparison of clinical and endocrine parameters among phenotypes of polycystic ovarian syndrome in iranian population. 2018 , 23, 425-430	4
723	Identification of mRNAs related to endometrium function regulated by lncRNA CD36-005 in rat endometrial stromal cells. 2018 , 16, 96	8

722	Improvement of the folliculogenesis by transplantation of bone marrow mesenchymal stromal cells in mice with induced polycystic ovary syndrome. 2018 , 20, 1445-1458		12
721	Assessing C reactive protein/albumin ratio as a new biomarker for polycystic ovary syndrome: a case-control study of women from Bahraini medical clinics. 2018 , 8, e021860		7
720	The Current Description and Future Need for Multidisciplinary PCOS Clinics. 2018 , 7,		9
719	Assessment of anogenital distance as a diagnostic tool in polycystic ovary syndrome. 2018 , 37, 741-749		11
718	Time-to-pregnancy and offspring finger-length ratio (2D:4D). 2018 , 30, e23176		1
717	PCOS: update and diagnostic approach. 2018 , 62, 24-31		10
716	Gestational Weight Gain in Women With Polycystic Ovary Syndrome: A Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 4315-4323	5.6	14
715	Early gonadotropin-releasing hormone antagonist protocol in women with polycystic ovary syndrome: A preliminary randomized trial. 2018 , 45, 135-142		5
714	Evaluation of ovarian and metabolic effects of GnRH modulators in two rat models of polycystic ovary syndrome. 2018 , 85, 778-789		2
713	Environmental toxicant induced epigenetic transgenerational inheritance of ovarian pathology and granulosa cell epigenome and transcriptome alterations: ancestral origins of polycystic ovarian syndrome and primary ovarian insufficiency. 2018 , 13, 875-895		36
712	Lean Women with Polycystic Ovary Syndrome. 2018 ,		0
711	A review on role of medicinal plants in polycystic ovarian syndrome: Pathophysiology, neuroendocrine signaling, therapeutic status and future prospects. 2018 , 23, 255-262		10
710	Influence of tumour suppressor gene (TP53, BRCA1 and BRCA2) polymorphisms on polycystic ovary syndrome in South Indian women. 2018 , 227, 13-18		9
709	Evaluation of endometrial and subendometrial vascularity in obese women with polycystic ovarian disease. 2018 , 23, 324-330		1
708	ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. 2018 , 131, e157-e171		68
707	The value of prolactin in predicting prolactinemia in hyperprolactinaemic polycystic ovarian syndrome. 2018 , 48, e12961		12
706	Simplified 4-item criteria for polycystic ovary syndrome: A bridge too far?. 2018 , 89, 202-211		15
705	Abnormal irisin level in serum and endometrium is associated with metabolic dysfunction in polycystic ovary syndrome patients. 2018 , 89, 474-480		10

704	Developmental programming of the female neuroendocrine system by steroids. 2018 , 30, e12632	4
703	Fertility management experiences of women with polycystic ovary syndrome in Australia. 2018 , 23, 282-287	6
702	Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. 2018 , 110, 523-533.e14	18
701	Association of Androgen Excess with Glucose Intolerance in Women with Polycystic Ovary Syndrome. 2018 , 2018, 6869705	18
700	Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis. 2018 , 24, 694-709	70
699	Polycystic ovary syndrome and autism: A test of the prenatal sex steroid theory. 2018 , 8, 136	49
698	The Polycystic Ovary Syndrome Quality of Life scale (PCOSQOL): Development and preliminary validation. 2018 , 5, 2055102918788195	4
697	Liver X Receptors: A Possible Link between Lipid Disorders and Female Infertility. 2018 , 19,	9
696	Infertility Treatment in PCOS. 2018 , 290-295	1
695	Prevalence of vitamin D deficiency in infertile women with polycystic ovarian syndrome and its association with metabolic syndrome - A prospective observational study. 2018 , 229, 15-19	13
694	Impacts of Air Pollution on Gynecologic Disease: Infertility, Menstrual Irregularity, Uterine Fibroids, and Endometriosis: a Systematic Review and Commentary. 2018 , 5, 197-204	2
693	Effectiveness of Laser Acupoints on Women With Polycystic Ovarian Syndrome: A Randomized Controlled Trial. 2018 , 9, 113-120	3
692	The Rise, Fall, and Resurrection of 11-Oxygenated Androgens in Human Physiology and Disease. 2018 , 89, 284-291	27
691	Is Afamin a novel biomarker for gestational diabetes mellitus? A pilot study. 2018 , 16, 30	21
690	New Biomarkers to Evaluate Hyperandrogenemic Women and Hypogonadal Men. 2018 , 86, 71-125	10
689	Indication-oriented Ovulation Induction in Assisted Reproduction. 2018 , 14,	
688	Dose-effect analysis of treatment by modified Zhibaidihuang decoction on polycystic ovary syndrome hyperandrogenism. 2018 , 38, 280-286	1
687	Trends in anti-Müllerian hormone concentrations across different stages of pregnancy in women with polycystic ovary syndrome. 2018 , 37, 367-374	4

686	Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats. 2018 , 49, 154-163	5
685	Why we need epidemiologic studies of polycystic ovary syndrome in Africa. 2018 , 143, 251-254	5
684	Adipose Tissue is a Potential Source of Hyperandrogenism in Obese Female Rats. 2018 , 26, 1161-1167	1
683	Systematic review and meta-analysis of letrozole and clomiphene citrate in polycystic ovary syndrome. 2018 , 23, 163-170	1
682	A negative correlation of thyroid stimulating hormone with anti_mullerian hormone and with luteinizing hormone in polycystic ovary syndrome and/or hypothyroid women. 2018 , 23, 388-392	
681	Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome. 2018 , 27, 892-902	6
680	Prolactin and Its Role in Human Reproduction. 2019 , 58-74.e8	6
679	Polycystic Ovary Syndrome and Hyperandrogenic States. 2019 , 520-555.e13	2
678	Increased platelet factor 4 and aberrant permeability of follicular fluid in PCOS. 2019 , 118, 249-259	7
677	Circulating insulin-like peptide 5 levels and its association with metabolic and hormonal parameters in women with polycystic ovary syndrome. 2019 , 42, 303-312	5
676	Depression, anxiety and perceived stress in women with and without PCOS: a community-based study. 2019 , 49, 1510-1520	45
675	Follicular dynamics of glycerophospholipid and sphingolipid metabolisms in polycystic ovary syndrome patients. 2019 , 185, 142-149	21
674	Assessment of follicular fluid metabolomics of polycystic ovary syndrome in kidney yang deficiency syndrome. 2019 , 30, 100944	7
673	The evolving role of genetic tests in reproductive medicine. 2019 , 17, 267	31
672	Analysis of VEGF gene polymorphisms and serum VEGF protein levels contribution in polycystic ovary syndrome of patients. 2019 , 46, 5821-5829	10
671	Developmental Programming of PCOS Traits: Insights from the Sheep. 2019 , 7,	7
670	Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with Polycystic Ovarian Syndrome: An observational study. 2019 , 9, 10182	12
669	Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. 2019 , 35, 1088-1093	17

668	Emerging Roles of Anti-Müllerian Hormone in Hypothalamic-Pituitary Function. 2019 , 109, 218-229	23
667	Insulin gene VNTR class III allele is a risk factor for insulin resistance in Kashmiri women with polycystic ovary syndrome. 2019 , 21, 100597	4
666	PCOS. 2019 , 91-109	
665	The effects of physical exercise on cardiometabolic outcomes in women with polycystic ovary syndrome not taking the oral contraceptive pill: a systematic review and meta-analysis. 2019 , 18, 597-612	5
664	Changes in whole metabolites after exenatide treatment in overweight/obese polycystic ovary syndrome patients. 2019 , 91, 508-516	14
663	Polycystic ovary syndrome is a risk factor for sarcopenic obesity: a case control study. 2019 , 19, 70	4
662	Intrauterine insemination versus timed intercourse in ovulation induction cycles with clomiphene citrate for polycystic ovary syndrome: A retrospective cohort study. 2019 , 48, 805-809	1
661	The effects of curcumin supplementation on glycemic status, lipid profile and hs-CRP levels in overweight/obese women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled clinical trial. 2019 , 47, 102201	26
660	Creatine Kinase Is a Marker of Metabolic Syndrome in Qatari Women With and Without Polycystic Ovarian Syndrome. 2019 , 10, 659	3
659	Alterations in long noncoding RNAs in women with and without polycystic ovarian syndrome. 2019 , 91, 793-797	11
658	Relationship of Biological Markers of Body Fat Distribution and Corticosteroidogenic Enzyme Activities in Women with Polycystic Ovary Syndrome. 2019 , 51, 639-648	4
657	Diffuse idiopathic skeletal hyperostosis in a 33-year-old woman with PCOS and metabolic syndrome: a rare scenario. 2019 , 12,	2
656	Expression of microRNA in follicular fluid in women with and without PCOS. 2019 , 9, 16306	23
655	Treatment with Metformin and Combination of Metformin Plus Pioglitazone on Serum Levels of IL-6 and IL-8 in Polycystic Ovary Syndrome: A Randomized Clinical Trial. 2019 , 51, 714-722	19
654	Basal Anti Mullerian hormone levels and endometrial thickness at midcycle can predict the outcome after clomiphene citrate stimulation in anovulatory women with PCOS, a retrospective study. 2019 , 300, 1751-1757	5
653	Phenotype and genotype of polycystic ovary syndrome in Asia: Ethnic differences. 2019 , 45, 2330-2337	17
652	Prevalence of polycystic ovary syndrome in women with severe obesity - Effects of a structured weight loss programme. 2019 , 91, 750-758	7
651	Ovarian drilling in polycystic ovary syndrome: Long term pregnancy rate. 2019 , 4, 100093	11

650	Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies. 2019 , 13, 1179558119874042	53
649	Prevalence of Self-reported Polycystic Ovary Syndrome and Profiles of Health Among Women of Different Generations: A Cross Sectional Study. 2019 , 01, 141-147	1
648	Vitamin C suppresses ovarian pathophysiology in experimental polycystic ovarian syndrome. 2019 , 26, 331-341	5
647	Changes in serum markers of patients with PCOS during consecutive clomiphene stimulation cycles: a retrospective study. 2019 , 12, 91	2
646	Association Between Vitamin D Receptor Gene Polymorphisms and Polycystic Ovary Syndrome Risk: A Meta-Analysis. 2018 , 9, 1902	7
645	The Impact of Obesity on the Incidence of Type 2 Diabetes Among Women With Polycystic Ovary Syndrome. 2019 , 42, 560-567	50
644	Relationship between surrogate estimates and direct measurement of insulin resistance in women with polycystic ovary syndrome. 2019 , 42, 987-993	10
643	The association between metabolic syndrome and polycystic ovary syndrome: A systematic review and meta-analysis. 2019 , 13, 1481-1489	14
642	Immunophenotypic profile of leukocytes in hyperandrogenemic female rat an animal model of polycystic ovary syndrome. 2019 , 220, 44-49	8
641	The Possibilities of Using Chromium Salts as an Agent Supporting Treatment of Polycystic Ovary Syndrome. 2019 , 192, 91-97	3
640	Extensive Phenotyping for Potential Weight-Inducing Factors in an Outpatient Population with Obesity. 2019 , 12, 369-384	5
639	The diagnosis of androgenetic alopecia in children: Considerations of pathophysiological plausibility. 2019 , 60, e279-e283	4
638	Altered miR-186 and miR-135a contribute to granulosa cell dysfunction by targeting ESR2: A possible role in polycystic ovary syndrome. 2019 , 494, 110478	14
637	G276T polymorphism in the ADIPOQ gene is associated with a reduced risk of polycystic ovarian syndrome: A meta-analysis of Asian population. 2019 , 58, 409-416	3
636	Chronic low-grade inflammation in polycystic ovary syndrome: is there a (patho)-physiological role for interleukin-1?. 2019 , 41, 447-459	19
635	Depression Over the Lifespan in a Population-Based Cohort of Women With Polycystic Ovary Syndrome: Longitudinal Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2809-2819 ^{5,6}	21
634	Functional Genetic Variation in the Anti-Müllerian Hormone Pathway in Women With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2855-2874	5.6 35
633	Sexual Function and Socio-Sexual Difficulties in Women with Polycystic Ovary Syndrome (PCOS). 2019 , 79, 498-509	7

632	Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome. 2019 , 65, 175-183	5
631	The effects of exercise on cardiometabolic outcomes in women with polycystic ovary syndrome not taking the oral contraceptive pill: protocol for a systematic review and meta-analysis. 2019 , 8, 116	5
630	Medical conditions, pregnancy perspectives and contraceptive decision-making among young people: an exploratory, qualitative analysis. 2019 , 100, 72-78	9
629	Prevalence of Dyslipidaemia and Pre-Diabetes Among Women with Polycystic Ovary Syndrome (PCOS): Do We Overestimate Cardiovascular Risk?. 2019 , 51, 539-545	4
628	How much insulin resistance in polycystic ovary syndrome? Comparison of HOMA-IR and insulin resistance (Belfiore) index models. 2019 , 15, 613-618	17
627	The impact of a standardized micronutrient supplementation on PCOS-typical parameters: a randomized controlled trial. 2019 , 300, 455-460	8
626	Polycystic Ovary Syndrome and Cardiovascular Diseases: Still an Open Door. 2019 , 112, 430-431	0
625	Peripheral precocious puberty including congenital adrenal hyperplasia: causes, consequences, management and outcomes. 2019 , 33, 101273	6
624	Children born to women with polycystic ovary syndrome-short- and long-term impacts on health and development. 2019 , 111, 1065-1075	17
623	Evaluation of antioxidant defense markers in relation to hormonal and insulin parameters in women with polycystic ovary syndrome (PCOS): A case-control study. 2019 , 13, 1957-1961	13
622	Long non-coding RNA H19 is associated with polycystic ovary syndrome in Chinese women: a preliminary study. 2019 , 66, 587-595	22
621	Are there differences in basal thrombophilias and C-reactive protein between women with or without PCOS?. 2019 , 38, 1018-1026	3
620	Low-Dose Tacrolimus Prevents Dysregulated Peri-Conceptional Ovarian and Systemic Immune Cellular Homeostasis in Subjects with PCOS. 2019 , 9, 6528	5
619	The epicardial adipose tissue and the coronary arteries: dangerous liaisons. 2019 , 115, 1013-1025	25
618	Plasma level of peroxiredoxin 3 in patients with polycystic ovarian syndrome. 2019 , 19, 32	1
617	Increased circulating conjugated primary bile acids are associated with hyperandrogenism in women with polycystic ovary syndrome. 2019 , 189, 171-175	9
616	Ovulation: Parallels With Inflammatory Processes. 2019 , 40, 369-416	113
615	Polycystic Ovary Syndrome in Active Duty Service Women: A Retrospective Analysis. 2019 , 184, 440-446	2

614	Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study. 2019 , 12, 25	15
613	What does acne genetics teach us about disease pathogenesis?. 2019 , 181, 665-676	18
612	Dysregulated miR-142, -33b and -423 in granulosa cells target TGFBR1 and SMAD7: a possible role in polycystic ovary syndrome. 2019 , 25, 638-646	21
611	Biomarkers of Endothelial Dysfunction in Women With Polycystic Ovary Syndrome. 2019 , 70, 797-801	10
610	Association between the vascular endothelial growth factor gene polymorphisms and the risk of polycystic ovary syndrome in Northern Chinese women. 2019 , 35, 706-709	3
609	Differential activity of the corticosteroidogenic enzymes in normal cycling women and women with polycystic ovary syndrome. 2019 , 20, 3-13	4
608	Letrozole versus laparoscopic ovarian drilling in clomiphene citrate-resistant women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. 2019 , 17, 17	13
607	Association of Vitamin D Metabolites With Embryo Development and Fertilization in Women With and Without PCOS Undergoing Subfertility Treatment. 2019 , 10, 13	10
606	Metabolomics of Dynamic Changes in Insulin Resistance Before and After Exercise in PCOS. 2019 , 10, 116	17
605	Reproductive Outcomes of Women with Polycystic Ovarian Syndrome Following In-Vitro Fertilization [A Meta-Analysis and Systematic Review]. 2019 , 01, 193-201	
604	Awareness of polycystic ovarian syndrome among young women in Western India. 2019 , 8, 4716	1
603	Altered cooperativeness in patients with polycystic ovary syndrome. 2019 , 29, 880-886	
602	Baicalin ameliorates polycystic ovary syndrome through AMP-activated protein kinase. 2019 , 12, 109	12
601	Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource. 2019 , 34, 2254-2265	25
600	Vitamin D receptor and binding protein polymorphisms in women with polycystic ovary syndrome: a case control study. 2019 , 19, 145	4
599	Exploring the Pharmacological Mechanism of Quercetin-Resveratrol Combination for Polycystic Ovary Syndrome: A Systematic Pharmacological Strategy-Based Research. 2019 , 9, 18420	9
598	Skin Manifestations of Paediatric Metabolic Syndrome. 2019 , 841-858	
597	'I drew the parts of my body in proportion to how much PCOS ruined them': Experiences of polycystic ovary syndrome through drawings. 2019 , 6, 2055102919896238	3

596	Fertility Treatment Options for Women With Polycystic Ovary Syndrome. 2019 , 13, 1179558119890867	9
595	Alterations in plasma non-esterified fatty acid (NEFA) kinetics and relationship with insulin resistance in polycystic ovary syndrome. 2019 , 34, 335-344	1
594	Cardiometabolic risks in PCOS: a review of the current state of knowledge. 2019 , 14, 23-33	21
593	Advantages of Serum Anti-Müllerian Hormone as a Marker for Polycystic Ovarian Syndrome. 2019 , 50, 236-242	1
592	The efficacy and use of finasteride in women: a systematic review. 2019 , 58, 759-776	22
591	The roles of cytosolic quality control proteins, SGTA and the BAG6 complex, in disease. 2019 , 114, 265-313	9
590	Body image, personality profiles and alexithymia in patients with polycystic ovary syndrome (PCOS). 2019 , 40, 294-303	9
589	Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. 2019 , 92, 108-120	85
588	The pressing need for standardization in epidemiologic studies of PCOS across the globe. 2019 , 35, 1-3	19
587	Serum metabolomics analysis of patients with polycystic ovary syndrome by mass spectrometry. 2019 , 86, 292-297	12
586	Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome. 2019 , 13, 1065-1069	13
585	Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome. 2019 , 234, 149-154	14
584	Effect of irisin on endometrial receptivity of rats with polycystic ovary syndrome. 2019 , 35, 395-400	11
583	Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome. 2019 , 35, 506-510	10
582	Higher menopausal age but no differences in parity in women with polycystic ovary syndrome compared with controls. 2019 , 98, 320-326	18
581	Development of a novel risk prediction and risk stratification score for polycystic ovary syndrome. 2019 , 90, 162-169	5
580	Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. 2019 , 35, 220-223	42
579	Serum betatrophin levels are reduced in patients with full-blown polycystic ovary syndrome. 2019 , 35, 224-227	5

578 Polycystic Ovary Syndrome. **2019**, 415-435

577 Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study. **2019**, 170, 43-52 49

576 Metabolic syndrome in Iranian adolescents with polycystic ovary syndrome. **2017**, 31, 4

575 Impact of mitochondrial DNA copy number and displacement loop alterations on polycystic ovary syndrome risk in south Indian women. **2019**, 44, 35-40 18

574 The prevalence of obstructive sleep apnoea in women with polycystic ovary syndrome: a systematic review and meta-analysis. **2020**, 24, 339-350 31

573 Decreased levels of liver-expressed antimicrobial peptide-2 and ghrelin are related to insulin resistance in women with polycystic ovary syndrome. **2020**, 36, 222-225 4

572 MALAT1 is involved in the pathophysiological process of PCOS by modulating TGF β signaling in granulosa cells. **2020**, 499, 110589 14

571 Genome-wide methylation profiling in granulosa lutein cells of women with polycystic ovary syndrome (PCOS). **2020**, 500, 110611 10

570 Elevated circulating levels of secreted frizzled-related protein 4 in relation to insulin resistance and androgens in women with polycystic ovary syndrome. **2020**, 43, 305-313 3

569 S100-A9 protein in exosomes derived from follicular fluid promotes inflammation via activation of NF- κ B pathway in polycystic ovary syndrome. **2020**, 24, 114-125 25

568 Dysregulated immunological and metabolic functions discovered by a polygenic integrative analysis for PCOS. **2020**, 40, 160-167 5

567 Polycystic Ovary Syndrome Signs and Metabolic Syndrome in Premenopausal Hispanic/Latina Women: the HCHS/SOL Study. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105, 5.6 3

566 Impaired heat shock protein 72 expression in women with polycystic ovary syndrome following a supervised exercise programme. **2020**, 25, 73-80 1

565 Disparate Relationship of Sexual Satisfaction, Self-Esteem, Anxiety, and Depression with Endocrine Profiles of Women With or Without PCOS. **2020**, 27, 432-442 3

564 Association between vascular endothelial growth factor gene polymorphisms and PCOS risk: a meta-analysis. **2020**, 40, 287-295 6

563 Relationship between adipocytokines and angiotensin converting enzyme gene insertion/deletion polymorphism in lean women with and without polycystic ovary syndrome. **2020**, 36, 496-500 5

562 Successful IVF outcome after repeat laparoscopic ovarian drilling in a case of resistant PCOS. **2020**, 13, 2

561 Antiproliferative and ameliorative effects of *Tetracera pottatoria* and its constituent. **2020**, 1 3

560	Reporting quality of polycystic ovary syndrome practice guidelines based on the RIGHT checklist. 2020 , 99, e22624	0
559	Evaluation of angiopoietin-like protein 3 (ANGPTL3) levels in polycystic ovary syndrome. 2020 , 263, 118595	2
558	Elevated Circulating Fetuin-B Levels Are Associated with Insulin Resistance and Reduced by GLP-1RA in Newly Diagnosed PCOS Women. 2020 , 2020, 2483435	5
557	Pediatric Gynecology. 2020 ,	
556	The risk of chronic kidney disease among women with polycystic ovary syndrome: A long-term population-based cohort study. 2020 , 93, 590-597	0
555	Cost-effective analysis of infertility treatment in women with anovulatory polycystic ovarian syndrome. 2020 , 5, e38-e38	
554	Risk of Cardiovascular and Cerebrovascular Events in Polycystic Ovarian Syndrome Women: A Meta-Analysis of Cohort Studies. 2020 , 7, 552421	3
553	Diet quality scores in relation to fatness and nutritional knowledge in women with polycystic ovary syndrome: case-control study. 2021 , 24, 3389-3398	6
552	Anogenital distance and anti-Müllerian hormone combined improves the diagnosis of polycystic ovary syndrome. 2020 , 1-9	2
551	miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): A review. 2020 , 259, 118174	22
550	Associations between white blood cells count and obesity in apparently healthy young adults. 2020 , 50, 1013-1019	
549	Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome. 2020 , 7,	14
548	Cross-sectional Study on the Knowledge and Prevalence of PCOS at a Multiethnic University. 2020 , 5, e0028	9
547	Increased MicroRNA Levels in Women With Polycystic Ovarian Syndrome but Without Insulin Resistance: A Pilot Prospective Study. 2020 , 11, 571357	7
546	Elevation of markers of endotoxemia in women with polycystic ovary syndrome. 2020 , 35, 2303-2311	6
545	Beneficial health effects of Menaquinone-7 on body composition, glycemic indices, lipid profile, and endocrine markers in polycystic ovary syndrome patients. 2020 , 8, 5612-5621	4
544	D-Chiro-Inositol Treatment Affects Oocyte and Embryo Quality and Improves Glucose Intolerance in Both Aged Mice and Mouse Models of Polycystic Ovarian Syndrome. 2020 , 21,	4
543	Inositols and metabolic disorders: From farm to bedside. 2020 , 10, 252-259	13

542	Expression of serum lncRNA-Xist in patients with polycystic ovary syndrome and its relationship with pregnancy outcome. 2020 , 59, 372-376		8
541	Adipocyte Insulin Resistance in PCOS: Relationship With GLUT-4 Expression and Whole-Body Glucose Disposal and β Cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	5
540	Mitochondrial function in women with polycystic ovary syndrome. 2020 , 32, 205-212		4
539	Biochemistry of infertility. 2020 , 508, 185-190		10
538	Left ventricular myocardial mass index and its correlates as an early marker of cardiovascular risk among nonobese normotensive Indian women with polycystic ovary syndrome: lessons from a cross-sectional study. 2020 , 113, 1299-1307.e2		
537	Pooled genetic analysis identifies variants that confer enhanced susceptibility to PCOS in Indian ethnicity. 2020 , 752, 144760		3
536	The effects of soy isoflavones on total testosterone and follicle-stimulating hormone levels in women with polycystic ovary syndrome: a systematic review and meta-analysis. 2020 , 25, 305-310		1
535	Recent Updates in Female Pelvic Ultrasound. 2020 , 8, 1		
534	Deletion of c16orf45 in zebrafish results in a low fertilization rate and increased thigmotaxis. 2020 , 62, 1003-1010		0
533	Ovulation Rate after Metformin and Clomiphene vs Clomiphene Alone in Polycystic Ovary Syndrome (PCOS): A Randomized, Double-Blind, Placebo-Controlled Trial. 2020 , 02, 32-36		1
532	Elevated and diagnostic androgens of polycystic ovary syndrome. 2020 , 19, 1-5		5
531	Increased DHEAS and Decreased Total Testosterone Serum Levels in a Subset of Men with Early-Onset Androgenetic Alopecia: Does a Male PCOS-Equivalent Exist?. 2020 , 2020, 1942126		8
530	Curcumin-loaded super-paramagnetic iron oxide nanoparticle affects on apoptotic factors expression and histological changes in a prepubertal mouse model of polycystic ovary syndrome-induced by dehydroepiandrosterone - A molecular and stereological study. 2020 , 249, 117515		10
529	Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women. 2020 , 36, 755-759		9
528	11-Oxygenated androgens in health and disease. 2020 , 16, 284-296		37
527	Impact of interleukin-6 on central obesity measures in women with polycystic ovarian syndrome. 2020 , 40, 1133-1137		5
526	Relationship between the characteristic traits of polycystic ovary syndrome and susceptibility genes. 2020 , 10, 10479		6
525	Potential causes of male and female infertility in Qatar. 2020 , 141, 103173		4

524	Long non-coding RNA expression in non-obese women with polycystic ovary syndrome and weight-matched controls. 2020 , 41, 579-583	2
523	Obesity and clinical psychosomatic women's health. 2020 , 293-312	
522	The impact of polycystic ovary syndrome and body mass index on the absorption of recombinant human follicle stimulating hormone. 2020 , 37, 2293-2304	0
521	HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA). 2020 , 36, 588-593	8
520	Dynamic Analysis of the Biochemical Changes in Rats with Polycystic Ovary Syndrome (PCOS) Using Urinary 1H NMR-Based Metabonomics. 2020 , 52, 49-57	2
519	Environmental toxin exposure in polycystic ovary syndrome women and possible ovarian neoplastic repercussion. 2020 , 36, 693-703	5
518	The association of dynamic thiol-disulfide homeostasis and inflammatory markers in patients with polycystic ovary syndrome. 2020 , 59, 79-84	7
517	Letrozole and human menopausal gonadotropin for ovulation induction in clomiphene resistance polycystic ovary syndrome patients: A randomized controlled study. 2020 , 99, e18383	9
516	Association analysis between the tag single nucleotide polymorphisms of DENND1A and the risk of polycystic ovary syndrome in Chinese Han women. 2020 , 21, 14	2
515	The effect of prednisolone on endometrial VEGF concentrations, Gene polymorphisms and pregnancy outcome in women with polycystic ovary syndrome: A retrospective cohort study. 2020 , 137, 103081	
514	Women with Polycystic Ovary Syndrome: A Marginalized Population in the United States. 2020 , 45, 40-46	3
513	Up-regulated FHL2 inhibits ovulation through interacting with androgen receptor and ERK1/2 in polycystic ovary syndrome. 2020 , 52, 102635	6
512	Associations of childhood adiposity with menstrual irregularity and polycystic ovary syndrome in adulthood: the Childhood Determinants of Adult Health Study and the Bogalusa Heart Study. 2020 , 35, 1185-1198	11
511	microRNA Expression in Women With and Without Polycystic Ovarian Syndrome Matched for Body Mass Index. 2020 , 11, 206	6
510	Metabolomics in Central Sensitivity Syndromes. 2020 , 10,	10
509	Steroid biomarkers for identifying non-classic adrenal hyperplasia due to 21-hydroxylase deficiency in a population of PCOS with suspicious levels of 17OH-progesterone. 2020 , 43, 1499-1509	5
508	Carotid intima-media thickness in polycystic ovary syndrome and its association with hormone and lipid profiles. 2020 , 15, e0232299	5
507	Neudesin: a neuropeptide hormone decreased in subjects with polycystic ovary syndrome. 2020 , 36, 849-853	1

506	Association of decreased myonectin levels with metabolic and hormonal disturbance in polycystic ovary syndrome. 2020 , 36, 947-950	4
505	Psychological distress in women with polycystic ovary syndrome: the role of attachment and coping. 2021 , 26, 735-744	1
504	Racial and ethnic differences in the metabolic response of polycystic ovary syndrome. 2020 , 93, 163-172	12
503	Decreased levels of spexin are associated with hormonal and metabolic disturbance in subjects with polycystic ovary syndrome. 2021 , 41, 408-413	4
502	Pathophysiological roles of chronic low-grade inflammation mediators in polycystic ovary syndrome. 2021 , 236, 824-838	38
501	Body- and symptom-related concerns in women diagnosed with polycystic ovary syndrome: A gap in symptom management. 2021 , 26, 701-712	3
500	Identification of epigenetic interactions between microRNA and DNA methylation associated with polycystic ovarian syndrome. 2021 , 66, 123-137	14
499	Can a mother's polycystic ovary syndrome (PCOS)-related symptoms be used to predict the future clinical profile of PCOS in her adolescent daughter? A pilot study. 2021 , 26, 17-22	1
498	Postpartum weight retention in women with polycystic ovary syndrome. 2021 , 224, 76.e1-76.e10	2
497	Effect of hypocaloric high-protein, low-carbohydrate diet supplemented with fennel on androgenic and anthropometric indices in overweight and obese women with polycystic ovary syndrome: A randomized placebo-controlled trial. 2021 , 56, 102633	1
496	In utero exposure to maternal stressful life events and risk of polycystic ovary syndrome in the offspring: The Raine Study. 2021 , 125, 105104	
495	Comparison of metabolic and obesity biomarkers between adolescent and adult women with polycystic ovary syndrome. 2021 , 303, 739-749	4
494	Humanin regulates oxidative stress in the ovaries of polycystic ovary syndrome patients via the Keap1/Nrf2 pathway. 2021 , 27,	10
493	Comparison of the effects of bilateral and unilateral laparoscopic ovarian drilling on pregnancy rates in infertile patients with polycystic ovary syndrome. 2021 , 47, 778-784	
492	Anti-Müllerian Hormone Levels in Adolescence in Relation to Long-term Follow-up for Presence of Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e1084-e1095	5.6 2
491	Does ischaemia-modified albumin level predict clomiphene citrate resistant polycystic ovary syndrome patients?. 2021 , 41, 462-466	
490	Serum kisspeptin levels correlated with anti-mullerian hormone levels in women with and without polycystic ovarian syndrome. 2021 , 37, 462-466	3
489	Dark cortical rim: an MRI feature of polycystic ovarian syndrome. 2021 , 46, 1148-1156	4

488	The Relationship Between Polycystic Ovarian Syndrome, Periodontal Disease, and Osteoporosis. 2021 , 28, 950-962	2
487	Hyperandrogenism in polycystic ovary syndrome affects psychological well-being of adolescents. 2021 , 47, 137-146	3
486	Relationship of PD-1 (PDCD1) and PD-L1 (CD274) Single Nucleotide Polymorphisms with Polycystic Ovary Syndrome. 2021 , 2021, 9596358	3
485	Cardiovascular risk in menopausal women and our evolving understanding of menopausal hormone therapy: risks, benefits, and current guidelines for use. 2021 , 12, 20420188211013917	2
484	Features of the Functional State of the Hypophysis-Ovarian System and Processes of Lipid Peroxidation Antioxidant Protection in Women with Hyperandrogenism of Ovary Genesis in the Early Reproductive Period. 2021 , 5, 20-26	
483	Long-term androgen-induced nonalcoholic fatty liver disease in a polycystic ovary syndrome mouse model is related to mitochondrial dysfunction. 2021 , 5, 71	0
482	Cosmetic Endocrinology. 2021 , 64, 96-101	
481	Contraceptive Choice in Women with PCOS. 2021 , 249-266	
480	Does intracytoplasmic sperm injection increase the risk of gestational diabetes in patients with polycystic over?. 2021 , 3, 53-58	2
479	POLİBİSTİR OVER SENDROMUNDA (PKOS) ENDOTELYAL DİFONKSİYONUN ERKEN SERUM BELİRTECİ ENDOCAN.	
478	How polycystic ovary syndrome came into its own.. 2021 , 2, 2-10	1
477	Polycystic ovary syndrome and extremely preterm birth: A nationwide register-based study. 2021 , 16, e0246743	1
476	DNA methylation of AMHR11 and INSR gene is associated with the pathogenesis of Polycystic Ovary Syndrome (PCOS). 2021 , 29, 11-25	3
475	Polycystic Ovary Syndrome: Pathophysiology, Presentation and Treatment a Mini-Review Article. 2021 ,	
474	Incidence and Predictors of Hypertension in a Cohort of Australian Women With and Without Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 1585-1593	5.6 3
473	Body Composition and Characterization of Skinfold Thicknesses from Polycystic Ovary Syndrome Phenotypes. A Preliminar Case-Control Study. 2021 , 18,	
472	The Role of Chronic Inflammation in Polycystic Ovarian Syndrome-A Systematic Review and Meta-Analysis. 2021 , 22,	13
471	A systematic review of N-acetylcysteine for treatment of acne vulgaris and acne-related associations and consequences: Focus on clinical studies. 2021 , 34, e14915	1

470	The Role of Genetics, Epigenetics and Lifestyle in Polycystic Ovary Syndrome Development: the State of the Art. 2021 , 1	5
469	Integrated Transcriptomic and Epigenetic Study of PCOS: Impact of and Promoter Methylation on Autophagy. 2021 , 12, 620241	3
468	A review on inositol's potential in cyclic disturbances of adipose-endocrinology-associated polycystic ovary syndrome. 2021 , 476, 2943-2949	
467	Gonadotrophin-releasing hormone receptor autoantibodies induce polycystic ovary syndrome-like features in a rat model. 2021 , 106, 902-912	2
466	The use of N-Acetyl cysteine versus chromium picolinate as adjuvant to clomiphene citrate and metformin in PCOS women to improve ovulation induction and insulin resistance A pilot randomized controlled trial. 2021 , 17,	
465	Back where it belongs: 11 β hydroxyandrostenedione compels the re-assessment of C11-oxy androgens in steroidogenesis. 2021 , 525, 111189	4
464	Nutrition in Gynecological Diseases: Current Perspectives. 2021 , 13,	9
463	Identification of predictors of the ovarian response to clomiphene citrate in infertile women with polycystic ovary syndrome: a prospective cohort study. 2021 , 49, 3000605211000569	
462	Complementary and Alternative Medicine for the Treatment of Abnormal Endometrial Conditions in Women with PCOS: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2021 , 2021, 5536849	1
461	Polycystic Ovary Syndrome, Affective Symptoms, and Neuroactive Steroids: a Focus on Allopregnanolone. 2021 , 23, 36	2
460	Bioinformatics analysis of the molecular mechanism of obesity in polycystic ovary syndrome. 2021 , 13, 12631-12640	1
459	Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis. 2021 , 20, 449-461	3
458	Total testosterone is not associated with lean mass or handgrip strength in pre-menopausal females. 2021 , 11, 10226	5
457	Eflornithine. 2021 , 13, 179-182	
456	Effects of Synbiotic Supplementation and Lifestyle Modifications on Women With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 2566-2573	5.6 2
455	The Release of Peripheral Immune Inflammatory Cytokines Promote an Inflammatory Cascade in PCOS Patients Altering the Follicular Microenvironment. 2021 , 12, 685724	6
454	Non-Classical Congenital Adrenal Hyperplasia-Causing Alleles in Adolescent Girls with PCOS and in Risk Group for PCOS Development. 2021 , 11,	0
453	Clinico-investigative attributes of 122 patients with hirsutism: A 5-year retrospective study from India. 2021 , 7, 237-242	1

452	Vasectomy reversal vs. sperm retrieval with in vitro fertilization: a contemporary, comparative analysis. 2021 , 115, 1377-1383	1
451	Endometrial Receptivity in Patients with Polycystic Ovary Syndrome.	
450	A CROSS SECTIONAL STUDY OF POLY CYSTIC OVARIAN SYNDROME (PCOS) AMONGST ADOLESCENT GIRLS IN LUCKNOW.. 2021 , 3-5	
449	Serum Metabolomics in PCOS Women with Different Body Mass Index. 2021 , 10,	3
448	Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism. 2021 , 115, 1557-1568	2
447	Comparison of Clinical, Metabolic and Hormonal Effects of Metformin Versus Combined Therapy of Metformin With Myoinositol Plus D-Chiro-Inositol in Women With Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial. 2021 , 13, e15510	0
446	Bioinformatics Analysis of ceRNA Network Related to Polycystic Ovarian Syndrome. 2021 , 2021, 9988347	1
445	Sleep disturbances may influence lifestyle behaviours in women with self-reported polycystic ovary syndrome. 2021 , 1-9	0
444	Polycystic ovary syndrome and postpartum depression symptoms: a population-based cohort study. 2021 , 224, 591.e1-591.e12	4
443	Polycystic ovary syndrome and its possible association with sleep complaints : PCOS and sleep. 2021 , 24, 1055-1057	
442	Metabolomic Profiling of Pregnancies With Polycystic Ovary Syndrome Identifies a Unique Metabolic Signature and Potential Predictive Biomarkers of Low Birth Weight. 2021 , 12, 638727	2
441	Anthropometric Characteristics of Polycystic Ovary Syndrome and Their Associations with Insulin Resistance and Lipid Profile. 2021 , 11, 5395	1
440	The Need to Reassess the Diagnosis of Polycystic Ovary Syndrome (PCOS): A Review of Diagnostic Recommendations from the International Evidence-Based Guideline for the Assessment and Management of PCOS. 2021 , 39, 71-77	1
439	Obesity alters ovarian folliculogenesis through disrupted angiogenesis from increased IL-10 production. 2021 , 49, 101189	4
438	Can polyunsaturated fatty acids regulate Polycystic Ovary Syndrome via TGF-β signalling?. 2021 , 276, 119416	0
437	Differences in the individual curative effect of acupuncture for obese women with polycystic ovary syndrome based on metagenomic analysis: study protocol for a randomized controlled trial. 2021 , 22, 454	0
436	Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. 2021 , 12, 932-938	3
435	Premenstrual dysphoric disorder is associated with the longer length from clitoris to urethra. 2021 , 21, 266	

- 434 Serum amyloid A in polycystic ovary syndrome. **2021**, 518, 151-155 0
- 433 A STUDY ON INSULIN RESISTANCE AND ITS ASSOCIATION WITH OBESITY IN POLYCYSTIC OVARY SYNDROME. **2021**, 65-67
- 432 CLINICAL, METABOLIC, ENDOCRINE AND SONOGRAPHIC CHARACTERISTICS OF OBESE ADOLESCENT WITH PCOS. **2021**, 6-9
- 431 Involvement of ferroptosis in the granulosa cells proliferation of PCOS through the circRHBG/miR-515/SLC7A11 axis. **2021**, 9, 1348 3
- 430 Effect of Ubiquinol supplementation on ovulation induction in Clomiphene Citrate resistance. **2021**, 26,
- 429 Aberrant miRNA-mRNA regulatory network in polycystic ovary syndrome is associated with markers of insulin sensitivity and inflammation. **2021**, 9, 1405 2
- 428 Development and Evaluation of Curcumin Encapsulated Self-assembled Nanoparticles as Potential Remedial Treatment for PCOS in a Female Rat Model. **2021**, 16, 6231-6247 2
- 427 Prevalence of Hirsutism Among Reproductive-Aged African American Women. **2021**, 30, 1580-1587 2
- 426 Practical Approach to Hyperandrogenism in Women. **2021**, 105, 1099-1116 0
- 425 Characterization of comorbidity heterogeneity among 13,667 patients with hidradenitis suppurativa. **2021**, 6, 0
- 424 Cutaneous manifestation of polycystic ovary syndrome. **2021**, 13, 8799 2
- 423 Polycystic ovarian syndrome: A review covering phytoconstituents for its outstrip management. **2021**, 1, 100011
- 422 An Insight on Polycystic Ovary Syndrome (PCOS) and Use of Herbal Medicines as Alternative Treatment. **2021**, 125-163
- 421 Pathophysiology of Obstructive Sleep Apnea Syndrome in Childhood. **2021**, 437-457 1
- 420 Abnormal Uterine Bleeding in the Adolescent. **2021**,
- 419 Obesity and polycystic ovary syndrome. **2021**, 95, 531-541 18
- 418 Obesity, Metabolic Syndrome and Disorders of Energy Balance. **2021**, 939-1003 0
- 417 Is there a Relationship between Serum IGF-1 and Thyroid Nodule, Thyroid or Ovarian Volume in Polycystic Ovarian Syndrome?. **2021**, 17, 138-146

416	Berberine Improves the Symptoms of DHEA-Induced PCOS Rats by Regulating Gut Microbiotas and Metabolites. 2021 , 86, 388-397	1
415	Hypoglycaemic agents for pregnant women with polycystic ovarian syndrome.	2
414	Polycystic Ovarian Syndrome. 559-570	1
413	Medical Treatment. 2009 , 209-232	2
412	Hyperandrogenism in PCOS. 2009 , 105-110	1
411	Diagnostic Criteria and Epidemiology of PCOS. 2014 , 3-10	5
410	Childhood and Adolescent Obesity: Implications for Reproductive Health and Function. 2015 , 15-30	1
409	Polycystic Ovary Syndrome and Its Metabolic Complications. 2006 , 255-276	1
408	Impact of Diagnostic Criteria. 2008 , 333-344	1
407	Fetal Origins of Polycystic Ovary Syndrome. 2008 , 87-106	2
406	Clinical Features of the Polycystic Ovary Syndrome. 2006 , 155-167	1
405	The Genetic Basis of the Polycystic Ovary Syndrome. 2006 , 223-233	2
404	Clinical and Hormonal Evaluation of Androgen Excess. 2006 , 365-375	1
403	Long-Term Sequelae of Polycystic Ovary Syndrome. 2007 , 335-348	1
402	Oxidative Stress Impact on the Fertility of Women with Polycystic Ovary Syndrome. 2013 , 169-180	1
401	Polycystic Ovarian Syndrome. 2019 , 31-40	2
400	Exercise and Polycystic Ovary Syndrome. 2020 , 1228, 123-136	5
399	Association between VEGF gene polymorphisms (11 sites) and polycystic ovary syndrome risk. 2020 , 40,	4

398	Prenatal Exposure to Endocrine Disruptors: A Developmental Etiology for Polycystic Ovary Syndrome. 2017 , 24, 19-27	33
397	Lifestyle and environmental contributions to ovulatory dysfunction in women of polycystic ovary syndrome. 2020 , 20, 19	11
396	Intersection of Polycystic Ovary Syndrome and the Gut Microbiome. 2021 , 5, bvaa177	13
395	Relationship between Polycystic Ovary Syndrome and Hyperuricemia. 2017 , 05, 113-119	1
394	Systems Genetics Reveals the Functional Context of PCOS Loci and Identifies Genetic and Molecular Mechanisms of Disease Heterogeneity. 2015 , 11, e1005455	59
393	Environmentally induced epigenetic transgenerational inheritance of ovarian disease. 2012 , 7, e36129	182
392	Genetic alterations within the DENND1A gene in patients with polycystic ovary syndrome (PCOS). 2013 , 8, e77186	26
391	In an Ovine Model of Polycystic Ovary Syndrome (PCOS) Prenatal Androgens Suppress Female Fetal Renal Gluconeogenesis. 2015 , 10, e0132113	12
390	Are Dieting and Dietary Inadequacy a Second Hit in the Association with Polycystic Ovary Syndrome Severity?. 2015 , 10, e0142772	8
389	A Single Arm Pilot Study of Effects of Berberine on the Menstrual Pattern, Ovulation Rate, Hormonal and Metabolic Profiles in Anovulatory Chinese Women with Polycystic Ovary Syndrome. 2015 , 10, e0144072	15
388	Association between High Serum Homocysteine Levels and Biochemical Characteristics in Women with Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis. 2016 , 11, e0157389	22
387	The Role of Serum MicroRNA-6767-5p as a Biomarker for the Diagnosis of Polycystic Ovary Syndrome. 2016 , 11, e0163756	13
386	Analysis of VEGFA Variants and Changes in VEGF Levels Underscores the Contribution of VEGF to Polycystic Ovary Syndrome. 2016 , 11, e0165636	21
385	CRP LEVELS AND ENDOTHELIAL FUNCTION IN YOUNG WOMEN WITH PCOS. 2016 , 5, 5783-5786	1
384	Serum Copeptin, Pentraxin 3, Anti-Mullerian Hormone Levels With Echocardiography and Carotid Artery Intima-Media Thickness in Adolescents With Polycystic Ovary Syndrome. 2015 , 7, 989-94	9
383	Prevalence and Risk Factors of Elevated Liver Enzymes in Japanese Women With Polycystic Ovary Syndrome. 2018 , 10, 904-910	7
382	Up-regulation of miR-21 and 146a expression and increased DNA damage frequency in a mouse model of polycystic ovary syndrome (PCOS). 2016 , 6, 85-91	10
381	Relationship between IL-17 serum level and ambulatory blood pressure in women with polycystic ovary syndrome. 2017 , 6, 15-24	8

380	Association between PCOS and autoimmune thyroid disease: a systematic review and meta-analysis. 2018 , 7, 1158-1167	23
379	Comparison of uterine and ovarian stromal blood flow in patients with polycystic ovarian syndrome. 2019 , 8, 50-56	3
378	Approach to patients with pseudo-Cushing's states. 2020 , 9, R1-R13	22
377	Overweight and Obesity Prevalence in Referral Population of Infertile Women with Polycystic Ovary Syndrome. 2017 , 7,	1
376	Polycystic ovary syndrome: controversies and challenges. 2015 , 61, 485-7	10
375	[Difficulties and pitfalls in the diagnosis of polycystic ovary syndrome]. 2011 , 55, 6-15	6
374	Incidence of prediabetes and risk of developing cardiovascular disease in women with polycystic ovary syndrome. 2016 , 16, 298-306	11
373	Evaluating the Association of Ovarian Reserve with Age in Women with Polycystic Ovary Syndrome. 2017 , 2, 004-008	1
372	INCIDENCE OF NON - ALCOHOLIC HEPATIC FATTY INFILTRATION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME. 2014 , 1, 867-875	2
371	Matrix metalloproteinase-9 increases and Interleukin-10 reduces with increase in body mass index in polycystic ovary syndrome: A cross-sectional study. 2020 , 18, 605-610	1
370	Follicular metabolic changes and effects on oocyte quality in polycystic ovary syndrome patients. 2017 , 8, 80472-80480	33
369	Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome. 2018 , 9, 4522-4536	16
368	Coronary artery disease risk in young women with polycystic ovary syndrome. 2018 , 9, 8756-8764	22
367	Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. 2016 , 7, 33715-21	67
366	Evaluation of Ovaries in Patients with Polycystic Ovary Syndrome using Shear Wave Elastography. 2020 , 16, 578-583	3
365	"Less Than A Wife": A Study of Polycystic Ovary Syndrome Content in Teen and Women's Digital Magazines. 2016 , 18, e89	11
364	Comparing the Effects of Oral Contraceptives Containing Levonorgestrel With Products Containing Antiandrogenic Progestins on Clinical, Hormonal, and Metabolic Parameters and Quality of Life in Women With Polycystic Ovary Syndrome: Crossover Randomized Controlled Trial Protocol. 2017 , 6, e191	2
363	Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. 2017 , 18, 17-21	50

362	The Lys469glu/K469E Polymorphism of the Inflammatory Gene Intercellular Adhesion Molecule-1 Lacks any Apparent Role in the Polycystic Ovary Syndrome in Kashmiri Women: A Case Control Study. 2017 , 18, 2925-2930	1
361	Association of Glomerular Filtration Rate with Inflammation in Polycystic Ovary Syndrome. 2015 , 9, 176-82	8
360	Criteria, phenotypes and prevalence of polycystic ovary syndrome. 2019 , 71, 211-223	29
359	Associations between vitamin D levels and polycystic ovary syndrome phenotypes. 2019 , 44, 176-184	16
358	Polycystic ovary syndrome: current status and future perspective. 2014 , 6, 104-19	73
357	Association of vitamin D receptor gene variants with polycystic ovary syndrome: A case control study. 2015 , 13, 793-800	8
356	Nitric oxide donors improve the ovulation and pregnancy rates in anovulatory women with polycystic ovary syndrome treated with clomiphene citrate: A RCT. 2016 , 14, 9-14	3
355	Relative associations of polycystic ovarian syndrome vs metabolic syndrome with thyroid function, volume, nodularity and autoimmunity. 2011 , 34, e259-64	8
354	Understanding polycystic ovarian syndrome pathogenesis: an updated of its genetic aspects. 2011 , 34, 630-44	7
353	Haplotype TGTG from SNP 45T/G and 276G/T of the adiponectin gene contributes to risk of polycystic ovary syndrome. 2013 , 36, 497-502	6
352	Endocrine disruptors, obesity, and cytokines - how relevant are they to PCOS?. 2020 , 69, S279-S293	11
351	Reproduction and Metabolism: Insights from Polycystic Ovary Syndrome. 2012 , 27, 180	2
350	The Modified Ferriman-Gallwey Score and Hirsutism among Filipino Women. 2019 , 34, 374-381	8
349	Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Müllerian hormone cutoff value. 2017 , 32, 690-698	15
348	Polycystic Ovary Syndrome and Central Serous Chorioretinopathy. 2015 , 46, 684-6	5
347	Prevalence of metabolic syndrome in relation to body mass index and polycystic ovarian syndrome in Indian women. 2015 , 8, 202-8	20
346	Endocrinal and autoimmune linkage: Evidences from a controlled study of subjects with polycystic ovarian syndrome. 2016 , 9, 18-22	10
345	Cutaneous Manifestations of Polycystic Ovary Syndrome: A Cross-Sectional Clinical Study. 2017 , 8, 104-110	21

344	Prevalence of polycystic ovary syndrome in young women from North India: A Community-based study. 2012 , 16, S389-92	21
343	Letrozole as the first-line treatment of infertile women with poly cystic ovarian syndrome (PCOS) compared with clomiphene citrate: A clinical trial. 2016 , 5, 6	7
342	Evaluation of Endometrial Receptivity by Measuring HOXA-10, HOXA-11, and Leukemia Inhibitory Factor Expression in Patients with Polycystic Ovary Syndrome. 2019 , 8, 118-122	19
341	Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. 2019 , 150, 333-344	30
340	The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. 2020 , 13, 261-271	28
339	Polycystic Ovarian Syndrome-Related Depression in Adolescent Girls: A Review. 2018 , 10, 55-59	15
338	Prevalence of reproductive abnormalities among women with familial partial lipodystrophy. 2008 , 14, 1126-32	16
337	Pancreatic β cell dysfunction in polycystic ovary syndrome: the role of metformin. 2012 , 18, 685-93	11
336	ADIPONECTIN AS A SERUM MARKER OF ADIPOSE TISSUE DYSFUNCTION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: CORRELATION WITH INDICATORS OF METABOLIC DISTURBANCES. 2018 , 14, 346-352	1
335	Association between Common Genetic Variants and Polycystic Ovary Syndrome Risk in a Chinese Han Population. 2016 , 8, 405-410	4
334	The assessment of thyroid autoantibody levels in euthyroid patients with polycystic ovary syndrome. 2018 , 19, 215-219	3
333	Association of decreased C1q/tumor necrosis factor-related protein-5 levels with metabolic and hormonal disturbance in polycystic ovary syndrome. 2019 , 20, 89-96	5
332	Body Image, Self-Esteem and Depressive Symptomatology in Women with Polycystic Ovary Syndrome. 2014 , 51, 129-132	13
331	Circulating SCUBE1 levels in women with polycystic ovary syndrome. 2018 , 15, 152-158	1
330	The prevalence of uterine anomalies in infertile patients with polycystic ovary syndrome: A retrospective study in a tertiary center in Southeastern Turkey. 2019 , 16, 224-227	5
329	Bioelectric Impedance Analysis of Visceral Fat in Women with Polycystic Ovarian Syndrome and the Effect of Exercise: A Pilot Study. 2016 , 7, 89-93	1
328	Hirsutism in Saudi females of reproductive age: a hospital-based study. 2008 , 28, 28-32	14
327	The metabolic effects of drugs used for the treatment of polycystic ovary syndrome. 2013 , 14, 168-73	1

326	Metabolic and carbohydrate characteristics of different phenotypes of polycystic ovary syndrome. 2016 , 17, 201-208	4
325	The Effect of Exercise in PCOS Women Who Exercise Regularly. 2010 , 1, 35-40	7
324	The Polycystic Ovary Syndrome Health-Related Quality-of-Life Questionnaire: Confirmatory Factor Analysis. 2018 , 16, e12400	5
323	Anthropometric and Biochemical Characteristics of Polycystic Ovarian Syndrome in South Indian Women Using AES-2006 Criteria. 2014 , 12, e12470	26
322	Association of mean platelet volume with androgens and insulin resistance in nonobese patients with polycystic ovary syndrome. 2014 , 12, e18642	8
321	Female Gender Scheme is Disturbed by Polycystic Ovary Syndrome: A Qualitative Study From Iran. 2014 , 16, e12423	11
320	Comparison of Metformin and Simvastatin Administration in Women With Polycystic Ovary Syndrome Before Intra-Cytoplasmic Sperm Injection Cycle: A Prospective, Randomized, Clinical Trial Study. 2015 , 17, e20082	4
319	Influence of PCOS in Obese vs. Non-Obese women from Mesenchymal Progenitors Stem Cells and Other Endometrial Cells: An in silico biomarker discovery. 2017 , 13, 111-115	5
318	The ICAM-1 Gly241Arg Polymorphism is Not Associated With Polycystic Ovary Syndrome - Results from a Case Control study in Kashmir, India. 2016 , 17, 1583-8	3
317	Follicular hyperandrogenism and insulin resistance in polycystic ovary syndrome patients with normal circulating testosterone levels. 2017 ,	3
316	Polycystic ovarian syndrome: long-term surgical outcomes (literature review). 2021 , 8, 61-66	
315	Investigating Fetuin-A and Paraoxonase-1 Activity as Markers in Polycystic Ovary Syndrome Based on Body Mass Index: A Prospective Case-Control Study. 2021 , 13, e18553	2
314	Aberrant H19 Expression Disrupts Ovarian Cyp17 and Testosterone Production and Is Associated with Polycystic Ovary Syndrome in Women. 2021 , 1	0
313	Polycystic ovary syndrome is an independent risk factor for hypertensive disorders of pregnancy: A systematic review, meta-analysis, and meta-regression. 2021 , 74, 518-529	1
312	Coronary Artery Disease in Women: A Comprehensive Appraisal. 2021 , 10,	2
311	Prevalence, Symptomatology and Herbal Management of Polycystic Ovarian Syndrome.	
310	Brown Adipose Tissue Activation by Cold Treatment Ameliorates Polycystic Ovary Syndrome in Rat. 2021 , 12, 744628	0
309	Polycystic ovary syndrome. 2006 , 35, 888-96	

308 Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome. **2007**, 303-315

307 Mosby's Guide to Women's Health - Pages 249-275. **2007**, 249-275

306 Serine Phosphorylation, Insulin Resistance, and the Regulation of Androgen Synthesis. **2007**, 99-114

305 Gynkologische Erkrankungen. **2007**, 1095-1110

304 Polycystic Ovary Syndrome. **2007**, 287-296

303 Lifestyle Intervention in Polycystic Ovarian Syndrome. **2007**, 371-383

302 Genes Related to Metabolic Abnormalities or Insulin Resistance in Polycystic Ovary Syndrome. **2007**, 49-67

301 Statins, Oxidative Stress, and Polycystic Ovary Syndrome. **2007**, 263-278

300 Polycystic Ovary Syndrome in the Peripubertal Period. **2007**, 285-308

299 Polycystic Ovary Syndrome and the Metabolic Syndrome. **2007**, 537-552

298 Gynecological Morbidity. **2008**, 88-101

297 Special Issues in Treatment of Pediatric Obesity. **2008**, 569-592

296 Endometrial Cancer. **2009**, 13-24

295 Genetics of Metabolic Syndrome and Genetic Lipodystrophies. **2009**, 63-81

294 Polycystic ovary syndrome: multiple pathways to a common phenotype?. **2009**, 15, 387-9

293 Polycystic Ovary Syndrome. **2010**, 45-53

292 The prevalence and clinical features of polycystic ovary syndrome in a Moscow population. **2010**, 56, 3-8

1

291 Syndrome of hyperandrogenism in girls of pubertal age. **2010**, 56, 48-54

1

- 290 Polycystic ovary syndrome. **2011**, 119-125
- 289 Hormonale Status En Cardiovasculair Risico. **2011**, 141-151
- 288 Androgen Deficiency. **2011**, 195-215
- 287 Serum Adiponectin levels in Different Phenotypes of Polycystic Ovary Syndrome. **2012**, 02, 125-131 0
- 286 Polycystic Ovarian Syndrome. **2012**, 345-352.e2
- 285 Predictors of abnormal glucose tolerance among women with polycystic ovary syndrome. **2012**, 55, 477
- 284 Hirsutism: causes and management. **2012**, 2012,
- 283 Bariatric Surgery in Pediatric Weight Management. **2012**, 947-964
- 282 Prevalence and characteristics of polycystic ovarian syndrome in a sample of infertile Kurdish women attending IVF infertility center in maternity teaching hospital of Erbil City. **2013**, 03, 577-585 3
- 281 Ethnicity and IVF. **2013**, 115-126
- 280 Fertility Differences Among Ethnic Groups. **2013**, 39-72
- 279 Emerging Concepts: Role of Vitamin D Deficiency in the Pathogenesis of PCOS. **2014**, 317-331 1
- 278 Abnormal Menstrual Cycles. **2014**, 67-72
- 277 Leptin Causes the Early Inhibition of Glycolysis- and TCA Cycle-Related Genes in the Brain of Ob/Ob Mice to Restore Fertility. **2014**, 04, 105-113
- 276 Enhancement of Sister Chromatid Exchanges (SCEs) in Peripheral Blood Lymphocytes of Women with Polycystic Ovary Syndrome (PCOS) <i>in Vitro&/i>. **2015**, 05, 378-384
- 275 Introduction. **2015**, 1-4
- 274 Polycystic Ovarian Syndrome and Response to Stimulation. **2015**, 329-345
- 273 The importance of speckle tracking echocardiography in the early detection of left ventricular dysfunction in patients with polycystic ovary syndrome. **2015**, 15, 44-9

272 Physical Activity and Pregnancy. **2016**, 253-285

271 Endocrine Abnormalities in RPL. **2016**, 37-51

270 Endocrine Disease and Liver. **2016**, 251-270

269 Insulin resistance and hyperinsulinemia. **2016**, 65, 75-86

3

268 Prediction of Ovarian Response by Antimullerian Hormone in Women with Polycystic Ovarian Syndrome: A Randomized Prospective Study. **2016**, 2, 033-037

1

267 Case Report of 20 Amenorrhea or Oligomenorrhea Patients due to Polycystic Ovarian Syndrome. **2016**, 29, 47-56

1

266 Glycemic Index and Women's Health. **2016**, 199-218

265 Polikistik Over Sendromu Olan Kadınlarda Artan Lökosit Sayısı Hyperandrojenizm ve Vücut Kitle İndeksi ile İlişisi. **2016**, 16,

264 Clinical efficacy of with followed by in the management of w. s. r to polycystic ovarian syndrome. **2017**, 38, 127-132

1

263 Cardiovascular Disease Risk in Women: What Makes It Different from Men. **2017**, 1-31

0

262 Assessment of central corneal thickness, intraocular pressure and retinal nerve fiber layer thickness at women with polycystic ovary syndrome. 65-68

1

261 Comparing the Effects of Oral Contraceptives Containing Levonorgestrel With Products Containing Antiandrogenic Progestins on Clinical, Hormonal, and Metabolic Parameters and Quality of Life in Women With Polycystic Ovary Syndrome: Crossover Randomized Controlled Trial Protocol (Preprint)

260 PREDICTORS OF PREGNANCY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME. **2017**, 4, 4196-4200

259 The relation between serum anti-Mullerian hormone levels and follicle count in polycystic ovary syndrome.

258 Case of a Girl with Heavy, Prolonged Periods and Anemia. **2018**, 65-72

257 Sociodemographic Characteristics and Clinical Presentation of Infertile Women with Polycystic Ovary Syndrome in a Tertiary Care Hospital. **2018**, 9, 14-18

3

256 Prevalence of Polycystic Ovary Syndrome in Nigerian Women with Infertility: A Prospective Study of the Three Assessment Criteria. **2018**, 08, 1109-1120

1

255 Research-Based Applied Psychophysiology. **2018**, 121-150

- 254 Prostate specific antigen is raised in polycystic ovary syndrome. **2018**, 6,
- 253 THE EFFECTS OF TREATMENT WITH ORAL CONTRACEPTIVE PILL CONTAINING ETHINYL ESTRADIOL-CYPROTERONE ACETATE ALONE OR IN COMBINATION WITH METFORMIN ON CLINICAL, HORMONAL, METABOLIC AND ULTRASONOGRAPHIC CHARACTERISTICS IN POLYCYSTIC OVARIAN SYNDROME. **2018**, 5, 2351-2355
- 252 POLİKİSTİK OVER SENDROMLU OLGULARDA NİSİN DİRENÇLİVE BOZULMUŞ GLÜKÖZ TOLERANSININ SERUM ANDROJEN DÜZEYLERİNE ETKİSİ VAR MI?.
- 251 Obstructive sleep apnea: from the beginnings, to the risk factors and to occupational medicine assessment. **2018**, 69, 6-11
- 250 Ovarian Metabolic activity in Dehydroepiandrosterone-Induced Polycystic Ovary in Wistar rats Treated with Aspirin. **2020**, 24, 41-54 2
- 249 Polikistik Over Sendromunda Obezite ve Metabolik Durumun Fertil ve İfertil Gruplarda Değerlendirilmesi.
- 248 New markers for the detection of polycystic ovary syndrome. **2019**, 10, 2
- 247 Prevalence and Clinical Profile of Patients with Polycystic Ovary Syndrome- A Hospital Based Study. **2019**, 8, 2573-2576
- 246 Oocytes Retrieval in Metabolic Syndrome. **2020**, 225-242
- 245 Hypertensive Diseases in Female and Pregnancy. **2020**, 569-638
- 244 Evaluation of the treatment with D-chiroinositol on levels of oxidative stress in pcos patients. **2019**, 67-72
- 243 A review of 300 consecutive cases of Polycystic ovarian syndrome: clinical presentation and management. **2020**, 9, 92-96
- 242 GnRH Agonist Uzun Protokol tedavi uygulanan Polikistik Over Sendromu olan ve olmayan hastaların gebelik sonuçları ile karşılaştırılması
- 241 High risk of psychological disorders: anxiety and depression in adolescent girls with polycystic ovary syndrome. **2020**, 8, 73-77 1
- 240 Characteristics and Risk Factors for Polycystic Ovarian Syndrome Among Females. **2020**, 5, 200-209
- 239 Total testosterone is not associated with lean mass or handgrip strength in pre-menopausal females: findings from the NHANES.
- 238 The Impact of COVID-19 Lockdown on Weight Loss Program in Infertile Polycystic Ovary Syndrome Women with Obesity. **2021**, 14, 650-657 1
- 237 An Efficient Decision Tree Establishment and Performance Analysis with Different Machine Learning Approaches on Polycystic Ovary Syndrome. **2020**, 4

- 236 Persistent risk: psychological comorbidity in polycystic ovary syndrome. **2020**, 8, 139-141 0
- 235 Tailoring treatment for PCOS phenotypes. **2021**, 16, 9-18 4
- 234 Autoimmune activation of the GnRH receptor induces insulin resistance independent of obesity in a female rat model. **2021**, 8, e14672 1
- 233 Determination of Neurodegeneration in Polycystic Ovary Syndrome with Retinal Segmentation Analysis. **2021**, 46, 831-838 1
- 232 Features of the course of pregnancy in women with polycystic ovary syndrome. **2020**, 69, 105-112 1
- 231 Self-Administered Questionnaire to Screen for Polycystic Ovarian Syndrome. **2020**, 1, 566-573
- 230 Polycystic ovary syndrome and increased risk of psychiatric disorders. **2020**, 8, 133-137
- 229 Polycystic Ovarian Syndrome. **2020**, 253-274
- 228 Exploring the activity of the enzyme 11 β hydroxylase in the polycystic ovary syndrome. **2020**, 41, 1
- 227 Prevalence of Cutaneous Disorders in Patients with Polycystic Ovary Syndrome. **2020**, 10, 1246-1264
- 226 Psychometric Properties of the Iranian Version of Physical Disability Sexual and Body Esteem Questionnaire in Women with Polycystic Ovary Syndrome. **2020**, 1, 5-10 1
- 225 Circ_0043532 regulates miR-182/SGK3 axis to promote granulosa cell progression in polycystic ovary syndrome. **2021**, 19, 167 1
- 224 Mechanisms and Treatment of Obesity in Polycystic Ovary Syndrome. **2008**, 217-240
- 223 Variations in the Expression of the Polycystic Ovary Syndrome Phenotype. **2008**, 123-132
- 222 Definition and Epidemiology of the Polycystic Ovary Syndrome. **2006**, 145-153
- 221 Hypothalamic-Pituitary-Adrenal Dysfunction in the Polycystic Ovary Syndrome. **2006**, 213-222
- 220 Pediatric Hyperandrogenism and the Polycystic Ovary Syndrome in Adolescence. **2006**, 235-246
- 219 Reproductive and Obstetrical Consequences of the Polycystic Ovary Syndrome. **2006**, 333-341

- 218 Psychosocial and Quality-of-Life Consequences of Androgen Excess and the Polycystic Ovary Syndrome. **2006**, 343-352
- 217 Overview of Long-Term Morbidity and Economic Cost of the Polycystic Ovary Syndrome. **2006**, 353-362 1
- 216 Polycystic Ovary Syndrome and Ovulation Induction. **2006**, 389-404
- 215 Abnormal Menstrual Cycles. **2008**, 131-136
- 214 Metabolic Complications of Polycystic Ovary Syndrome. **2008**, 377-390
- 213 Prevalence of acne vulgaris among women with polycystic ovary syndrome: a systemic review and meta-analysis. **2021**, 37, 392-405 6
- 212 A Case of Successful Treatment with Unilateral Oophorectomy in a Patient with Resistant Polycystic Ovary Syndrome. **2020**, 2020, 8893000
- 211 CLINICAL, BIOCHEMICAL AND HORMONE PROFILE IN HIRSUTE VS NONHIRSUTE PATIENTS WITH POLYCYSTIC OVARY SYNDROME. **2020**, 28-30
- 210 Metabolic Syndrome in Patients with Polycystic Ovary Syndrome in Iran. **2016**, 9, 490-6 23
- 209 Cardiometabolic aspects of polycystic ovarian syndrome. **2007**, 3, 55-63 27
- 208 The changing role of the clinical laboratory in the investigation of polycystic ovarian syndrome. **2007**, 28, 79-92 9
- 207 A new perspective in diagnosing polycystic ovary syndrome. **2007**, 99, 149-52 1
- 206 Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. **2009**, 2, 232-9 30
- 205 Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome. **2011**, 16, 999-1005 12
- 204 Effect of metformin on serum ferritin level in women with polycystic ovary syndrome. **2011**, 13, 487-92 1
- 203 Lack of Association of Vitamin D Receptor FokI (rs10735810) (C/T) and BsmI (rs1544410) (A/G) Genetic Variations with Polycystic Ovary Syndrome Risk: a Case-control Study from Iranian Azeri Turkish Women. **2012**, 7, 303-8 9
- 202 The role of androgen receptor activity mediated by the CAG repeat polymorphism in the pathogenesis of PCOS. **2013**, 6, 18-25 17
- 201 Sex hormone-binding globulin genetic variation: associations with type 2 diabetes mellitus and polycystic ovary syndrome. **2010**, 35, 271-80 10

200	Anti-Nuclear Antibodies in Patients with Polycystic Ovary Syndrome before and after Laparoscopic Electrocauterization. 2013 , 38, 187-90	6
199	The relationship between thyroiditis and polycystic ovary syndrome: a meta-analysis. 2013 , 6, 880-9	21
198	Overweight and obesity adversely affect outcomes of assisted reproductive technologies in polycystic ovary syndrome patients. 2013 , 6, 991-5	14
197	Endothelial progenitor cell dysfunction in polycystic ovary syndrome: implications for the genesis of cardiovascular diseases. 2013 , 6, 208-13	4
196	Assessment of C-reactive Protein and C3 as Inflammatory Markers of Insulin Resistance in Women with Polycystic Ovary Syndrome: A Case-Control Study. 2013 , 14, 197-201	10
195	The effect of omega-3 supplementation on androgen profile and menstrual status in women with polycystic ovary syndrome: A randomized clinical trial. 2013 , 11, 665-72	18
194	Relationship between polymorphism of insulin receptor gene, and adiponectin gene with PCOS. 2013 , 11, 185-94	17
193	Effects of simvastatin pretreatment on clomiphene response in clomiphene - resistant women with polycystic ovary syndrome. 2013 , 7, 165-70	3
192	Locus coeruleus lesions and PCOS: role of the central and peripheral sympathetic nervous system in the ovarian function of rat. 2012 , 10, 113-20	2
191	Evaluation of the effect of metformin and aspirin on utero placental circulation of pregnant women with PCOS. 2012 , 10, 265-70	25
190	The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in PCOS patients: a randomized placebo- controlled clinical trial. 2012 , 10, 465-72	22
189	The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms. 2015 , 8, 142-5	33
188	Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. 2015 , 8, 8276-83	14
187	Features of Polycystic Ovary Syndrome in adolescence. 2015 , 8, 291-6	18
186	Prevalence of polycystic ovary syndrome and its associated complications in Iranian women: A meta-analysis. 2015 , 13, 591-604	32
185	Association of vitamin D receptor gene variants with polycystic ovary syndrome: A case control study. 2015 , 13, 793-800	10
184	Nitric oxide donors improve the ovulation and pregnancy rates in anovulatory women with polycystic ovary syndrome treated with clomiphene citrate: A RCT. 2016 , 14, 9-14	3
183	Should Subclinical Hypothyroidism Be an Exclusion Criterion for the Diagnosis of Polycystic Ovary Syndrome?. 2017 , 18, 242-250	4

182	Dehydroepiandrosterone-Sulfate, Insulin Resistance and Ovarian Volume Estimation in Patients With Polycystic Ovarian Syndrome. 2017 , 11, 24-29		6
181	Comparison of Two Statistical Methods to Determine Normal Range of Androgen Hormones: K-Means Cluster Analysis and Receiver Operating Characteristic Curve. 2018 , 12, 96-102		2
180	Update on Management of Polycystic Ovarian Syndrome for Dermatologists. 2019 , 10, 97-105		3
179	Effect of six-month use of oral contraceptive pills on plasminogen activator inhibitor-1 & factor VIII among women with polycystic ovary syndrome: An observational pilot study. 2018 , 148, S151-S155		1
178	Association Between Sex Steroids and Oxidative Status with Vitamin D Levels in Follicular Fluid of Non-obese PCOS and Healthy Women. 2019 , 20, 132-142		12
177	Nutrient Patterns and Risk of Polycystic Ovary Syndrome. 2019 , 20, 161-168		4
176	Long-term effects and significant Adverse Drug Reactions (ADRs) associated with the use of Gonadotropin-Releasing Hormone analogs (GnRHa) for central precocious puberty: a brief review of literature. 2019 , 90, 345-359		2
175	Polycystic ovarian syndrome in adolescents: From diagnostic criteria to therapeutic management. 2020 , 91, e2020085		
174	A Study on the Clinical and Hormonal Profile of Polycystic Ovarian Syndrome Patients Attending a Tertiary Care Hospital: A Descriptive Cross-sectional Study. 2020 , 58, 875-888		
173	Acupuncture therapy protects PCOS patients with diabetes by regulating miR-32-3p/PLA2G4A pathway. 2021 , 13, 8819-8832		
172	Defining PCOS: A syndrome with an intrinsic heterogeneous nature. 2022 , 3-13		1
171	Combined oral contraceptives: Why, when, where?. 2022 , 135-152		
170	Early Sexual Health and Reproductive Implications in Pediatric Rheumatic Diseases. 2022 , 48, 91-112		
169	Modeling Pregnancy Outcomes through Sequentially Nested Regression Models. 1-33		
168	Profile of Daughters and Sisters of Women with Polycystic Ovary Syndrome: The Role of Proband's Glucose Tolerance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	1
167	Anorexigenic peptide (leptin, obestatin, nesfatin-1) levels and their impact on assisted reproductive technology treatment outcomes in patients with polycystic ovary syndrome. 2021 , 48, 368-373		
166	A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III. 2021 , 29, 100821		0
165	De-novo and depot-specific androgen production in human adipose tissue - a source of hyperandrogenism in women with obesity.. 2022 ,		1

- 164 Obez ve Obez Olmayan Polikistik Over Sendromlu Adölesanların Klinik ve Laboratuvar Özelliklerinin Karşılaştırılması. **2022**, 8, 75-81
- 163 Polycystic ovary syndrome and postpartum depression: A systematic review and meta-analysis of observational studies.. **2021**, 299, 463-469 1
- 162 MALAT1 downregulation is associated with polycystic ovary syndrome via binding with MDM2 and repressing P53 degradation. **2021**, 111528 1
- 161 A Study on the Clinical and Hormonal Profile of Polycystic Ovarian Syndrome Patients Attending a Tertiary Care Hospital: A Descriptive Cross-sectional Study. **2020**, 58, 875-888
- 160 Prevalence of Metabolic Syndrome in Polycystic Ovarian Syndrome. **2021**, 5,
- 159 Uncovering Evidence: Associations between Environmental Contaminants and Disparities in Women's Health.. **2022**, 19, 1
- 158 Multiomics Analysis-Based Biomarkers in Diagnosis of Polycystic Ovary Syndrome.. **2022**, 1 0
- 157 Implementation of International Guidelines for Polycystic Ovary Syndrome: Barriers and Facilitators Among Gynecologists and Primary Care Providers. **2022**,
- 156 Deconstructing a Syndrome: Genomic Insights into PCOS Causal Mechanisms and Classification.. **2022**, 5
- 155 Prevalence of ocular anomalies is increased in women with polycystic ovary syndrome-exploration of association with PAX6 genotype.. **2022**, 1-4
- 154 Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome.. **2022**,
- 153 Ayurveda management of infertility associated with Poly Cystic Ovarian Syndrome: A case report.. **2021**, 13, 100513 0
- 152 Evaluation of insulin resistance and vitamin D levels in patients with polycystic ovary syndrome.
- 151 Psychosomatic Features of Menstrual Cycle Disorders in Women of Reproductive Age. **2021**, 255-261
- 150 Association of eNOS and STAT6 Gene Polymorphisms with the Susceptibility of Polycystic Ovary Syndrome in South Indian Women. **2022**, 3, 007-013
- 149 Ferroptosis inhibitor ferrostatin-1 alleviates homocysteine-induced ovarian granulosa cell injury by regulating TET activity and DNA methylation.. **2022**, 25, 0
- 148 Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) in the 18th Century: Mitochondrial Disorders Are Not of Recent Origin.. **2022**, 14, e22314 0
- 147 Adrenal Androgen Predictive Effects on Clinical and Metabolic Abnormalities of Polycystic Ovary Syndrome.. **2022**, 44, 142-153

- 146 Prevalence of Metabolic Syndrome in Polycystic Ovarian Syndrome. **2022**, 5,
- 145 Association of Insulin Resistance and Elevated Androgen Levels with Polycystic Ovarian Syndrome (PCOS): A Review of Literature.. **2022**, 2022, 9240569 4
- 144 Approach to androgen excess in women: Clinical and biochemical insights.. **2022**, 1
- 143 Anti-Mullerian Hormone Levels Increase After Bariatric Surgery in Obese Female Patients With and Without Polycystic Ovary Syndrome.. **2022**, 54, 194-198 0
- 142 A Systematic Review and Meta-analysis of Polycystic Ovary Syndrome and Mental Health among Black Asian Minority Ethnic populations.
- 141 Effects of clinical and metabolic variables and hormones on the expression of immune protein biomarkers in the endometrium of women with polycystic ovary syndrome and normal-cycling controls.. **2022**, 1-8 1
- 140 Inhibition of Nicotinamide adenine dinucleotide phosphate oxidase 4 attenuates cell apoptosis and oxidative stress in a rat model of polycystic ovary syndrome through the activation of Nrf-2/HO-1 signaling pathway.. **2022**, 111645 1
- 139 Effect of vitamin E supplementation on cardiometabolic risk factors, inflammatory and oxidative markers and hormonal functions in PCOS (polycystic ovary syndrome): a systematic review and meta-analysis.. **2022**, 12, 5770 1
- 138 PKOS Hastalarıda Yrsek Kan Basincisi Ve Bunun Klinik ve Laboratuvar Parametrelerle Ilisi. **2021**, 10, 173-179
- 137 COMPARISON OF POLYCYSTIC OVARIES IN OBESE AND NON-OBESE PATIENTS. **2021**, 4,
- 136 Re: "Prevalence of Hirsutism Among Reproductive-Aged African American Women," by Chin et al.. **2021**, 30, 1824-1825 1
- 135 PCOS and Assisted Reproduction Technique: Role and Relevance of Inositols. **2021**, 2, 515-522
- 134 The main directions and prospects in polycystic ovary syndrome treatment. **2021**, 41, 18-29
- 133 Obesity, Dysmetabolic and Proinflammatory Milieu of Polycystic Ovary Syndrome. **2022**, 155-190
- 132 Role of Statins and Resveratrol in PCOS Management. **2022**, 255-277
- 131 Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS. **2022**, 527-553
- 130 Emerging Concepts: Role of Vitamin D Deficiency in the Pathogenesis of PCOS. **2022**, 489-509
- 129 Diagnostic Criteria and Epidemiology of PCOS. **2022**, 3-11

128 Economic Burden of Polycystic Ovary Syndrome. **2022**, 431-446

127 A study on lipoprotein-a and PAI-1 in women with polycystic ovary syndrome.. **2022**,

0

126 Quantitative Changes in White Blood Cells: Correlation with the Hallmarks of Polycystic Ovary Syndrome.. **2022**, 58,

1

125 Special Considerations on Hyperandrogenism and Insulin Resistance in Nonobese Polycystic Ovaries Syndrome.

124 Image_1.JPEG. **2019**,

123 Image_2.JPEG. **2019**,

122 Table_1.XLSX. **2019**,

121 Table_2.DOCX. **2019**,

120 Table_1.DOCX. **2020**,

119 Table_1.docx. **2020**,

118 Table_1.DOCX. **2018**,

117 Image_1.pdf. **2020**,

116 Table_1.docx. **2020**,

115 Adrenomedullin: possible predictor of insulin resistance in women with polycystic ovary syndrome. **2012**, 35, 553-6

2

114 Application of proteomics to the study of polycystic ovary syndrome. **2011**, 34, 869-75

6

113 Update on management of polycystic ovarian syndrome for dermatologists. **2019**, 10, 97

12

112 Exercise interventions in women with Polycystic Ovary Syndrome. **2022**, 273-286

111 Burden of polycystic ovary syndrome in the Middle East and North Africa region, 1990-2019.. **2022**, 12, 7039

1

110 The Epidemiology of Polycystic Ovary Syndrome. **2022**, 21-28

109 Correlations Between Gonadotropin Hormones and the Manifestations of Polycystic Ovary Syndrome. **2022**, 11,

108 The effects of metformin on hyperandrogenism and menstrual functions in insulin resistant adolescents with PCOS.

107 Prediction model of persistent ovulatory dysfunction in Korean women with polycystic ovary syndrome.

106 An Insight on Polycystic Ovary Syndrome (PCOS) and Use of Herbal Medicines as Alternative Treatment. **2022**, 78-116

105 Familial Diabetes in Obese PCOS Predisposes Individuals to Compensatory Hyperinsulinemia and Insulin Resistance (IR) Also for Reduced Hepatic Insulin Extraction (HIE). **2022**, 3, 296-302

1

104 Comparative effectiveness of aerobic exercise versus Yi Jin Jing on ovarian function in young overweight/obese women with polycystic ovary syndrome: study protocol for a randomized controlled trial. **2022**, 23,

0

103 High-frequency audiometry, speech perception in quiet and noise, and vestibular-evoked myogenic potential in women with polycystic ovary syndrome. **2022**, 38,

102 Association between gynaecological disorders and body mass index in a South African cohort: a retrospective observational study. 1-6

0

101 Assessment of knowledge, awareness and practice of dental practitioners on the relationship between poly cystic ovarian syndrome (PCOS) in periodontally compromised women-A questionnaire based survey. **2022**, 7, 68-73

100 Adverse Pregnancy Outcome in Polycystic Ovarian Syndrome: A Comparative Study. **2022**,

99 Role of Oxidative Stress and Carnitine in PCOS Patients.

98 Polycystic ovary syndrome: Insights from pre-clinical research. 10.34067/KID.0002052022

0

97 Familial diabetes predisposes PCOS patients to insulin resistance (IR), reproductive impairment and hepatic dysfunction: effects of d-chiro inositol (DCI) and alpha lipoic acid (ALA) administration on hepatic insulin extraction (HIE) index. 1-8

0

96 Relationship of inflammatory and metabolic parameters in adolescents with PCOS: BMI matched case-control study. **2022**,

0

95 Endokrinologische Sprechstunde. **2022**, 223-230

94 The ovarian immune pathology and reproductive failures. **2022**, 333-350

93 MIR146A and ADIPOQ genetic variants are associated with birth weight in relation to gestational age: a cohort study.

0

- 92 Exploring the relationship between osteoporosis and polycystic ovary syndrome based on bioinformatics. **2022**, 101, e29434
- 91 Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model.
- 90 Polycystic Ovary Syndrome: An exploration of unmarried women's knowledge and attitudes. **2022**, e09835
- 89 Identification of the shared gene signatures and pathways between polycystic ovary syndrome and endometrial cancer: An omics data based combined approach. **2022**, 17, e0271380 1
- 88 Assessment of Biochemical Markers in Polycystic Ovarian Syndrome Patients in the Niger Delta Region, Nigeria. **2022**, 100-110
- 87 Cardiovascular Risk Predictors High Sensitivity C-Reactive Protein and Plasminogen Activator Inhibitor-1 in Women with Lean Phenotype of Polycystic Ovarian Syndrome: A Prospective Case-Control Study.
- 86 Interplay between polycystic ovary syndrome and hypothyroidism on serum testosterone, oxidative stress and StAR gene expression in female rats.
- 85 Effect of Two Different Doses of Vitamin D Supplementation on Clinical, Metabolic, and Hormonal Profiles of Patients with Polycystic Ovary Syndrome (PCOS) with Insulin Resistance: A Randomized Controlled Trial. **2022**, 14, 307-312
- 84 Leveraging Systematic Reviews to Explore Disease Burden and Costs of Per- and Polyfluoroalkyl Substance Exposures in the United States. 1
- 83 The relationship between polycystic ovary syndrome and insulin resistance from 1983 to 2022: A bibliometric analysis. 10, 0
- 82 Effect of vitamin K2 administration on depression status in patients with polycystic ovary syndrome: a randomized clinical trial. **2022**, 22,
- 81 Study of occurrence of risk factors of metabolic syndrome in women with PCOS. **2022**, 9, 357-360
- 80 Evaluation of socio-demographic and clinical characteristics of PCOS patients attending a tertiary care institute in Colombo.
- 79 Ibuprofen Reduces Testosterone Level in women with Polycystic Ovary Syndrome.
- 78 Ovulation induction techniques in women with polycystic ovary syndrome. 9, 1
- 77 The Upregulation of HAS2-AS1 Relates to the Granulosa Cell Dysfunction by Repressing TGF- β Signaling and Upregulating HAS2.
- 76 Gestational diabetes and other adverse pregnancy outcomes in polycystic ovary syndrome. Publish Ahead of Print,
- 75 Effects of probiotic supplementation on hormonal and clinical outcomes of women diagnosed with polycystic ovary syndrome: A double-blind, randomized, placebo-controlled clinical trial. **2022**, 96, 105203

- 74 Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model. **2022**, 22, ○
- 73 Characterizing skeletal muscle dysfunction in women with polycystic ovary syndrome. **2022**, 13, 204201882211631
- 72 Polycystic Ovarian Syndrome and Increased Risk of Female Cancers. **2022**, ○
- 71 Gas chromatography-mass spectrometry based steroid metabolomics in women with different phenotypes of polycystic ovarian syndrome and normal body weight. **2022**, 13, 107-117 ○
- 70 Habitual physical activity levels in women attending the one-stop infertility clinic: a prospective cross-sectional observational study. **2022**, 3, 231-237 ○
- 69 SONOGRAPHIC ASSESSMENT OF PRIMARY INFERTILITY IN WOMEN HAVING PCOS. 03-06 ○
- 68 Are there new insights for the definition of PCOS?. **2022**, 38, 703-704 ○
- 67 Depression, anxiety, body image scores, and sexual dysfunction in patients with polycystic ovary syndrome according to phenotypes. 1-7 1
- 66 Endophenotypic Correlates of Cognitive Function in Reproductive Aged Individuals with Polycystic Ovary Syndrome. **2022**, ○
- 65 Polikistik over sendromlu hastalarda anti mllerian hormon düzeyi ile endometrial polip sıklığı arasındaki ilişki. **2022**, 3, 263-267 ○
- 64 A meta-analysis of the relationship between polycystic ovary syndrome and sleep disturbances risk. 13, ○
- 63 The Effect of Green Coffee Supplementation on Lipid Profile, Glycemic Indices, Inflammatory Biomarkers and Anthropometric Indices in Iranian Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial. **2022**, 11, 241 1
- 62 Gallic acid reverses ovarian disturbances in mice with letrozole-induced PCOS via modulating Adipo R1 expression. **2022**, 9, 1938-1949 1
- 61 Use of myo-inositol in women with polycystic ovary syndrome in the application of auxiliary reproductive technologies. **2022**, 50-56 ○
- 60 Compatible cut-off values for luteinizing hormone and the luteinizing hormone/follicle-stimulating hormone ratio in diagnostic criteria of the Japan Society of Obstetrics and Gynecology for polycystic ovary syndrome. ○
- 59 The potential diagnostic use of clinical characteristics and mitochondrial DNA copy numbers of peripheral blood and ovarian tissue in polycystic ovary syndrome (PCOS) patient. ○
- 58 From an Apple to a Pear: Moving Fat around for Reversing Insulin Resistance. **2022**, 19, 14251 ○
- 57 Racial and Ethnic Disparities in Reproductive Health Outcomes Among Women Veterans: A Research Note. 0095327X2211313 ○

- 56 Benefits of physical activity on reproductive health functions among polycystic ovarian syndrome women: A systematic review. ○
- 55 A bibliometric and visual analysis of obesity and polycystic ovary syndrome from 2012 to 2022. 13, ○
- 54 Prevalence of polycystic ovary syndrome in European countries and USA: A systematic review and meta-analysis. **2022**, 279, 159-170 ○
- 53 Acne in Women. **2022**, 73-119 ○
- 52 Androgen Signaling in Uterine Diseases: New Insights and New Targets. **2022**, 12, 1624 1
- 51 An Optimistic Bayesian Optimization Based Extreme Learning Machine for Polycystic Ovary Syndrome Diagnosis. **2023**, 175-193 ○
- 50 Trend changes and factor analysis of endometrial hyperplasia in patients with polycystic ovarian syndrome based on the Korean National Health Insurance Database. **2022**, 22, ○
- 49 Evaluation of socio-demographic and clinical characteristics of PCOS patients attending a tertiary care institute in Colombo. **2022**, 22, ○
- 48 Assessment of Health-Related Quality of Life Using PCOSQ Tool, Its Determinants and Coping Mechanisms Used by Women with Polycystic Ovarian Syndrome Attending Multidisciplinary Clinic in Mumbai, India. ○
- 47 Identification of key genes and miRNAs related to polycystic ovary syndrome by comprehensive analysis of microarray. **2022**, 15, ○
- 46 A PPAR γ Splice Variant in Granulosa Cells Is Associated with Polycystic Ovary Syndrome. **2022**, 11, 7285 1
- 45 Fat mass and Obesity Associated (FTO) gene and polycystic ovary syndrome: Insight into pathogenesis and association with insulin resistance. **2022**, 30, 200174 ○
- 44 Prevalence of Polycystic Ovarian Syndrome in India: A Systematic Review and Meta-Analysis. **2022**, ○
- 43 Development of the First Health-Related Quality of Life Questionnaires in Arabic for Women With Polycystic Ovary Syndrome (Part III): Scoring System Interpretation. **2022**, ○
- 42 Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features. **2023**, 15, 18 ○
- 41 Comparative Meta-analysis of Adipose Tissue Transcriptomics Data in PCOS Patients and Healthy Control Women. ○
- 40 Polycystic Ovary Syndrome and Endocrine Disruptors (Bisphenols, Parabens, and Triclosan) Systematic Review. **2023**, 13, 138 ○
- 39 Genetic variations in OLR1 gene associated with PCOS and atherosclerotic risk factors. 108155892211418 ○

- 38 Role of structured exercise programs in polycystic ovary syndrome: a systematic review. 1-11 ○
- 37 Comparison of physical activity levels and dietary habits between women with polycystic ovarian syndrome and healthy controls of reproductive age: A case-control study. ○
- 36 The Implication of Mechanistic Approaches and the Role of the Microbiome in Polycystic Ovary Syndrome (PCOS): A Review. **2023**, 13, 129 ○
- 35 New approaches to early detection of polycystic ovary syndrome in obese women. **2022**, 20-25 ○
- 34 Endocrine Disrupting Chemicals in Polycystic Ovary Syndrome: The Relevant Role of the Theca and Granulosa Cells in the Pathogenesis of the Ovarian Dysfunction. **2023**, 12, 174 1
- 33 GIMAP7 induces oxidative stress and apoptosis of ovarian granulosa cells in polycystic ovary syndrome by inhibiting sonic hedgehog signalling pathway. **2022**, 15, ○
- 32 The molecular mechanism of miR-96-5p in the pathogenesis and treatment of polycystic ovary syndrome. **2022**, ○
- 31 Developmental programming of the neuroendocrine axis by steroid hormones: Insights from the sheep model of PCOS. 14, ○
- 30 Polycystic ovarian disease: Preventive approach. **2023**, 8, 53-56 ○
- 29 Molecular characterization of extracellular vesicles derived from follicular fluid of women with and without PCOS: integrating analysis of differential miRNAs and proteins reveals vital molecules involving in PCOS. ○
- 28 Assessing the accuracy of a digital symptom checker tool for suggestion of reproductive health conditions: a clinical vignettes study. ○
- 27 Role of diacerein on steroidogenesis and folliculogenesis related genes in ovary of letrozole-induced PCOS mice. **2023**, 377, 110468 ○
- 26 An artificial intelligence-based decision support system for early diagnosis of polycystic ovaries syndrome. **2023**, 3, 100164 ○
- 25 Androgen-Induced Cardiovascular Risk in Polycystic Ovary Syndrome: The Role of T Lymphocytes. **2023**, 13, 1010 ○
- 24 Epidemiological Aspects and Results of the Management of Polycystic Ovary Syndrome at the CNHU-HKM of Cotonou. **2022**, 12, 266-282 ○
- 23 Association of Pregnancy Outcome Complications Among Females with Polycystic Ovary Syndrome. 12-16 ○
- 22 Differential Strain-dependent Ovarian and Metabolic Responses in a Mouse Model of PCOS. **2023**, 164, ○
- 21 Use of myo-inositol in the treatment of PCOS symptoms in adolescents. **2023**, 151-165 ○

- 20 Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. **2023**, 12, 1454 ○
- 19 PHENOTYPES OF POLYCYSTIC OVARY SYNDROME AND THEIR ASSOCIATION WITH METABOLIC SYNDROME- A NORTH INDIAN TERTIARY CARE CENTER BASED STUDY. **2023**, 6-9 ○
- 18 Past and present: a bibliometric study on polycystic ovary syndrome. **2023**, 16, ○
- 17 Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome. **2023**, ○
- 16 Study on Metabolism of Adolescent and Adult PCOS Patients. **2023**, 13, 3419-3423 ○
- 15 Association Study between Polycystic Ovary Syndrome and Autoimmune Thyroiditis. **2023**, 13, 3408-3412 ○
- 14 Insulin Resistance and Bone Metabolism Markers in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study on Females from the Islamic University Medical Center. **2023**, 59, 593 ○
- 13 Molecular Mechanisms in the Etiology of Polycystic Ovary Syndrome (PCOS): A Multifaceted Hypothesis Towards the Disease with Potential Therapeutics. ○
- 12 The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials. ○
- 11 CircRNAs and RNA-Binding Proteins Involved in the Pathogenesis of Cancers or Central Nervous System Disorders. **2023**, 9, 23 ○
- 10 Polycystic ovary syndrome phenotypes. **2024**, 6-10 ○
- 9 Introduction to polycystic ovary syndrome. **2024**, 1-5 ○
- 8 Global approach to polycystic ovary syndrome in Africa. **2024**, 220-228 ○
- 7 Polycystic ovary syndrome in North America. **2024**, 229-236 ○
- 6 Male polycystic ovary syndrome equivalent. **2024**, 100-110 ○
- 5 Metformin Treatment of Hidradenitis Suppurativa: Effect on Metabolic Parameters, Inflammation, Cardiovascular Risk Biomarkers, and Immune Mediators. **2023**, 24, 6969 ○
- 4 A Scoping Review of Vitamin D for Nonskeletal Health: A Framework for Evidence-Based Clinical Practice. **2023**, ○
- 3 Association Between Mental Health and Reproductive System Disorders in Women. **2023**, 6, e238685 ○

- 2 Advances in Neuroendocrine Research on Polycystic Ovary Syndrome: New Hope for Treatment Decoding the Link between Hormones and the Brain. **2023**, 15, 114-119 ○
- 1 Clinico-Metabolic Profile in Lean Versus Obese Polycystic Ovarian Syndrome Women. **2023**, ○